fluoxetine has been researched along with Depressive Disorder, Major in 699 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Severity of anxiety does not appear to influence the antidepressant response to fluoxetine during acute treatment of major depressive disorder (MDD)." | 10.21 | Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. ( Fava, M; Joliat, MJ; Michelson, D; Miner, CM; Schmidt, ME; Trapp, NJ; Zhang, S, 2004) |
| " Fluoxetine is one of the main first-line medications used for depression, and it is hypothesized that it participates in the decrease of pro-inflammatory cytokines." | 9.22 | Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis. ( García-García, ML; Genis-Mendoza, AD; González-Castro, TB; Juárez-Rojop, IE; López-Nárvaez, ML; Martinez-Magaña, JJ; Ramos-Méndez, MÁ; Ruiz-Quiñones, JA; Saucedo-Osti, AS; Tovilla-Zárate, CA; Villar-Soto, M, 2022) |
| " This open-label study evaluated the efficacy and safety of modafinil treatment initiated with an SSRI in patients with MDD and fatigue." | 9.11 | Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004) |
| "Low-dose cotherapy of fluoxetine with clonazepam was safe and accelerated response over 21 days of treatment, decreasing anxiety and sleep disturbance as symptoms and partially suppressed them as SSRI side-effects; it also modestly reduced core symptoms of low mood and loss of interest." | 9.09 | Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. ( Glaudin, V; Londborg, PD; Painter, JR; Smith, WT, 2000) |
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 8.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| "This meta-analysis assessed aggression and/or hostility-related events in children and adolescents treated with fluoxetine (n = 376) compared with placebo (n = 255)." | 8.84 | Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo. ( Allen, AJ; Caldwell, C; Nilsson, M; Plewes, J; Tauscher-Wisniewski, S, 2007) |
| "The aim of the study was to determine whether baseline pain was associated with discernible clinical features and treatment outcomes for patients with major depressive disorder (MDD) receiving 6-week fluoxetine treatment." | 7.81 | Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine. ( Lin, CH; Lin, HS; Wang, FC, 2015) |
| "Following zuclopenthixol acuphase administration, dangerous extra-pyramidal side effects were observed, including severe laryngeal dystonia necessitating emergency medical treatment." | 7.76 | Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. ( Bennett, L; Davies, S; Hood, S; Orr, K, 2010) |
| "Blood from pregnant women taking fluoxetine (n = 9), during pregnancy was sampled in the third trimester and at delivery (maternal and cord venous blood), and from the infants 48 h after delivery." | 7.73 | Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. ( Fitzgerald, C; Grunau, RE; Kent, N; Kim, J; Misri, S; Oberlander, TF; Riggs, KW; Rurak, DW, 2006) |
| "Effective treatment of depression is a key target for suicide prevention strategies." | 7.01 | Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people. ( Berk, M; Chanen, A; Cotton, S; Davey, CG; Dean, O; Hetrick, S; Madsen, T; McGorry, PD; Witt, K, 2021) |
| "Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear." | 6.90 | The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. ( Amminger, GP; Berk, M; Catania, L; Chanen, AM; Cotton, SM; Davey, CG; Dean, OM; Harrison, BJ; Hetrick, SE; Kazantzis, N; Kerr, M; Koutsogiannis, J; McGorry, PD; Mullen, E; Parker, AG; Phelan, M; Quinn, AL; Ratheesh, A; Rice, S; Weller, A, 2019) |
| "Fluoxetine was not different from placebo in Greene Climacteric Scale." | 6.80 | Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial. ( Aguilar-Faisal, L; Asbun-Bojalil, J; Llanes-González, L; Macías-Cortés, Edel C, 2015) |
| "Fluoxetine (FLX) has been one of the most widely studied selective serotonin reuptake inhibitors in adolescents." | 6.79 | Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. ( Arnaiz, JA; Blázquez, A; Gassó, P; Lafuente, A; Lázaro, L; Mas, S; Méndez, I; Plana, MT; Torra, M, 2014) |
| "Adolescent major depressive disorder (MDD) is a life-threatening brain disease with limited interventions." | 6.76 | Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. ( Fiedler, KK; Hellem, TL; Jeong, EK; Kondo, DG; Renshaw, PF; Shi, X; Sung, YH, 2011) |
| "Discontinuation syndrome is associated with a rostral anterior cingulate Cho/Cre metabolite ratio decrease that may reflect dynamics of rostral anterior cingulate function." | 6.71 | Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. ( Cohen, BM; Frederick, Bd; Hennen, J; Henry, ME; Kaufman, MJ; Renshaw, PF; Schmidt, ME; Stoddard, EP; Villafuerte, RA, 2003) |
| "The incidence of treatment-emergent nausea during 6-month continuation of duloxetine treatment (80 mg/d, 2." | 6.71 | Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. ( Greist, J; Mallinckrodt, CH; McNamara, RK; Raskin, J; Rayamajhi, JN, 2004) |
| "Treatment with olanzapine may impact a patient's weight; thus, long-term weight gain and potential predictors (e." | 6.71 | Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005) |
| "Severity of anxiety does not appear to influence the antidepressant response to fluoxetine during acute treatment of major depressive disorder (MDD)." | 6.21 | Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. ( Fava, M; Joliat, MJ; Michelson, D; Miner, CM; Schmidt, ME; Trapp, NJ; Zhang, S, 2004) |
| " Fluoxetine is one of the main first-line medications used for depression, and it is hypothesized that it participates in the decrease of pro-inflammatory cytokines." | 5.22 | Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis. ( García-García, ML; Genis-Mendoza, AD; González-Castro, TB; Juárez-Rojop, IE; López-Nárvaez, ML; Martinez-Magaña, JJ; Ramos-Méndez, MÁ; Ruiz-Quiñones, JA; Saucedo-Osti, AS; Tovilla-Zárate, CA; Villar-Soto, M, 2022) |
| "Saffron is a tolerable and efficacious treatment for fluoxetine-related erectile dysfunction." | 5.16 | Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. ( Akhondzadeh, S; Ashrafi, M; Jamshidi, A; Modabbernia, A; Nasehi, AA; Raisi, F; Saroukhani, S; Sohrabi, H; Tabrizi, M, 2012) |
| " This study aimed to establish the effects of fluoxetine and sertraline treatments on thyroid function and thyroid autoimmunity in patients with major depression and primary hypothyroidism and in patients with major depression and normal thyroid function." | 5.14 | Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function. ( Bahls, SC; Boeving, A; de Carvalho, GA; Graf, H, 2009) |
| "The objective of this study was to assess the relationship between early changes in anxiety/somatization symptoms and treatment outcome among major depressive disorder patients during a 12-week trial of fluoxetine." | 5.14 | Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. ( Alpert, J; Baer, L; Bitran, S; Chuzi, S; Clain, AJ; Dording, C; Farabaugh, AH; Fava, M; McGrath, PJ; Mischoulon, D; Papakostas, GI; Witte, J, 2010) |
| "This study compared the acute phase (12-week) efficacy of fluoxetine versus placebo for the treatment of the depressive symptoms and the cannabis use of adolescents and young adults with comorbid major depression (MDD) and a cannabis use disorder (CUD) (cannabis dependence or cannabis abuse)." | 5.14 | Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. ( Brown, SJ; Bukstein, OG; Chung, TA; Clark, DB; Cornelius, JR; Daley, DC; Douaihy, AB; Wood, DS, 2010) |
| "To add to the limited data on the clinical pharmacology of antidepressants during pregnancy, we examined the dose-corrected chiral and racemic levels (level/dose) of fluoxetine (FLX) and norfluoxetine (NorFLX) during pregnancy and early postpartum." | 5.14 | Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. ( Helsel, JC; Luther, JF; Perel, JM; Sit, D; Wisner, KL; Wisniewski, SR, 2010) |
| " Following maprotiline treatment, the body weight and BMI were significantly increased (P=0." | 5.12 | Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. ( Chen, YC; Chou, CH; Hung, YJ; Perng, CH; Shen, YC; Yeh, CB, 2007) |
| " We compare the effects of 2 combined therapies, fluoxetine and interpersonal therapy (IPT) or fluoxetine and cognitive therapy (CT), on major depression in patients with borderline personality disorder (BPD)." | 5.12 | Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. ( Bellino, S; Bogetto, F; Rinaldi, C; Zizza, M, 2007) |
| " This open-label study evaluated the efficacy and safety of modafinil treatment initiated with an SSRI in patients with MDD and fatigue." | 5.11 | Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004) |
| " This is the first report aimed at studying the beneficial therapeutic effects of fluoxetine alone on anxiety dimension in first episode drug naive patients suffering from DSM-IV major depression (MDD) and double depression (DD)." | 5.10 | Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial. ( Caltagirone, C; Pasini, A; Spalletta, G, 2002) |
| "Low-dose cotherapy of fluoxetine with clonazepam was safe and accelerated response over 21 days of treatment, decreasing anxiety and sleep disturbance as symptoms and partially suppressed them as SSRI side-effects; it also modestly reduced core symptoms of low mood and loss of interest." | 5.09 | Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. ( Glaudin, V; Londborg, PD; Painter, JR; Smith, WT, 2000) |
| "This study assessed the effect of fluoxetine 20 mg/day on weight loss in older patients treated for major depression in a multicenter, double-blind placebo-controlled, 6-week clinical trial." | 5.08 | Fluoxetine in medically stable, depressed geriatric patients: effects on weight. ( Beasley, CM; Goldstein, DJ; Hamilton, SH; Masica, DN, 1997) |
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 4.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| "This meta-analysis assessed aggression and/or hostility-related events in children and adolescents treated with fluoxetine (n = 376) compared with placebo (n = 255)." | 4.84 | Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo. ( Allen, AJ; Caldwell, C; Nilsson, M; Plewes, J; Tauscher-Wisniewski, S, 2007) |
| "We report here the case of a patient with fluoxetine and selegiline induced serotonin syndrome, which presented as encephalopathy, generalized myoclonias, fever, stiffness and sweating, complicated with acute renal failure, rhabdomyolysis and disseminated intravascular coagulation findings." | 4.81 | [Serotonin syndrome: report of a fatal case and review of the literature]. ( Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N, 2002) |
| "We conclude that oral G115® significantly potentiates the antidepressant-like effect of fluoxetine in the FST in the absence of potentially confounding effects on locomotion and anxiety." | 4.02 | Standardised ginseng extract G115® potentiates the antidepressant-like properties of fluoxetine in the forced swim test. ( MacDonald, DS; Tasker, RA; Terstege, DJ, 2021) |
| "Electroconvulsive therapy was superior to fluoxetine in resolving suicidal ideation during acute treatment." | 3.96 | Electroconvulsive Therapy Versus Fluoxetine in Suicidal Resolution for Patients With Major Depressive Disorder. ( Chen, CC; Huang, CJ; Lin, CH, 2020) |
| "A 21-year-old female with a history of generalized anxiety disorder and major depression presented with increased depressive symptoms over several months while taking fluoxetine 20 mg daily." | 3.96 | A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy. ( Blake, CS; Hudd, TR; Nguyen, TT; Rimola-Dejesus, Y; Zaiken, K, 2020) |
| "In this item-based, patient-level, post-hoc analysis, we pooled data from all completed, acute-phase, placebo-controlled, industry-sponsored, HDRS-based trials of the SSRIs citalopram, paroxetine, or sertraline in adult major depression." | 3.91 | Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. ( Eriksson, E; Hieronymus, F; Lisinski, A; Nilsson, S, 2019) |
| " We carried out a study to compare the behavioural effects of fluoxetine (FLX) in a model of depression in two mice strains: C57BL6/J and BALB/c." | 3.85 | Fluoxetine induces paradoxical effects in C57BL6/J mice: comparison with BALB/c mice. ( Belzung, C; Brizard, B; Gosselin, T; Hommet, C; Le Guisquet, AM; Minier, F, 2017) |
| "We measured [(3)H]AF-DX 384 binding in BA 46 and BA 24 from subjects with bipolar disorders (n = 14), major depressive disorders (n = 19), as well as age- and sex-matched controls (n = 19) and the CNS of rats treated with fluoxetine or imipramine." | 3.83 | Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants. ( Dean, B; Gibbons, AS; Jeon, WJ; Scarr, E, 2016) |
| " Subsequently, density of [(3)H]LY341495 binding was measured in BA24(anterior cingulate cortex), BA17(visual cortex) and BA46(dorsolateral prefrontal cortex) from subjects with MDD, Bipolar Disorder(BPD), Schizophrenia(SCZ), and controls, as well as rats treated with imipramine (20mg/kg), fluoxetine (10mg/kg), or vehicle." | 3.83 | Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia. ( Dean, B; Gibbons, A; Hopper, S; McOmish, CE; Pavey, G; Scarr, E; Udawela, M, 2016) |
| "The aim of the study was to determine whether baseline pain was associated with discernible clinical features and treatment outcomes for patients with major depressive disorder (MDD) receiving 6-week fluoxetine treatment." | 3.81 | Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine. ( Lin, CH; Lin, HS; Wang, FC, 2015) |
| " In situ [3H]ketanserin binding and autoradiography was used to measure levels of HTR2A in Brodmann's area (BA) 46 and 24 from people with major depressive disorders (MDD, n = 16), bipolar disorders (BD, n = 14) and healthy controls (n = 14) as well as the central nervous system (CNS) of rats (20 per treatment arm) treated for 10 or 28 d with fluoxetine (10 mg/kg/d) or imipramine (20 mg/kg/d)." | 3.80 | Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine. ( Dean, B; Everall, I; Gibbons, A; Jeon, WJ; Scarr, E; Seo, MS; Tawadros, N, 2014) |
| " We aimed to investigate the relationships among body weight, body mass index (BMI=kg/m(2)), change in a depression rating scale, and change in a functional scale with fluoxetine treatment for hospitalized patients with major depressive disorder (MDD)." | 3.80 | Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. ( Chen, CC; Lin, CH; McIntyre, RS; Wong, J, 2014) |
| " Anhedonia, brain BDNF and circulating corticosterone levels, considered endophenotypes of depression, were investigated." | 3.79 | Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice. ( Alleva, E; Branchi, I; Capoccia, S; Cirulli, F; D'Andrea, I; Poggini, S; Santarelli, S, 2013) |
| "The objective of this study was to investigate the effects of depression relief and pain relief on the improvement in daily functioning and quality of life (QOL) for depressed patients receiving a 6-week treatment of fluoxetine." | 3.79 | Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder. ( Chen, CC; Chen, MC; Lin, CH; Yen, YC, 2013) |
| "Following zuclopenthixol acuphase administration, dangerous extra-pyramidal side effects were observed, including severe laryngeal dystonia necessitating emergency medical treatment." | 3.76 | Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. ( Bennett, L; Davies, S; Hood, S; Orr, K, 2010) |
| "Anxiety disorders alone did not predict response or remission, but the total number of co-morbid illnesses was associated with remission in depressed children and adolescents treated with fluoxetine." | 3.76 | Anxiety as a predictor of treatment outcome in children and adolescents with depression. ( Cheung, A; Emslie, G; Kiss, A; Levitt, A; Mayes, T; Michalak, E; Schaffer, A, 2010) |
| "Our work suggests that the combination of the number of comorbid anxiety disorders, an attentional variable, and two planning variables makes it possible to correctly classify 82% of the depressed patients who responded to the treatment with fluoxetine, and 74% of the patients who did not respond to that treatment." | 3.76 | The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. ( Avilés Reyes, R; Camarena, B; Carrillo-Guerrero, MY; Cortés-Penagos, C; Cruz, D; Genis, A; Guàrdia-Olmos, J; Gudayol-Ferré, E; Hernández, S; Herrera-Abarca, JE; Herrera-Guzmán, I; Martínez-Medina, P, 2010) |
| " We report a case with no previous history of bipolar disorder, whereas developed full-blown psychotic manic symptoms soon after switch from fluoxetine to mirtazapine." | 3.75 | Antidepressant-associated mania: soon after switch from fluoxetine to mirtazapine in an elderly woman with mixed depressive features. ( Liang, KY; Liao, SC; Liu, CC, 2009) |
| "Blood from pregnant women taking fluoxetine (n = 9), during pregnancy was sampled in the third trimester and at delivery (maternal and cord venous blood), and from the infants 48 h after delivery." | 3.73 | Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. ( Fitzgerald, C; Grunau, RE; Kent, N; Kim, J; Misri, S; Oberlander, TF; Riggs, KW; Rurak, DW, 2006) |
| "The purpose of this study was to examine the relationship between the degree of anxiety or somatic symptoms present before treatment with the subsequent diagnosis of treatment-related adverse events (TRAEs) in patients with major depressive disorder (MDD) enrolled in an 8-week open trial of fluoxetine (20 mg)." | 3.72 | Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. ( Alpert, JE; Fava, M; Hughes, ME; Nierenberg, AA; Papakostas, GI; Petersen, T, 2004) |
| "One hundred and twenty-nine children, 2 to 8 years old, with idiopathic autistic spectrum disorder diagnosed by standard instruments (Childhood Austim Ratings Scale and Autism Diagnostic Observation Schedule) were treated with fluoxetine (0." | 3.71 | Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. ( Burch, S; DeLong, GR; Ritch, CR, 2002) |
| "Adolescent major depressive disorder (MDD) is associated with disrupted processing of emotional stimuli and difficulties in cognitive reappraisal." | 3.30 | Acute neural effects of fluoxetine on emotional regulation in depressed adolescents. ( Capitão, LP; Chapman, R; Cowen, PJ; Filippini, N; Harmer, CJ; James, A; Murphy, SE; Wright, L, 2023) |
| "Adolescent major depressive disorder (MDD) is a prevalent mental health problem with low treatment success rates." | 3.30 | Sequenced treatment alternatives to relieve adolescent depression (STAR-AD): a multicentre open-label randomized controlled trial protocol. ( Chen, F; Gan, X; He, Y; Huang, Y; Lei, T; Li, J; Li, X; Liu, R; Ouyang, X; Teng, T; Wang, T; Xie, Y; Zhou, X, 2023) |
| "Adults with major depressive disorder (MDD) often experience reduced quality of life (QOL)." | 3.01 | Quality of life after response to acute-phase cognitive therapy for recurrent depression. ( Jarrett, RB; Jha, MK; Minhajuddin, A; Thase, ME; Vittengl, JR, 2021) |
| "Effective treatment of depression is a key target for suicide prevention strategies." | 3.01 | Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people. ( Berk, M; Chanen, A; Cotton, S; Davey, CG; Dean, O; Hetrick, S; Madsen, T; McGorry, PD; Witt, K, 2021) |
| "fluoxetine in the treatment of postmenopausal MDD." | 3.01 | Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study. ( Boyce, P; Chen, R; Feng, L; Hu, Y; Shi, H; Wang, G; Wang, X; Xiao, L; Yang, R; Zhou, J; Zhu, X, 2021) |
| "Treatment with fluoxetine over 8 weeks led to reductions in cognitive distortions, with decreased negative and increased positive affect in adolescents with MDD." | 2.90 | Changes in cognitive distortions and affectivity levels in adolescent depression after acute phase fluoxetine treatment. ( Stevanovic, D; Zalsman, G, 2019) |
| " This will be the first clinical attempt of the intravenous administration of ATP and PCr combined with orally administered fluoxetine in MDD." | 2.90 | Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study. ( Cao, X; Chen, Y; Gao, T; Ou, CQ; Shen, X; Tan, S; Zang, W; Zhao, L, 2019) |
| "Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear." | 2.90 | The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. ( Amminger, GP; Berk, M; Catania, L; Chanen, AM; Cotton, SM; Davey, CG; Dean, OM; Harrison, BJ; Hetrick, SE; Kazantzis, N; Kerr, M; Koutsogiannis, J; McGorry, PD; Mullen, E; Parker, AG; Phelan, M; Quinn, AL; Ratheesh, A; Rice, S; Weller, A, 2019) |
| "Fluoxetine treatment was associated with an improvement in depressive symptomology and HRQOL." | 2.84 | Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine. ( Lin, CH; Lu, MJ; Wang, FC; Yang, WC, 2017) |
| "Thirty adults with major depressive disorder received 8 weeks of fluoxetine 20-40 mgs and were randomized to 8h TIB or 6h TIB for the first 2 weeks." | 2.84 | Relationships between circadian measures, depression, and response to antidepressant treatment: A preliminary investigation. ( Armitage, R; Bertram, H; Burgess, HJ; Dopp, R; Hoffmann, R; Huntley, ED; Mooney, A; Swanson, LM; Todd Arnedt, J; Zollars, J, 2017) |
| "However, the presence of recurrent major depressive disorder and multiple psychiatric comorbidities is associated with poorer functioning trajectories, offering targets for maintenance treatment or secondary prevention." | 2.82 | Trajectories of Functioning Into Emerging Adulthood Following Treatment for Adolescent Depression. ( Albano, AM; Curry, JF; Feldhaus, C; Henry, DB; Jacobs, RH; Langenecker, SA; Peters, AT; Reinecke, MA; Silva, SG, 2016) |
| "To prevent recurrence (i." | 2.82 | Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care. ( Clark, LA; Jarrett, RB; Minhajuddin, A; Thase, ME; Vittengl, JR, 2016) |
| "The crocin group (n=20) was given one selective serotonin reuptake inhibitor (SSRI) drug (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day) plus crocin tablets (30mg/day; 15mg BID) and placebo group (n=20) was administered one SSRI (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day) plus placebo (two placebo tablets per day) for 4 weeks." | 2.80 | Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. ( Hassanpour Moghadam, M; Mohajeri, SA; Sajadi Tabassi, SA; Talaei, A, 2015) |
| "Fluoxetine was not different from placebo in Greene Climacteric Scale." | 2.80 | Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial. ( Aguilar-Faisal, L; Asbun-Bojalil, J; Llanes-González, L; Macías-Cortés, Edel C, 2015) |
| "Most adults with Major Depressive Disorder (MDD) will not experience a remission with the first antidepressant trial." | 2.80 | A rest-activity biomarker to predict response to SSRIs in major depressive disorder. ( McCall, WV, 2015) |
| "Simvastatin-treated patients experienced significantly more reductions in HDRS scores compared to the placebo group by the end of the trial (p=0." | 2.80 | Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. ( Akhondzadeh, S; Farokhnia, M; Gougol, A; Iranpour, N; Raheb, S; Salimi, S; Yekehtaz, H; Zareh-Mohammadi, N, 2015) |
| " Safety measures included treatment-emergent adverse events (TEAEs), the Columbia-Suicide Severity Rating Scale, vital signs, electrocardiograms, laboratory samples, and growth (height and weight) assessments." | 2.80 | Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder. ( Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Wells, TG; Zhang, Q, 2015) |
| "After patients with major depressive disorder (MDD) respond to acute-phase cognitive therapy (CT), continuation-phase treatments may be applied to improve long-term outcomes." | 2.80 | Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder. ( Clark, LA; Jarrett, RB; Thase, ME; Vittengl, JR, 2015) |
| " Both the antidepressants were found to be safe and well tolerated." | 2.80 | Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine. ( Bhatia, MS; Ghosh, R; Gupta, LK; Gupta, R; Tripathi, AK, 2015) |
| "Youth (aged 8-17 years) with major depressive disorder (MDD) were treated with fluoxetine for 6 weeks." | 2.80 | Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder. ( Emslie, GJ; Foxwell, AA; Jones, JM; Kennard, BD; King, J; Mayes, TL; Moore, J; Nakonezny, PA, 2015) |
| " This study provides first clinical evidence that curcumin may be used as an effective and safe modality for treatment in patients with MDD without concurrent suicidal ideation or other psychotic disorders." | 2.79 | Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. ( Goel, A; Panchal, B; Patel, T; Sanmukhani, J; Satodia, V; Tiwari, D; Tripathi, CB; Trivedi, J, 2014) |
| " Tolerability and safety evaluations were based on emergent adverse events." | 2.79 | Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder. ( Crutel, VS; Fones Soon Leng, C; Huang, YS; Kim, YS; Shu, L; Sulaiman, AH, 2014) |
| "Fluoxetine (FLX) has been one of the most widely studied selective serotonin reuptake inhibitors in adolescents." | 2.79 | Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. ( Arnaiz, JA; Blázquez, A; Gassó, P; Lafuente, A; Lázaro, L; Mas, S; Méndez, I; Plana, MT; Torra, M, 2014) |
| " There were no significant differences between patients treated with OFC and fluoxetine in extrapyramidal symptoms or serious adverse events." | 2.79 | Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. ( Brunner, E; Landry, J; Osuntokun, O; Thase, ME; Tohen, M, 2014) |
| " Measures included: Children's Depression Rating Scale-Revised (CDRS-R), treatment-emergent adverse events (TEAEs), and Columbia-Suicide Severity Rating Scale (C-SSRS)." | 2.79 | A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. ( Atkinson, SD; Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Zhang, Q, 2014) |
| " Measures included: Children's Depression Rating Scale-Revised (CDRS-R), treatment-emergent adverse events (TEAEs), and Columbia-Suicide Severity Rating Scale (C-SSRS)." | 2.79 | A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. ( Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Zhang, Q, 2014) |
| "One hundred and three patients of major depressive disorders were observed." | 2.79 | Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period. ( Gu, S; Guo, J; Luo, H; Qu, W; Tang, Q, 2014) |
| "Though encouraging evidence exists for the use of folic acid as an augmenting agent to antidepressants, evidence regarding its optimal dosage is lacking." | 2.78 | A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes. ( Kumar, CN; Pandey, RS; Venkatasubramanian, R, 2013) |
| "Adult outpatients with recurrent major depressive disorder were randomly assigned to receive venlafaxine extended release (ER; 75-300 mg/day) or fluoxetine (20-60 mg/day)." | 2.78 | Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study. ( Dorries, KM; Dunner, DL; Gelenberg, AJ; Ninan, PT; Pedersen, R; Rothschild, AJ, 2013) |
| "Patients suffering from major depressive disorder (MDD) have been reported to have substantial long-lasting limitations in multiple domains of health-related quality of life (HRQoL)." | 2.78 | Health-related quality of life and symptom severity in Chinese patients with major depressive disorder. ( Cao, Y; Li, W; Luo, X; Malison, RT; Shen, J; Zhang, Y, 2013) |
| "A total of 523 adults with recurrent major depressive disorder began acute phase CT, of which 241 higher-risk responders were randomized and 181 subsequently entered the follow-up." | 2.78 | Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo. ( Friedman, ES; Gershenfeld, H; Jarrett, RB; Minhajuddin, A; Thase, ME, 2013) |
| "Twenty-one patients with major depressive disorder and without other Axis I or Axis II diagnoses were scanned before treatment and 2 and 6 months into treatment at the university's functional magnetic resonance imaging facility." | 2.78 | Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months. ( Davidson, RJ; Heller, AS; Johnstone, T; Kalin, NH; Kolden, GG; Peterson, MJ, 2013) |
| " High inter-individual variability in serum concentrations of the active moiety of FLX at each dosage level was observed and no relationship between serum concentration and clinical outcome was found." | 2.77 | Therapeutic drug monitoring of children and adolescents treated with fluoxetine. ( Burger, R; Egberts, K; Fegert, JM; Gerlach, M; Kliegl, K; Koelch, M; Ludolph, AG; Mehler-Wex, C; Pfalzer, AK; Rothenhöfer, S; Stingl, J; Taurines, R, 2012) |
| "There are limited data on the impact of insomnia in response to acute treatment, which is particularly relevant with serotonin-selective reuptake inhibitors, given their tendency to worsen sleep architecture." | 2.77 | Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth. ( Croarkin, P; Emslie, GJ; Hughes, C; Kennard, BD; Mayes, TL; Nakonezny, PA; Tao, R; Zhu, L, 2012) |
| "Fluoxetine treatment decreased activations in all three regions, as compared with the repeat scans of healthy comparison subjects." | 2.77 | Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. ( Calley, CS; Emslie, GJ; Hart, J; Kennard, BD; Lu, H; Mayes, TL; Nakonezny, PA; Tamminga, CA; Tao, R, 2012) |
| "Eighty-nine adults with Major Depressive Disorder (MDD), characterized as antidepressant-experienced or antidepressant-naive, received one week of single-blind placebo treatment prior to eight weeks of randomized treatment with medication (fluoxetine or venlafaxine; n = 47) or placebo (n = 42) in one of three similar placebo-controlled trials." | 2.77 | Does prior antidepressant treatment of major depression impact brain function during current treatment? ( Cook, IA; Hunter, AM; Leuchter, AF, 2012) |
| "35 patients with DSM IV-defined major depressive disorder of mild or moderate severity were randomized to receive either short-term psychodynamic psychotherapy or fluoxetine treatment for 16 weeks." | 2.76 | Personality traits and recovery from major depressive disorder. ( Hietala, J; Kajander, J; Karlsson, H; Kronström, K; Markkula, J; Rasi-Hakala, H; Salminen, JK; Vahlberg, T, 2011) |
| "Sex predicted recurrence (57." | 2.76 | Recovery and recurrence following treatment for adolescent major depression. ( Albano, AM; Becker-Weidman, E; Burns, B; Curry, J; Emslie, G; Feeny, N; Ginsburg, G; Jacobs, R; Kastelic, E; Kennard, B; Kirchner, J; Kratochvil, C; Lavanier, S; March, J; May, D; Mayes, T; Reinecke, M; Rohde, P; Silva, S; Simons, A; Walkup, J; Weller, E; Wells, K, 2011) |
| "Patients with major depressive disorder (MDD) and significant anxiety are less responsive to antidepressants than those without anxiety." | 2.76 | A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. ( Fava, M; Huang, H; Iosifescu, DV; Mischoulon, D; Schaefer, K; Wessel, TC; Wilson, A, 2011) |
| "Many patients with major depressive disorder (MDD) who achieve full remission after antidepressant treatment still have residual depressive symptoms." | 2.76 | Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. ( Baer, L; Clain, A; Iovieno, N; Nierenberg, AA; van Nieuwenhuizen, A, 2011) |
| "In treatment trials for major depressive disorder (MDD), early symptom improvement is predictive of eventual clinical response." | 2.76 | Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder. ( Cook, IA; Hunter, AM; Korb, AS; Leuchter, AF, 2011) |
| "Adolescent major depressive disorder (MDD) is a life-threatening brain disease with limited interventions." | 2.76 | Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. ( Fiedler, KK; Hellem, TL; Jeong, EK; Kondo, DG; Renshaw, PF; Shi, X; Sung, YH, 2011) |
| "The goal of treating major depressive disorder is to achieve remission." | 2.76 | Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. ( Chen, CC; Juo, SH; Lane, HY; Lin, CH; Yen, CF, 2011) |
| " Blood samples were collected for pharmacokinetic analysis of ADTs." | 2.75 | The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. ( Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K, 2010) |
| "Relapse of major depressive disorder (MDD) is a common clinical problem." | 2.75 | Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. ( Baer, L; Chen, Y; Chuzi, S; Clain, A; Fava, M; Johnson, D; McGrath, PJ; Papakostas, GI; Sinicropi-Yao, L; Stewart, JW; Yang, H, 2010) |
| "Individuals with Major Depressive Disorder (MDD) vary regarding the rate, magnitude and stability of symptom changes during antidepressant treatment." | 2.75 | Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. ( Cook, IA; Hunter, AM; Leuchter, AF; Muthén, BO, 2010) |
| "Sixty-nine patients diagnosed with major depressive disorder (MDD) according to DSM-IV and 36 healthy controls are included in the study." | 2.75 | Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis. ( Başterzi, AD; Buturak, V; Cimen, B; Eskandari, G; Taşdelen, B; Tot Acar, S; Yazici, A; Yazici, K, 2010) |
| "Personality disorders are neither particularly stable nor treatment resistant." | 2.75 | Personality disorders improve in patients treated for major depression. ( Frampton, CM; Joyce, PR; Mulder, RT, 2010) |
| "Anxious depression, defined as major depressive disorder (MDD) accompanied by high levels of anxiety, seems to be both common and difficult to treat, with antidepressant monotherapy often yielding modest results." | 2.75 | Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. ( Ameral, VE; Baer, L; Brintz, C; Clain, A; Fava, M; Glaudin, V; Londborg, PD; Painter, JR; Papakostas, GI; Smith, WT, 2010) |
| "Patients with major depressive disorder (MDD) took fluoxetine (20 mg/day) for 6 weeks." | 2.75 | Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. ( Feng, XL; Hu, J; Li, HC; Li, KQ; Li, M; Liu, P; Liu, Y; Liu, ZC; Tao, M; Wang, BY; Wang, Y; Wei, J; Xu, XP; Ye, DQ; Yu, X; Zang, TH; Zhang, KR; Zou, YF, 2010) |
| "Seventy-two major depressive disorder (MDD) subjects were treated with fluoxetine 20 mg (n = 13), venlafaxine 150 mg (n = 24), or placebo (n = 35) under double-blind conditions." | 2.75 | Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment. ( Abrams, M; Cook, IA; Hunter, AM; Leuchter, AF, 2010) |
| "A link between insomnia and suicide has not been previously examined in the setting of a clinical trial." | 2.75 | Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. ( Blocker, JN; Boggs, N; D'Agostino, R; Kimball, J; Lasater, B; McCall, WV; Rosenquist, PB, 2010) |
| "60 depressed, insomniac outpatients." | 2.75 | Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. ( Blocker, JN; Boggs, N; D'Agostino, R; Haskett, R; Kimball, J; Krystal, A; Lasater, B; McCall, WV; McDonald, WM; Rosenquist, PB, 2010) |
| "Adolescents with major depressive disorder (N=439) were randomly assigned to receive an initial 12 weeks of treatment with fluoxetine, cognitive-behavioral therapy (CBT), combination treatment with fluoxetine and CBT, or clinical management with placebo; those assigned to placebo received open active treatment as clinically indicated after 12 weeks of placebo." | 2.74 | Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. ( Curry, JF; Emslie, GJ; Hughes, JL; Kennard, BD; Kratochvil, CJ; March, JS; Mayes, TL; Reinecke, MA; Rohde, P; Silva, SG; Vitiello, B, 2009) |
| "The authors sought to identify predictors of self-harm adverse events in treatment-resistant, depressed adolescents during the first 12 weeks of treatment." | 2.74 | Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. ( Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009) |
| "Fluoxetine was well tolerated in this treatment population." | 2.74 | Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. ( Bukstein, OG; Clark, DB; Cornelius, JR; Douaihy, A; Kirisci, L; Wood, DS, 2009) |
| "95 outpatients with major depressive disorder were treated for 6 weeks with EA, fluoxetine or placebo." | 2.74 | Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. ( Halbreich, U; Han, C; Leonard, BE; Luo, H; Song, C, 2009) |
| "Fifty-one patients with major depressive disorder (DSM-IV) of mild or moderate severity were recruited through occupational health services providing primary health care." | 2.73 | Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study. ( Aalto, S; Hietala, J; Kajander, J; Karlsson, H; Markkula, J; Rasi-Hakala, H; Salminen, JK; Toikka, T, 2008) |
| " Quetiapine was flexibly dosed starting at 25 mg to a maximum of 100 mg daily." | 2.73 | A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. ( Fava, M; Garakani, A; Hirschowitz, J; Marcus, S; Martinez, JM; Rickels, K; Weaver, J, 2008) |
| " Adverse effects and other clinical features associated with the emergence of suicidality, defined using item 3 of the Hamilton Depression Rating Scale, were examined using Cox regression models." | 2.73 | Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. ( Amsterdam, J; Beasley, CM; Cusin, C; Fava, M; Perlis, RH; Quitkin, F; Rosenbaum, JF; Shear, D; Strong, RE; Tamura, RN; Wines, JD, 2007) |
| "Melatonin rhythms were similar between depressed patients and matched healthy controls." | 2.73 | Effect of fluoxetine on circadian rhythm of melatonin in patients with major depressive disorder. ( Bao, AM; Liu, YJ; Tan, ZL; Zhao, GQ; Zhou, JN, 2007) |
| "Insomnia and major depressive disorder (MDD) may coexist." | 2.73 | Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. ( Caron, J; Fava, M; Krystal, A; McCall, WV; Roth, T; Rubens, R; Wessel, T; Wilson, P, 2007) |
| "Sixty outpatients with a diagnosis of major depressive disorder based on DSM-IV criteria and a score >or=15 in the 17-item Hamilton Depression Rating Scale (HDRS) were randomly allocated to receive daily either 1000 mg EPA or 20 mg fluoxetine, or their combination for 8 weeks." | 2.73 | Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. ( Amini, H; Djazayery, A; Hosseini, M; Jalali, M; Jazayeri, S; Keshavarz, SA; Peet, M; Tehrani-Doost, M, 2008) |
| "Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT." | 2.73 | The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. ( Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH, 2008) |
| "Major depressive disorders have a significant impact on children and adolescents, including on educational and vocational outcomes, interpersonal relationships, and physical and mental health and well-being." | 2.72 | New generation antidepressants for depression in children and adolescents: a network meta-analysis. ( Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V, 2021) |
| "Patients with major depressive disorder or dysthymic disorder achieved similar clinical improvement in both treatment groups (mean MADRS ratings decrease in major depressive disorder from baseline to 6 months of 18." | 2.72 | Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine. ( Caramés, E; Gabarron, E; Garcia-Bayo, I; Haro, JM; Peñarrubia-Maria, MT; Pinto-Meza, A; Serrano-Blanco, A; Soler-Vila, M, 2006) |
| "Risk factors such as borderline personality disorder and childhood abuse experiences were systematically assessed, and patients were genotyped for polymorphisms of GNbeta3." | 2.72 | Genetic, developmental and personality correlates of self-mutilation in depressed patients. ( Joyce, PR; Kennedy, MA; Luty, SE; McKenzie, JM; Miller, AL; Mulder, RT; Sullivan, PF, 2006) |
| "Unawareness of impairment (anosognosia) is a phenomenon associated with right hemisphere lesions." | 2.72 | Response of emotional unawareness after stroke to antidepressant treatment. ( Bria, P; Caltagirone, C; Ripa, A; Robinson, RG; Spalletta, G, 2006) |
| "Treatment with fluoxetine is less likely to lead to remission of MDD in patients with stable PDs." | 2.72 | Problem-solving ability and comorbid personality disorders in depressed outpatients. ( Farabaugh, A; Fava, M; Harley, R; Papakostas, GI; Petersen, T; Scalia, M, 2006) |
| "Hyperprolactinemia was defined as a serum prolactin level greater than 16." | 2.72 | Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. ( Fava, M; Hilliker, SE; Klibanski, A; Miller, KK; Papakostas, GI; Petersen, T; Sklarsky, KG, 2006) |
| "Five hundred seventy persons with major depressive disorder were treated with fluoxetine for 12 weeks and their pattern of response was determined." | 2.72 | Predictors of relapse in a prospective study of fluoxetine treatment of major depression. ( Alpert, JE; Chen, Y; Cheng, J; Fava, M; McGrath, PJ; Nierenberg, AA; Petkova, E; Quitkin, FM; Stewart, JW, 2006) |
| "Fluoxetine was superior to CBT on the CGAS (p < ." | 2.72 | Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). ( Casat, C; Kratochvil, C; March, J; Pathak, S; Reinecke, M; Robins, M; Rohde, P; Silva, S; Simons, A; Vitiello, B; Walkup, J; Waslick, B; Weller, E; Wells, K, 2006) |
| "Safety assessments included adverse events (AEs) collected by spontaneous report, as well as systematic measures for specific physical and psychiatric symptoms." | 2.72 | Treatment for Adolescents with Depression Study (TADS): safety results. ( Casat, C; Emslie, G; Kratochvil, C; March, J; Mayes, T; McNulty, S; Pathak, S; Posner, K; Rohde, P; Silva, S; Vitiello, B; Walkup, J; Waslick, B; Weller, E, 2006) |
| "Up to 50% of patients with major depressive disorder (MDD) fail to respond to an antidepressant trial, with most taking a selective serotonin reuptake inhibitor (SSRI) as an initial treatment." | 2.71 | Switching to bupropion in fluoxetine-resistant major depressive disorder. ( Fava, M; Mahal, Y; McGrath, P; Papakostas, GI; Petersen, T; Quitkin, F; Stewart, J, 2003) |
| " Safety was evaluated by recording spontaneously reported adverse events." | 2.71 | Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. ( Fava, M; McGrath, PJ; Sheu, WP, 2003) |
| "Discontinuation syndrome is associated with a rostral anterior cingulate Cho/Cre metabolite ratio decrease that may reflect dynamics of rostral anterior cingulate function." | 2.71 | Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. ( Cohen, BM; Frederick, Bd; Hennen, J; Henry, ME; Kaufman, MJ; Renshaw, PF; Schmidt, ME; Stoddard, EP; Villafuerte, RA, 2003) |
| "Fluoxetine was associated with some adverse events in 46." | 2.71 | Fluoxetine once every third day in the treatment of major depressive disorder. ( Onder, E; Tural, U, 2003) |
| "Forty-two outpatients with DSM-IV major depressive disorder who had an insufficient response to an adequate trial of an SSRI (fluoxetine, paroxetine, or sertraline) were randomly assigned to pindolol, 2." | 2.71 | Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. ( Anand, A; Berman, RM; Charney, DS; Lynch-Colonese, K; Perry, EB; Sanacora, G, 2004) |
| "The yohimbine dose was titrated based on blood pressure changes over the treatment period, in a blind-preserving manner." | 2.71 | Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. ( Berman, RM; Cappiello, A; Charney, DS; Fasula, D; Gueorguieva, R; Kugaya, A; Liu, N; Oren, DA; Sanacora, G, 2004) |
| "Sixty nondiabetic patients with major depressive disorder (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) entered this randomized, double-blind study." | 2.71 | Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. ( Dashti-Khavidaki, S; Ghaeli, P; Kamkar, MZ; Mesbahi, M; Sadeghi, M; Shahsavand, E, 2004) |
| "Fifty-one subjects with major depressive disorder (MDD) were enrolled in a 1-week single blind placebo lead-in, followed by an 8-week, double-blind placebo-controlled treatment with either fluoxetine or venlafaxine." | 2.71 | Predictors of improved mood over time in clinical trials for major depression. ( Azen, SP; Chou, CP; James Gauderman, W; Leuchter, AF; Marie-Mitchell, A, 2004) |
| "Fluoxetine alone is a superior treatment to CBT alone (P =." | 2.71 | Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. ( Burns, B; Curry, J; Domino, M; Fairbank, J; March, J; McNulty, S; Petrycki, S; Severe, J; Silva, S; Vitiello, B; Wells, K, 2004) |
| "Reboxetine is a novel selective noradrenaline reuptake inhibitor." | 2.71 | Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression. ( Held, K; Kuenzel, HE; Murck, H; Steiger, A; Ziegenbein, M, 2004) |
| "Fluoxetine was not different from placebo." | 2.71 | Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. ( Alpert, J; Fava, M; Mannel, M; Mischoulon, D; Murck, H; Nierenberg, AA; Otto, MW; Rosenbaum, JF; Zajecka, J, 2005) |
| "The incidence of treatment-emergent nausea during 6-month continuation of duloxetine treatment (80 mg/d, 2." | 2.71 | Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. ( Greist, J; Mallinckrodt, CH; McNamara, RK; Raskin, J; Rayamajhi, JN, 2004) |
| "Fluoxetine-treated patients gained statistically significantly less height (fluoxetine: 1." | 2.71 | Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. ( Brown, EB; Heiligenstein, JH; Joliat, MJ; Miner, CM; Nilsson, M, 2004) |
| "Phenytoin was the first non-sedative anticonvulsant introduced and is still the anticonvulsant most widely used worldwide in neurology." | 2.71 | Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. ( Belmaker, RH; Bersudsky, Y; Nemets, B, 2005) |
| " All adverse events which developed during the study period were recorded." | 2.71 | Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. ( Chee, IS; Choe, BM; Ham, BJ; Jung, HY; Kee, BS; Kim, JB; Lee, C; Lee, MS; Oh, BH; Oh, KS; Paik, IH; Yeon, BK, 2005) |
| "Treatment with olanzapine may impact a patient's weight; thus, long-term weight gain and potential predictors (e." | 2.71 | Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005) |
| "We identified 101 outpatients with major depressive disorder (52 men and 49 women; mean age, 41." | 2.70 | Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. ( Alpert, J; Baer, L; Fava, M; Lagomasino, I; Nierenberg, A; Rosenbaum, JF; Sonawalla, S; Tedlow, J; Worthington, J, 2002) |
| "Patients with major depressive disorder remain at risk for relapse following remission and often continue to experience subthreshold symptoms." | 2.70 | Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. ( Alpert, JE; Buchin, J; Fava, M; Matthews, JD; Nierenberg, AA; Pava, J; Perlis, RH; Sickinger, AH, 2002) |
| "Patients (N = 284) with DSM-IV major depressive disorder were randomly assigned in a double-blind fashion to fluoxetine, paroxetine, or sertraline for 10 to 16 weeks of treatment." | 2.70 | Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. ( Fava, M; Gonzales, JS; Hoog, SL; Judge, RA; Kopp, JB; Nilsson, ME, 2002) |
| " This raises the important question of whether once-weekly enteric-coated fluoxetine, 90 mg, is effective for maintenance of response in patients whose depressive symptoms have responded to daily dosing with selective serotonin reuptake inhibitors (SSRIs) such as citalopram, paroxetine, or sertraline." | 2.70 | Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. ( Brown, EB; Gonzales, JS; Miner, CM; Munir, R, 2002) |
| "Paroxetine appears to produce an earlier improvement in agitation and psychic anxiety symptoms compared with fluoxetine." | 2.69 | A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. ( Bakish, D; Beauclair, L; Bélanger, MC; Chouinard, G; Manchanda, R; Morris, P; O'Neill, MC; Ravindran, A; Reesal, R; Remick, R; Saxena, B; Vasavan Nair, NP, 1999) |
| "Relapse was defined as a 50% increase in HDRS with total < or = 17." | 2.69 | Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. ( Charney, DS; Delgado, PL; Heninger, GR; Krystal, JH; Licinio, J; Miller, HL; Moreno, FA; Salomon, RM, 1999) |
| " No cases of serotonin syndrome occurred, and the combination was well tolerated, although the 4 g per day dosage of tryptophan produced daytime drowsiness." | 2.69 | Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. ( Driver, HS; Jindal, R; Kennedy, SH; Levitan, RD; Shapiro, CM; Shen, JH, 2000) |
| " The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder." | 2.53 | Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. ( Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016) |
| "Major depressive disorder is one of the most common mental disorders in children and adolescents." | 2.53 | Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. ( Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X, 2016) |
| " In this article, we report the evidence that contributed to the implementation of pharmacokinetic pharmacogenetic guidelines for antidepressants primarily metabolized by CYP2D6 and CYP2C19." | 2.53 | Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. ( Black, JL; Elliott, MA; Frye, MA; Nassan, M; Nicholson, WT; Rohrer Vitek, CR, 2016) |
| "At any one time, major depressive disorder (MDD) affects 4 - 6% of adolescents." | 2.46 | Pharmacotherapy of major depressive disorder in adolescents. ( Brovedani, P; Liboni, F; Masi, G, 2010) |
| "Mirtazapine-treated patients had a 74% higher likelihood of achieving remission during the first 2 weeks of therapy compared with patients treated with SSRIs." | 2.46 | Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. ( Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P, 2010) |
| " A secondary analysis of dose-response relationships indicated that this advantage was not attributable to the studies using higher doses of duloxetine." | 2.44 | Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. ( Detke, MJ; Ossanna, MJ; Pritchett, YL; Swindle, RW; Thase, ME; Xu, J, 2007) |
| "Fluoxetine treatment did not result in greater worsening but was associated with greater improvement and faster resolution of ideation (P < or = 0." | 2.44 | Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials. ( Acharya, N; Ball, SG; Beasley, CM; Nilsson, ME; Plewes, J; Polzer, J; Tauscher-Wisniewski, S, 2007) |
| "Major depressive disorder is a common, chronic, recurring, and disabling illness in children and adolescents." | 2.43 | Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. ( Emslie, GJ; Ryan, ND; Wagner, KD, 2005) |
| "Adolescents with major depressive disorder (MDD), their families and clinicians experience significant challenges when weighing the potential risks versus benefits of available choices in the treatment of MDD." | 2.43 | Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study. ( Kratochvil, CJ; March, JS; Pathak, S; Rogers, GM; Silva, S; Vitiello, B; Weller, EB, 2005) |
| "Sixteen trials studied patients with major depressive disorder, and the remaining 8 studied obsessive-compulsive disorder (n = 4), generalized anxiety disorder (n = 2), attention-deficit/hyperactivity disorder (n = 1), and social anxiety disorder (n = 1)." | 2.43 | Suicidality in pediatric patients treated with antidepressant drugs. ( Hammad, TA; Laughren, T; Racoosin, J, 2006) |
| "Fluoxetine was not statistically different in either tolerability or efficacy when compared with duloxetine." | 2.43 | Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. ( Eckert, L; Lançon, C, 2006) |
| "The patient also had untreated Polycystic Ovarian Syndrome (PCOS)." | 2.41 | Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. ( Bauer, M; Carter, MS; Elman, S; Korenman, SG; Love, M; Rasgon, NL, 2002) |
| " The rate of discontinuation due to adverse effects with reboxetine was not significantly different from that observed with placebo in short-term studies." | 2.41 | Reboxetine: tolerability and safety profile in patients with major depression. ( Tanum, L, 2000) |
| " It is also suggested that positron emission tomography may be used to define therapeutic dosing early on in the process of clinical evaluation of new treatment strategies." | 2.41 | Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies. ( Broft, A; Laruelle, M; Martinez, D, 2000) |
| " Spontaneously reported treatment-emergent adverse events, reasons for discontinuation, and events leading to discontinuation were compared between groups." | 2.41 | Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. ( Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000) |
| "Pharmacotherapy for major depressive disorder (MDD) typically consists of trial-and-error and clinician preference approaches, where patients often fail one or more antidepressants before finding an optimal regimen." | 1.91 | Case Report: Performing a Medication Safety Review Assisted by Pharmacogenomics to Explain a Prescribing Cascade Resulting in a Patient Fall. ( Amin, NS; Arwood, MJ; Cambridge, MD; Michaud, V; Russell, J; Toro-Pagán, NMD; Turgeon, J, 2023) |
| "Antidepressants are the first-line treatment for major depressive disorder, but if patients don't respond adequately, brain stimulation therapy may be needed as second-line treatment." | 1.91 | Right-side frontal-central cortical hyperactivation before the treatment predicts outcomes of antidepressant and electroconvulsive therapy responsivity in major depressive disorder. ( Lin, CH; Tsai, HJ; Tsai, SJ; Yang, AC; Yang, WC, 2023) |
| "Fluoxetine (Flx) has been widely used to treat MDD, but its mechanisms of action remain elusive." | 1.91 | Chronic fluoxetine treatment in socially-isolated rats modulates the prefrontal cortex synaptoproteome. ( Bernardi, RE; Filipović, D; Novak, B; Turck, CW; Xiao, J; Yan, Y, 2023) |
| "Our study included 101 patients with major depressive disorder and alcohol use disorder (average age: 41." | 1.62 | Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders. ( Bryun, EA; Grishina, EA; Pankratenko, EP; Petukhov, AE; Ryzhikova, KA; Shipitsyn, VV; Skryabin, VY; Sychev, DA; Torrado, MV; Zastrozhin, MS, 2021) |
| "Fluoxetine was continued for a total of 12 weeks." | 1.62 | Higher dose weekly fluoxetine in hemodialysis patients: A case series report. ( Dolata, J; Figueroa, M; Gunzler, D; Huml, A; Kauffman, KM; Pencak, J; Sajatovic, M; Sehgal, AR, 2021) |
| "The synaptogenic hypothesis of major depressive disorder implies that preventing the onset of depressive-like behavior also prevents the loss of hippocampal spine synapses." | 1.62 | Stress Resilience is Associated with Hippocampal Synaptoprotection in the Female Rat Learned Helplessness Paradigm. ( Baka, J; Csakvari, E; Dobos, N; Duman, RS; Farkas, T; Hajszan, T; Huzian, O; Leranth, C; Siklos, L, 2021) |
| "Rates of major depressive disorder (MDD) increase with living at altitude." | 1.62 | Sex-Based Impact of Creatine Supplementation on Depressive Symptoms, Brain Serotonin and SSRI Efficacy in an Animal Model of Treatment-Resistant Depression. ( Brown, J; Ettaro, R; Hoffman, MD; Kanekar, S; Lynch, C; Ombach, HJ; Renshaw, PF; Sheth, CS, 2021) |
| "placebo in adolescents with major depressive disorder." | 1.56 | Neural effects of a single dose of fluoxetine on resting-state functional connectivity in adolescent depression. ( Capitão, LP; Chapman, R; Cowen, PJ; Filippini, N; Harmer, CJ; James, A; Murphy, SE; Wright, L, 2020) |
| "The etiology of major depressive disorder (MDD), the leading cause of worldwide disability, is unknown." | 1.51 | Activating newborn neurons suppresses depression and anxiety-like behaviors. ( Contractor, A; Dunlop, SR; Kessler, JA; Peng, CY; Tunc-Ozcan, E; Zhu, Y, 2019) |
| "The prevalence of juvenile major depressive disorder has resulted in a parallel increase in the prescription rates of fluoxetine (FLX) within this age group." | 1.51 | Adolescent fluoxetine history impairs spatial memory in adult male, but not female, C57BL/6 mice. ( Alipio, JB; Castillo, SA; Flores-Ramirez, FJ; Garcia-Carachure, I; Iñiguez, SD; Lira, O; Parise, LF; Preciado-Piña, J; Rodriguez, M; Themman, A, 2019) |
| "The burden of major depressive disorder includes suffering due to symptom severity, functional impairment, and quality of life deficits." | 1.48 | ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis. ( Chen, CC; Huang, CJ; Lin, CH, 2018) |
| "Vortioxetine is a novel antidepressant capable of improving depressive and cognitive symptoms associated with major depressive disorder (MDD)." | 1.48 | Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. ( Ho, CS; Ho, RC; Lu, Y; McIntyre, RS; Wang, W, 2018) |
| "Women with major depressive disorder during pregnancy often use selective serotonin reuptake inhibitors (SSRIs) antidepressants." | 1.46 | Prenatal fluoxetine modifies the behavioral and hormonal responses to stress in male mice: role for glucocorticoid insensitivity. ( Avitsur, R, 2017) |
| " However, while the chronic administration of the SSRIs escitalopram or fluoxetine elicited a progressive increased in the firing rate of 5-HT neurons in 5-HT2A(+/+) mice, it failed to do so in 5-HT2A(-/-) mutants." | 1.43 | Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach. ( Becquemont, L; Colle, R; Corruble, E; Dahan, L; David, D; Gardier, AM; Guiard, BP; Guilloux, JP; Nguyen, HT; Petit, AC; Qesseveur, G; Robert, P; Rotenberg, S; Seif, I; Verstuyft, C, 2016) |
| "(DSM-IV) criteria for major depressive disorder (MDD) or anxiety disorders participated in study." | 1.43 | The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders. ( Amitai, M; Apter, A; Carmel, M; Chen, A; Eilat, T; Fennig, S; Michaelovsky, E; Orpaz, N; Taler, M; Weizman, A; Yablonski, M, 2016) |
| "Adolescents with major depressive disorder (MDD) were found to have deficits in executive function, attention, and memory." | 1.43 | Neurocognitive Changes in Selective Serotonin Reuptake Inhibitors-Treated Adolescents with Depression. ( Brent, D; Maalouf, FT; Shehab, AA, 2016) |
| "Only 30% of major depressive disorder (MDD) patients achieve complete remission with a serotonergic antidepressant (selective serotonin reuptake inhibitor)." | 1.43 | Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine. ( Manoharan, A; Muthuramalingam, A; Paul, A; Rajkumar, RP; Shewade, DG; Sundaram, R, 2016) |
| "Up to 30-40 % of the major depressive disorder patients do not respond sufficiently to antidepressant treatment." | 1.43 | Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients. ( Adithan, S; Manoharan, A; Rajkumar, RP; Shewade, DG, 2016) |
| " We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d." | 1.42 | Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. ( Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015) |
| " On the basis of these data, novel dosing strategies were developed for five antidepressants to mimic the pharmacological profile of the antidepressant with the longest half-life, fluoxetine." | 1.42 | The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression. ( Cao, YJ; Hendrix, CW; Kaplin, AI; Rahn, KA, 2015) |
| "Ketamine is an anesthetic with antidepressant properties." | 1.42 | The positive effect on ketamine as a priming adjuvant in antidepressant treatment. ( Dalla, C; Ferreira, C; Kokras, N; Melo, A; Pêgo, JM; Sousa, N; Ventura-Silva, AP, 2015) |
| "Fluoxetine treatment significantly reduced glucose stimulated insulin secretion (GSIS)." | 1.40 | Fluoxetine-induced pancreatic beta cell dysfunction: New insight into the benefits of folic acid in the treatment of depression. ( De Long, NE; Hardy, DB; Holloway, AC; Hyslop, JR; Raha, S, 2014) |
| "Treatment with fluoxetine/olanzapine demonstrated similar biomarkers of response to monotherapeutic strategies." | 1.39 | Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. ( Downar, J; Giacobbe, P; Kennedy, SH; Konarski, JZ; McIntyre, RS; Rizvi, SJ; Salomons, TV, 2013) |
| " Animal studies indicate that 5-HT1A receptor expression may be reduced by long-term administration of corticosterone." | 1.39 | Chronic effects of corticosterone on GIRK1-3 subunits and 5-HT1A receptor expression in rat brain and their reversal by concurrent fluoxetine treatment. ( Cortés, R; García del Caño, G; Mengod, G; Montaña, M; Saenz del Burgo, L; Sallés, J, 2013) |
| " Moderate to high dosing was the only significant associated factor for FSD (odds ratio = 4." | 1.38 | Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine. ( Asmidar, D; Guan, NC; Hod, R; Sidi, H, 2012) |
| "73) and moderate to high dosage of antidepressant (adjusted OR = 4." | 1.38 | Hypoactive sexual desire among depressed female patients treated with selective serotonin reuptake inhibitors: a comparison between escitalopram and fluoxetine. ( Asmidar, D; Guan, NC; Hod, R; Jaafar, NR; Sidi, H, 2012) |
| "Treatments (fluoxetine 10 mg/kg; NaCl 0." | 1.38 | Fluoxetine effect on aortic nitric oxide-dependent vasorelaxation in the unpredictable chronic mild stress model of depression in mice. ( Belzung, C; Camus, V; Freslon, JL; Isingrini, E; Machet, MC, 2012) |
| "Five patients in their first episode of major depressive disorder (MDD) on a single SSRI underwent [(123)I]5-I-A85380- SPECT neuroimaging prior to stopping their medication and again 6 weeks following medication cessation." | 1.36 | SSRI antidepressants do not confound single photon emission computed tomography (SPECT) imaging studies using the alpha4beta2 nicotinic acetylcholine receptor [123I]5-I-A85380 ligand: in vivo and in vitro evidence. ( Cavanagh, J; Dewar, D; Patterson, J; Pimlott, S; Wyper, D, 2010) |
| "Fluoxetine was the most commonly prescribed drug followed by TCAs." | 1.36 | Adherence to antidepressant therapy for major depressive patients in a psychiatric hospital in Thailand. ( Bertram, M; Burgess, P; Chaiyakunapruk, N; Prukkanone, B; Vos, T, 2010) |
| "Fluoxetine is the treatment of first choice." | 1.35 | [A place for SSRIs in the treatment of severely depressed children and adolescents]. ( Buitelaar, JK; Roobol, TH, 2008) |
| "A decision-tree model for the treatment of major depressive disorder was constructed using a Delphi panel." | 1.35 | Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. ( Burslem, K; Greenstreet, L; Knight, C; Lenox-Smith, A, 2009) |
| "All patients had a diagnosis of major depressive disorder as defined by DSM-III or DSM-IV criteria." | 1.35 | An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. ( Campbell, GM; Case, M; Corya, SA; Henley, DB; Osuntokun, O; Thase, ME; Trivedi, MH; Watson, SB, 2009) |
| "Seventy seven patients with major depressive disorder (MDD), divided into two groups were included in the study." | 1.35 | Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. ( Bieńkiewicz, M; Gałecka, E; Gałecki, P; Szemraj, J; Zboralski, K, 2009) |
| "Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine, paroxetine or citalopram." | 1.35 | 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. ( Huhtala, H; Illi, A; Kampman, O; Lehtimäki, T; Leinonen, E; Mononen, N; Poutanen, O; Setälä-Soikkeli, E; Viikki, M, 2009) |
| "Patients with major depressive disorder (DSM-IV) who showed favorable treatment response to venlafaxine (mean +/- SD dose = 116." | 1.35 | Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine. ( Chen, MC; Lane, HY; Lin, CH; Lin, CY; Lin, KS, 2008) |
| "The most common withdrawal symptoms among those with cannabis dependence were craving (82%), irritability (76%), restlessness (58%), anxiety (55%), and depression (52%)." | 1.35 | Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. ( Chung, T; Clark, DB; Cornelius, JR; Martin, C; Wood, DS, 2008) |
| "Salivary serotonin in patients with major depressive disorder showed clear circadian rhythm." | 1.34 | Circadian rhythm of salivary serotonin in patients with major depressive disorder. ( Bao, AM; Liu, YJ; Tan, ZL; Tao, M; Zhou, JN, 2007) |
| " In this study, we investigated plasma concentrations of norepinephrine, epinephrine and dopamine after acute and chronic administration of fluoxetine in depressive patients." | 1.33 | Plasma catecholamine levels after fluoxetine treatment in depressive patients. ( Auteri, A; Blardi, P; Castrogiovanni, P; de Lalla, A; Dell'Erba, A; Iapichino, S, 2005) |
| "Although adverse events are a key factor in compliance, their evolution during treatment with antidepressants is poorly documented." | 1.33 | What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? ( Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M, 2005) |
| "Patients with major depressive disorder showed pronounced psychomotor retardation in the visuomotor tasks." | 1.33 | [Psychomotor retardation in depression assessed by visuomotor tasks. Overview and achievements of ten years' research]. ( Hulstijn, W; Pier, MP; Sabbe, BG; van Hoof, JJ, 2006) |
| "Of 60 AIDS patients, 32 patients had received highly active antiretroviral therapy and received subsequent assessment of lymphocyte cell counts 1 month later." | 1.33 | Lymphocyte subsets and viral load in male AIDS patients with major depression: naturalistic study. ( Huang, TL; Leu, HS; Liu, JW, 2006) |
| "In addition, major depressive disorder (MDD) patients were found to have significantly higher plasma nitrate concentrations than normal subjects, an index of NO production, in comparison to normal subjects." | 1.32 | Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. ( Chen, TJ; Hong, CJ; Liou, YJ; Tsai, SJ; Wang, YC; Yu, YW, 2003) |
| " Treatment-emergent adverse effects were assessed at each study visit." | 1.32 | Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. ( Fava, M; Lamon-Fava, S; Lin, KM; Mischoulon, D; Perlis, RH; Rosenbaum, JF; Smoller, JW; Wan, YJ, 2003) |
| "For fluoxetine-treated patients, the odds ratio for completing therapy relative to tricyclic antidepressant-treated patients dropped from 3." | 1.31 | A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. ( Croghan, TW; McCombs, JS; Shi, L; Stimmel, GL, 2002) |
| " However, there is no data on the dosage of selective serotonin uptake inhibitors (SSRIs) required to maintain symptom resolution in women treated for major depression during pregnancy." | 1.31 | Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. ( Hostetter, A; Llewellyn, A; McLaughlin, E; Stowe, ZN; Strader, JR, 2000) |
| " Fluvoxamine brain elimination half-life (79 +/- 24 hours; n = 4) was significantly shorter than that of CF-norfluoxetine (382 +/- 48 hours; n = 2)." | 1.31 | Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ( Bolo, NR; Hodé, Y; Lainé, E; Macher, JP; Nédélec, JF; Wagner, G, 2000) |
| "A continuing challenge in the treatment of depression is how to determine whether an effective drug has been selected for a particular patient, given that individuals will respond to some antidepressants but not others." | 1.31 | Prefrontal changes and treatment response prediction in depression. ( Cook, IA; Leuchter, AF, 2001) |
| "Mood disorders are the leading causes of morbidity and mortality in children and adolescence." | 1.31 | Mood disorders in children and adolescents: psychopharmacological treatment. ( Emslie, GJ; Mayes, TL, 2001) |
| "Fluoxetine levels were also detectable in platelets, with a time variation similar to plasma values." | 1.31 | Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. ( Auteri, A; Blardi, P; Castrogiovanni, P; De Lalla, A; Dell'Erba, A; Di Muro, A; Iapichino, S; Leo, A, 2002) |
| "Patients meeting DSM-IV criteria for major depressive disorder (MDD) entered randomized, controlled medication trials." | 1.30 | Defense mechanisms and personality in depression. ( Blanco, C; Mullen, LS; Roose, SP; Vaughan, R; Vaughan, SC, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (3.15) | 18.2507 |
| 2000's | 320 (45.78) | 29.6817 |
| 2010's | 288 (41.20) | 24.3611 |
| 2020's | 69 (9.87) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 2 |
| Cai, G | 1 |
| Fang, F | 1 |
| Li, W | 4 |
| Fan, M | 1 |
| Lian, J | 1 |
| Qiu, Y | 1 |
| Xu, X | 1 |
| Lv, X | 1 |
| Li, Y | 3 |
| Zheng, R | 1 |
| Wang, Y | 6 |
| Zhang, G | 1 |
| Liu, Z | 2 |
| Huang, Z | 1 |
| Zhang, L | 1 |
| Zastrozhin, MS | 1 |
| Skryabin, VY | 1 |
| Petukhov, AE | 1 |
| Pankratenko, EP | 1 |
| Grishina, EA | 1 |
| Ryzhikova, KA | 1 |
| Torrado, MV | 1 |
| Shipitsyn, VV | 1 |
| Bryun, EA | 1 |
| Sychev, DA | 1 |
| Li, VW | 1 |
| Morton, E | 2 |
| Michalak, EE | 4 |
| Tam, EM | 4 |
| Levitt, AJ | 3 |
| Levitan, RD | 5 |
| Cheung, A | 3 |
| Morehouse, R | 4 |
| Ramasubbu, R | 4 |
| Yatham, LN | 4 |
| Lam, RW | 4 |
| García-García, ML | 1 |
| Tovilla-Zárate, CA | 1 |
| Villar-Soto, M | 1 |
| Juárez-Rojop, IE | 1 |
| González-Castro, TB | 1 |
| Genis-Mendoza, AD | 1 |
| Ramos-Méndez, MÁ | 1 |
| López-Nárvaez, ML | 1 |
| Saucedo-Osti, AS | 1 |
| Ruiz-Quiñones, JA | 1 |
| Martinez-Magaña, JJ | 1 |
| Ayyash, A | 1 |
| Holloway, AC | 2 |
| Findling, RL | 2 |
| DelBello, MP | 1 |
| Zuddas, A | 1 |
| Emslie, GJ | 24 |
| Ettrup, A | 1 |
| Petersen, ML | 1 |
| Schmidt, SN | 1 |
| Rosen, M | 1 |
| Fang, Y | 2 |
| Ding, X | 1 |
| Zhang, Y | 7 |
| Cai, L | 1 |
| Ge, Y | 1 |
| Ma, K | 1 |
| Xu, R | 1 |
| Li, S | 2 |
| Song, M | 1 |
| Zhu, H | 1 |
| Liu, J | 3 |
| Ding, J | 1 |
| Lu, M | 1 |
| Hu, G | 1 |
| Athreya, AP | 1 |
| Vande Voort, JL | 1 |
| Shekunov, J | 1 |
| Rackley, SJ | 1 |
| Leffler, JM | 1 |
| McKean, AJ | 1 |
| Romanowicz, M | 1 |
| Kennard, BD | 17 |
| Mayes, T | 9 |
| Trivedi, M | 2 |
| Wang, L | 1 |
| Weinshilboum, RM | 1 |
| Bobo, WV | 2 |
| Croarkin, PE | 5 |
| Teng, T | 2 |
| Zhang, Z | 1 |
| Yin, B | 1 |
| Guo, T | 1 |
| Wang, X | 5 |
| Hu, J | 3 |
| Ran, X | 1 |
| Dai, Q | 1 |
| Zhou, X | 3 |
| Liang, L | 1 |
| Wang, H | 2 |
| Hu, Y | 2 |
| Bian, H | 1 |
| Xiao, L | 2 |
| Wang, G | 3 |
| Capitão, LP | 3 |
| Chapman, R | 3 |
| Filippini, N | 2 |
| Wright, L | 2 |
| Murphy, SE | 4 |
| James, A | 3 |
| Cowen, PJ | 3 |
| Harmer, CJ | 3 |
| Hermanns, T | 1 |
| Graf-Boxhorn, S | 1 |
| Poeck, B | 1 |
| Strauss, R | 1 |
| Filipović, D | 4 |
| Novak, B | 2 |
| Xiao, J | 2 |
| Yan, Y | 3 |
| Yeoh, K | 1 |
| Turck, CW | 3 |
| Jang, DY | 1 |
| Yang, B | 1 |
| You, MJ | 1 |
| Rim, C | 1 |
| Kim, HJ | 1 |
| Sung, S | 1 |
| Kwon, MS | 1 |
| de Melo Martins, GM | 1 |
| Petersen, BD | 1 |
| Rübensam, G | 1 |
| da Silva, JMK | 1 |
| Gaspary, KV | 1 |
| Wiprich, MT | 1 |
| Altenhofen, S | 1 |
| Bonan, CD | 1 |
| Gaber, A | 1 |
| Alsanie, WF | 1 |
| Alhomrani, M | 1 |
| Alamri, AS | 1 |
| Alyami, H | 1 |
| Shakya, S | 1 |
| Habeeballah, H | 1 |
| Alkhatabi, HA | 1 |
| Felimban, RI | 1 |
| Alamri, A | 1 |
| Alhabeeb, AA | 1 |
| Raafat, BM | 1 |
| Refat, MS | 1 |
| Kishi, T | 1 |
| Ikuta, T | 1 |
| Sakuma, K | 1 |
| Okuya, M | 1 |
| Hatano, M | 1 |
| Matsuda, Y | 1 |
| Iwata, N | 1 |
| Park, DI | 1 |
| Horn, A | 1 |
| Golub, M | 1 |
| Tsujii, T | 1 |
| Sakurai, H | 1 |
| Takeuchi, H | 1 |
| Suzuki, T | 1 |
| Mimura, M | 1 |
| Uchida, H | 1 |
| Costina, V | 2 |
| Findeisen, P | 2 |
| Inta, D | 2 |
| Amada, N | 1 |
| Hirose, T | 1 |
| Suzuki, M | 1 |
| Kakumoto, Y | 1 |
| Futamura, T | 3 |
| Maeda, K | 1 |
| Kikuchi, T | 1 |
| Russell, J | 1 |
| Arwood, MJ | 1 |
| Toro-Pagán, NMD | 1 |
| Amin, NS | 1 |
| Cambridge, MD | 1 |
| Turgeon, J | 1 |
| Michaud, V | 1 |
| Nichols, AL | 1 |
| Blumenfeld, Z | 1 |
| Luebbert, L | 1 |
| Knox, HJ | 1 |
| Muthusamy, AK | 1 |
| Marvin, JS | 1 |
| Kim, CH | 1 |
| Grant, SN | 1 |
| Walton, DP | 1 |
| Cohen, BN | 1 |
| Hammar, R | 1 |
| Looger, L | 1 |
| Artursson, P | 1 |
| Dougherty, DA | 1 |
| Lester, HA | 1 |
| Li, L | 2 |
| Ma, S | 2 |
| Wang, J | 1 |
| Chen, Y | 5 |
| Wang, F | 2 |
| Zheng, M | 1 |
| Zhang, K | 1 |
| Miao, S | 1 |
| Shi, X | 2 |
| Tsai, HJ | 1 |
| Yang, WC | 2 |
| Tsai, SJ | 13 |
| Lin, CH | 16 |
| Yang, AC | 1 |
| Doan, J | 1 |
| Defaix, C | 1 |
| Mendez-David, I | 1 |
| Gardier, AM | 2 |
| Colle, R | 2 |
| Corruble, E | 3 |
| McGowan, JC | 1 |
| David, DJ | 1 |
| Guilloux, JP | 2 |
| Tritschler, L | 1 |
| Bernardi, RE | 1 |
| Rao, Y | 1 |
| Yang, R | 2 |
| Zhao, J | 1 |
| Cao, Q | 1 |
| Madjid, N | 1 |
| Lidell, V | 1 |
| Nordvall, G | 1 |
| Lindskog, M | 1 |
| Ögren, SO | 1 |
| Forsell, P | 1 |
| Sandin, J | 1 |
| Almeida, OP | 1 |
| Orrico-Sanchez, A | 1 |
| Guiard, BP | 2 |
| Manta, S | 1 |
| Callebert, J | 1 |
| Launay, JM | 3 |
| Louis, F | 1 |
| Paccard, A | 1 |
| Gruszczynski, C | 1 |
| Betancur, C | 1 |
| Vialou, V | 1 |
| Gautron, S | 1 |
| Wilson, GC | 1 |
| Keitsch, S | 1 |
| Soddemann, M | 1 |
| Wilker, B | 1 |
| Edwards, MJ | 1 |
| Gulbins, E | 2 |
| He, Y | 1 |
| Gan, X | 1 |
| Li, X | 1 |
| Wang, T | 1 |
| Li, J | 3 |
| Lei, T | 1 |
| Huang, Y | 1 |
| Liu, R | 1 |
| Chen, F | 1 |
| Xie, Y | 1 |
| Ouyang, X | 1 |
| Fricke, HP | 1 |
| Krajco, CJ | 1 |
| Perry, MJ | 1 |
| Desorcy-Scherer, KM | 1 |
| Wake, LA | 1 |
| Charles, JF | 1 |
| Hernandez, LL | 1 |
| Yan, T | 1 |
| Goldman, RD | 1 |
| Tunc-Ozcan, E | 1 |
| Peng, CY | 1 |
| Zhu, Y | 1 |
| Dunlop, SR | 1 |
| Contractor, A | 1 |
| Kessler, JA | 1 |
| Zimmerman, M | 1 |
| Balling, C | 1 |
| Chelminski, I | 1 |
| Dalrymple, K | 1 |
| Chen, C | 1 |
| Shan, W | 1 |
| Boland, EM | 1 |
| Vittengl, JR | 14 |
| Clark, LA | 11 |
| Thase, ME | 29 |
| Jarrett, RB | 18 |
| Becerril-Villanueva, E | 2 |
| Pérez-Sánchez, G | 2 |
| Alvarez-Herrera, S | 2 |
| Girón-Pérez, MI | 1 |
| Arreola, R | 2 |
| Cruz-Fuentes, C | 2 |
| Palacios, L | 2 |
| de la Peña, FR | 1 |
| Pavón, L | 2 |
| Levy, R | 1 |
| Mathai, M | 1 |
| Chatterjee, P | 1 |
| Ongeri, L | 1 |
| Njuguna, S | 1 |
| Onyango, D | 1 |
| Akena, D | 2 |
| Rota, G | 1 |
| Otieno, A | 1 |
| Neylan, TC | 1 |
| Lukwata, H | 1 |
| Kahn, JG | 1 |
| Cohen, CR | 1 |
| Bukusi, D | 1 |
| Aarons, GA | 1 |
| Burger, R | 2 |
| Blum, K | 1 |
| Nahum-Shani, I | 1 |
| McCulloch, CE | 1 |
| Meffert, SM | 1 |
| Amitai, M | 3 |
| Taler, M | 3 |
| Ben-Baruch, R | 2 |
| Lebow, M | 2 |
| Rotkopf, R | 1 |
| Apter, A | 4 |
| Fennig, S | 3 |
| Weizman, A | 3 |
| Chen, A | 3 |
| Kertys, M | 1 |
| Krivosova, M | 1 |
| Ondrejka, I | 1 |
| Hrtanek, I | 1 |
| Tonhajzerova, I | 1 |
| Mokry, J | 1 |
| Liao, XM | 1 |
| Su, YA | 1 |
| Yu, X | 4 |
| Si, TM | 1 |
| Gutsmiedl, K | 1 |
| Krause, M | 1 |
| Bighelli, I | 1 |
| Schneider-Thoma, J | 1 |
| Leucht, S | 3 |
| Bondar, J | 1 |
| Caye, A | 1 |
| Chekroud, AM | 2 |
| Kieling, C | 1 |
| Chen, CC | 9 |
| Huang, CJ | 4 |
| Kauffman, KM | 1 |
| Dolata, J | 1 |
| Figueroa, M | 1 |
| Gunzler, D | 1 |
| Huml, A | 1 |
| Pencak, J | 1 |
| Sehgal, AR | 1 |
| Sajatovic, M | 1 |
| Lorenzo-Luaces, L | 1 |
| Rodriguez-Quintana, N | 1 |
| Riley, TN | 1 |
| Weisz, JR | 1 |
| Almeida, IB | 1 |
| Gomes, IA | 1 |
| Shanmugam, S | 1 |
| de Moura, TR | 1 |
| Magalhães, LS | 1 |
| de Aquino, LAG | 1 |
| de Souza Araújo, AA | 1 |
| Oliveira, PD | 1 |
| Santos, MRV | 1 |
| Xue, SS | 1 |
| Zhou, CH | 1 |
| Xue, F | 1 |
| Liu, L | 2 |
| Cai, YH | 1 |
| Luo, JF | 1 |
| Tan, QR | 2 |
| Wang, HN | 1 |
| Peng, ZW | 1 |
| Zhang, H | 1 |
| Li, K | 1 |
| Zhao, Y | 1 |
| Sun, J | 1 |
| Lin, G | 1 |
| Martin, V | 1 |
| Mathieu, L | 1 |
| Diaz, J | 1 |
| Salman, H | 1 |
| Alterio, J | 1 |
| Chevarin, C | 1 |
| Lanfumey, L | 1 |
| Hamon, M | 1 |
| Austin, MC | 1 |
| Darmon, M | 1 |
| Stockmeier, CA | 2 |
| Masson, J | 1 |
| Levitt, A | 2 |
| Suresh, V | 1 |
| Mills, JA | 2 |
| Strawn, JR | 3 |
| Stutzman, S | 1 |
| Atluru, A | 1 |
| Gunlicks-Stoessel, M | 2 |
| Klimes-Dougan, B | 2 |
| VanZomeren, A | 1 |
| Jha, MK | 1 |
| Minhajuddin, A | 4 |
| Coulombe, J | 1 |
| Moodie, EEM | 1 |
| Shortreed, SM | 1 |
| Renoux, C | 1 |
| Gonçalves, CL | 1 |
| Abelaira, HM | 1 |
| Rosa, T | 1 |
| de Moura, AB | 1 |
| Veron, DC | 1 |
| Borba, LA | 1 |
| Botelho, MEM | 1 |
| Goldim, MP | 1 |
| Garbossa, L | 1 |
| Fileti, ME | 1 |
| Petronilho, F | 1 |
| Ignácio, ZM | 1 |
| Quevedo, J | 2 |
| Réus, GZ | 1 |
| Taylor, R | 1 |
| Bodoukhin, N | 1 |
| Botros, M | 1 |
| Luca, L | 1 |
| Gergues, MM | 1 |
| Yohn, CN | 1 |
| Bharadia, A | 1 |
| Levinstein, MR | 1 |
| Samuels, BA | 1 |
| Terstege, DJ | 1 |
| MacDonald, DS | 1 |
| Tasker, RA | 1 |
| Huzian, O | 1 |
| Baka, J | 1 |
| Csakvari, E | 1 |
| Dobos, N | 1 |
| Leranth, C | 1 |
| Siklos, L | 1 |
| Duman, RS | 2 |
| Farkas, T | 1 |
| Hajszan, T | 1 |
| Witt, K | 1 |
| Madsen, T | 1 |
| Berk, M | 5 |
| Dean, O | 1 |
| Chanen, A | 1 |
| McGorry, PD | 3 |
| Cotton, S | 1 |
| Davey, CG | 3 |
| Hetrick, S | 1 |
| Zhou, J | 1 |
| Feng, L | 1 |
| Zhu, X | 1 |
| Shi, H | 1 |
| Chen, R | 1 |
| Boyce, P | 1 |
| Hetrick, SE | 4 |
| McKenzie, JE | 1 |
| Bailey, AP | 1 |
| Sharma, V | 2 |
| Moller, CI | 1 |
| Badcock, PB | 1 |
| Cox, GR | 1 |
| Merry, SN | 1 |
| Meader, N | 1 |
| O'Dor, SL | 1 |
| Washburn, J | 1 |
| Howard, KR | 2 |
| Reinecke, MA | 12 |
| Qiu, W | 1 |
| Go, KA | 1 |
| Lamers, Y | 1 |
| Galea, LAM | 1 |
| Kanekar, S | 1 |
| Ettaro, R | 1 |
| Hoffman, MD | 1 |
| Ombach, HJ | 1 |
| Brown, J | 1 |
| Lynch, C | 1 |
| Sheth, CS | 1 |
| Renshaw, PF | 6 |
| Anna Clark, L | 1 |
| Avitsur, R | 1 |
| Gosselin, T | 1 |
| Le Guisquet, AM | 1 |
| Brizard, B | 1 |
| Hommet, C | 1 |
| Minier, F | 1 |
| Belzung, C | 2 |
| Çetin, B | 1 |
| Ergelen, M | 1 |
| Nouraei, H | 1 |
| Firouzabadi, N | 2 |
| Mandegary, A | 1 |
| Zomorrodian, K | 1 |
| Bahramali, E | 2 |
| Shayesteh, MRH | 1 |
| Ansari, S | 1 |
| Ma, M | 2 |
| Ren, Q | 2 |
| Fujita, Y | 1 |
| Yang, C | 2 |
| Dong, C | 5 |
| Ohgi, Y | 2 |
| Hashimoto, K | 2 |
| Gupta, K | 1 |
| Gupta, R | 2 |
| Bhatia, MS | 2 |
| Tripathi, AK | 2 |
| Gupta, LK | 2 |
| Holl, K | 1 |
| He, H | 1 |
| Wedemeyer, M | 1 |
| Clopton, L | 1 |
| Wert, S | 1 |
| Meckes, JK | 1 |
| Cheng, R | 1 |
| Kastner, A | 1 |
| Palmer, AA | 1 |
| Redei, EE | 1 |
| Solberg Woods, LC | 1 |
| Wang, FC | 2 |
| Lu, MJ | 2 |
| Dold, M | 1 |
| Bartova, L | 1 |
| Rupprecht, R | 2 |
| Kasper, S | 4 |
| Hales, CA | 1 |
| Houghton, CJ | 1 |
| Robinson, ESJ | 1 |
| Weihs, KL | 2 |
| Murphy, W | 1 |
| Abbas, R | 1 |
| Chiles, D | 2 |
| England, RD | 1 |
| Ramaker, S | 2 |
| Wajsbrot, DB | 2 |
| Stewart, RM | 2 |
| Wong, JWY | 2 |
| Runions, KC | 2 |
| Rao, P | 2 |
| Moore, JK | 2 |
| Davies, SR | 1 |
| von Ungern-Sternberg, BS | 1 |
| Sommerfield, D | 1 |
| Zepf, FD | 2 |
| Dong, L | 1 |
| Xu, L | 1 |
| Lv, Y | 1 |
| Liu, H | 2 |
| Xu, F | 1 |
| Wu, J | 1 |
| Zheng, Q | 1 |
| Chang, HH | 4 |
| Chen, PS | 4 |
| Cheng, YW | 1 |
| Wang, TY | 1 |
| Yang, YK | 4 |
| Lu, RB | 4 |
| Lu, Y | 2 |
| Ho, CS | 1 |
| McIntyre, RS | 4 |
| Wang, W | 2 |
| Ho, RC | 1 |
| Aguilar-Valles, A | 1 |
| Haji, N | 1 |
| De Gregorio, D | 1 |
| Matta-Camacho, E | 1 |
| Eslamizade, MJ | 1 |
| Popic, J | 1 |
| Cao, R | 1 |
| Rummel, C | 1 |
| Tanti, A | 1 |
| Wiebe, S | 1 |
| Nuñez, N | 1 |
| Comai, S | 1 |
| Nadon, R | 1 |
| Luheshi, G | 1 |
| Mechawar, N | 1 |
| Turecki, G | 1 |
| Lacaille, JC | 1 |
| Gobbi, G | 1 |
| Sonenberg, N | 1 |
| Gassó, P | 4 |
| Blázquez, A | 4 |
| Rodríguez, N | 2 |
| Boloc, D | 2 |
| Torres, T | 1 |
| Mas, S | 4 |
| Lafuente, A | 4 |
| Lázaro, L | 4 |
| Hood, SD | 1 |
| Foster, S | 2 |
| Mohler-Kuo, M | 2 |
| Smits, JAJ | 1 |
| Lewis, CP | 1 |
| Camsari, DD | 1 |
| Sonmez, AI | 1 |
| Nandakumar, AL | 1 |
| Gresbrink, MA | 1 |
| Daskalakis, ZJ | 1 |
| Stevanovic, D | 1 |
| Zalsman, G | 2 |
| Rodrigues, FTS | 1 |
| de Souza, MRM | 1 |
| Lima, CNC | 1 |
| da Silva, FER | 1 |
| Costa, DVDS | 1 |
| Dos Santos, CC | 1 |
| Miyajima, F | 1 |
| de Sousa, FCF | 1 |
| Vasconcelos, SMM | 1 |
| Barichello, T | 1 |
| Maes, M | 3 |
| de Lucena, DF | 1 |
| Macedo, D | 1 |
| Lin, HS | 2 |
| Chou, LS | 2 |
| Tang, SH | 1 |
| Narasimha, VL | 1 |
| Basavaraju, R | 1 |
| Mangalore, S | 1 |
| Mehta, UM | 1 |
| Cao, X | 1 |
| Zang, W | 1 |
| Tan, S | 1 |
| Ou, CQ | 1 |
| Shen, X | 1 |
| Gao, T | 1 |
| Zhao, L | 1 |
| Martínez-Levy, G | 1 |
| Hernández-Gutiérrez, ME | 1 |
| Velasco-Velásquez, MA | 1 |
| de la Peña, F | 1 |
| Harvey, CJ | 1 |
| Scott, K | 1 |
| Lewis, CC | 3 |
| Marti, CN | 1 |
| Flores-Ramirez, FJ | 1 |
| Parise, LF | 1 |
| Alipio, JB | 1 |
| Garcia-Carachure, I | 1 |
| Castillo, SA | 1 |
| Rodriguez, M | 1 |
| Themman, A | 1 |
| Lira, O | 1 |
| Preciado-Piña, J | 1 |
| Iñiguez, SD | 1 |
| Tay, L | 1 |
| Hothorn, T | 1 |
| Seibold, H | 1 |
| Chappell, P | 1 |
| Wei, YB | 1 |
| McCarthy, M | 1 |
| Ren, H | 1 |
| Carrillo-Roa, T | 1 |
| Shekhtman, T | 1 |
| DeModena, A | 1 |
| Liu, JJ | 1 |
| Leckband, SG | 1 |
| Mors, O | 1 |
| Rietschel, M | 1 |
| Henigsberg, N | 1 |
| Cattaneo, A | 1 |
| Binder, EB | 1 |
| Aitchison, KJ | 1 |
| Kelsoe, JR | 1 |
| Waldron, EM | 1 |
| Hudd, TR | 1 |
| Blake, CS | 1 |
| Rimola-Dejesus, Y | 1 |
| Nguyen, TT | 1 |
| Zaiken, K | 1 |
| Park, C | 1 |
| Eckshtain, D | 1 |
| Lee, S | 1 |
| Reigstad, K | 1 |
| Mufson, L | 1 |
| Weisz, J | 1 |
| Lu, Q | 1 |
| Mouri, A | 1 |
| Yang, Y | 1 |
| Kunisawa, K | 1 |
| Teshigawara, T | 1 |
| Hirakawa, M | 1 |
| Mori, Y | 1 |
| Yamamoto, Y | 1 |
| Libo, Z | 1 |
| Nabeshima, T | 1 |
| Saito, K | 1 |
| Hieronymus, F | 1 |
| Lisinski, A | 1 |
| Nilsson, S | 1 |
| Eriksson, E | 1 |
| Chanen, AM | 2 |
| Cotton, SM | 2 |
| Ratheesh, A | 2 |
| Amminger, GP | 2 |
| Koutsogiannis, J | 1 |
| Phelan, M | 2 |
| Mullen, E | 1 |
| Harrison, BJ | 2 |
| Rice, S | 1 |
| Parker, AG | 2 |
| Dean, OM | 2 |
| Weller, A | 1 |
| Kerr, M | 1 |
| Quinn, AL | 1 |
| Catania, L | 1 |
| Kazantzis, N | 1 |
| Demyttenaere, K | 2 |
| Hale, A | 2 |
| Quera-Salva, MA | 1 |
| Picarel-Blanchot, F | 1 |
| Venkatasubramanian, R | 1 |
| Kumar, CN | 1 |
| Pandey, RS | 1 |
| Amr, M | 1 |
| El-Mogy, A | 1 |
| Shams, T | 1 |
| Vieira, K | 1 |
| Lakhan, SE | 1 |
| Gelenberg, AJ | 1 |
| Dunner, DL | 2 |
| Rothschild, AJ | 5 |
| Pedersen, R | 5 |
| Dorries, KM | 1 |
| Ninan, PT | 4 |
| Ranjbar, E | 1 |
| Shams, J | 1 |
| Sabetkasaei, M | 1 |
| M-Shirazi, M | 1 |
| Rashidkhani, B | 1 |
| Mostafavi, A | 1 |
| Bornak, E | 1 |
| Nasrollahzadeh, J | 1 |
| Branchi, I | 2 |
| Santarelli, S | 1 |
| Capoccia, S | 1 |
| Poggini, S | 2 |
| D'Andrea, I | 1 |
| Cirulli, F | 2 |
| Alleva, E | 1 |
| Chi, MH | 3 |
| Lee, IH | 2 |
| Tsai, HC | 1 |
| Gean, PW | 3 |
| Shahsavand-Ananloo, E | 1 |
| Berenji, F | 1 |
| Sadeghniiat, K | 1 |
| Alimadadi, A | 1 |
| Zahiroddin, AR | 1 |
| Tabatabaee, M | 1 |
| Abbasi-Asl, M | 1 |
| Ghaeli, P | 3 |
| Nardi, B | 1 |
| Francesconi, G | 1 |
| Catena-Dell'osso, M | 1 |
| Bellantuono, C | 1 |
| Gudayol-Ferré, E | 4 |
| Guàrdia-Olmos, J | 4 |
| Peró-Cebollero, M | 2 |
| Herrera-Guzmán, I | 3 |
| Camarena, B | 3 |
| Cortés-Penagos, C | 3 |
| Herrera-Abarca, JE | 3 |
| Martínez-Medina, P | 3 |
| Sanmukhani, J | 1 |
| Satodia, V | 1 |
| Trivedi, J | 1 |
| Patel, T | 1 |
| Tiwari, D | 1 |
| Panchal, B | 1 |
| Goel, A | 1 |
| Tripathi, CB | 1 |
| Cao, Y | 2 |
| Shen, J | 2 |
| Malison, RT | 2 |
| Luo, X | 2 |
| Cullen, KR | 2 |
| Westlund, MK | 1 |
| LaRiviere, LL | 1 |
| Rizvi, SJ | 1 |
| Salomons, TV | 1 |
| Konarski, JZ | 1 |
| Downar, J | 1 |
| Giacobbe, P | 1 |
| Kennedy, SH | 3 |
| Yen, YC | 1 |
| Chen, MC | 4 |
| Gershenfeld, H | 1 |
| Friedman, ES | 5 |
| Quilty, LC | 4 |
| Robinson, JJ | 1 |
| Rolland, JP | 3 |
| Fruyt, FD | 1 |
| Rouillon, F | 2 |
| Bagby, RM | 4 |
| Bastos, AG | 1 |
| Guimarães, LS | 1 |
| Trentini, CM | 1 |
| Ghanizadeh, A | 4 |
| Hedayati, A | 1 |
| Yu, L | 1 |
| Xie, J | 1 |
| Chen, J | 4 |
| Wei, Q | 1 |
| Miller, MC | 1 |
| Heller, AS | 3 |
| Johnstone, T | 3 |
| Peterson, MJ | 3 |
| Kolden, GG | 3 |
| Kalin, NH | 3 |
| Davidson, RJ | 3 |
| Tuman, TC | 1 |
| Demir, N | 1 |
| Topal, Z | 1 |
| Tuman, BA | 1 |
| Tufan, EA | 1 |
| Kornstein, SG | 5 |
| Pedersen, RD | 1 |
| Holland, PJ | 1 |
| Nemeroff, CB | 3 |
| Trivedi, MH | 7 |
| Keller, MB | 5 |
| Kong, L | 1 |
| Wu, F | 1 |
| Tang, Y | 1 |
| Ren, L | 1 |
| Kong, D | 1 |
| Liu, Y | 4 |
| Xu, K | 1 |
| Asbun-Bojalil, J | 2 |
| Lira-Islas, Y | 1 |
| Reyes-Ponce, C | 1 |
| Dean, B | 3 |
| Tawadros, N | 1 |
| Seo, MS | 1 |
| Jeon, WJ | 2 |
| Everall, I | 1 |
| Scarr, E | 3 |
| Gibbons, A | 2 |
| Shu, L | 2 |
| Sulaiman, AH | 1 |
| Huang, YS | 1 |
| Fones Soon Leng, C | 1 |
| Crutel, VS | 1 |
| Kim, YS | 1 |
| Brenner, SL | 1 |
| Burns, BJ | 3 |
| Curry, JF | 8 |
| Silva, SG | 16 |
| Kratochvil, CJ | 13 |
| Domino, ME | 3 |
| Weck, F | 1 |
| Plana, MT | 3 |
| Méndez, I | 1 |
| Torra, M | 1 |
| Arnaiz, JA | 2 |
| Wong, J | 2 |
| Shorter, E | 1 |
| Brunner, E | 1 |
| Tohen, M | 2 |
| Osuntokun, O | 3 |
| Landry, J | 1 |
| Atkinson, SD | 1 |
| Prakash, A | 5 |
| Zhang, Q | 3 |
| Pangallo, BA | 3 |
| Bangs, ME | 3 |
| March, JS | 20 |
| Dembo, JS | 1 |
| Philip, NS | 1 |
| Mayes, TL | 15 |
| Nakonezny, PA | 7 |
| Jones, JM | 3 |
| Foxwell, AA | 2 |
| King, J | 2 |
| Cristancho, MA | 1 |
| Rutherford, BR | 1 |
| Wall, MM | 1 |
| Glass, A | 1 |
| Stewart, JW | 7 |
| De Long, NE | 1 |
| Hyslop, JR | 1 |
| Raha, S | 1 |
| Hardy, DB | 1 |
| Qu, W | 1 |
| Gu, S | 1 |
| Luo, H | 3 |
| Tang, Q | 1 |
| Guo, J | 1 |
| Thibodeau, MA | 1 |
| De Fruyt, F | 3 |
| De Bolle, M | 2 |
| Ventura-Juncá, R | 1 |
| Symon, A | 1 |
| López, P | 1 |
| Fiedler, JL | 1 |
| Rojas, G | 1 |
| Heskia, C | 1 |
| Lara, P | 1 |
| Marín, F | 1 |
| Guajardo, V | 1 |
| Araya, AV | 1 |
| Sasso, J | 1 |
| Herrera, L | 1 |
| Isa, A | 1 |
| Bernstein, I | 1 |
| Kennard, B | 9 |
| Emslie, G | 12 |
| Wong, ML | 5 |
| Flores, DL | 2 |
| Ehrhart-Bornstein, M | 2 |
| Bornstein, S | 2 |
| Arcos-Burgos, M | 2 |
| Licinio, J | 6 |
| Birmaher, B | 7 |
| Kerr, MJ | 1 |
| Yuen, K | 1 |
| Schäfer, MR | 1 |
| Piskulic, D | 1 |
| Harrigan, S | 1 |
| Mackinnon, AJ | 1 |
| Citrome, L | 1 |
| Chen, JX | 1 |
| Yao, LH | 1 |
| Xu, BB | 1 |
| Qian, K | 1 |
| Wang, HL | 1 |
| Liu, ZC | 3 |
| Wang, XP | 1 |
| Wang, GH | 1 |
| Talaei, A | 1 |
| Hassanpour Moghadam, M | 1 |
| Sajadi Tabassi, SA | 1 |
| Mohajeri, SA | 1 |
| Wagner, GJ | 1 |
| Ngo, VK | 1 |
| Nakasujja, N | 1 |
| Aunon, F | 1 |
| Musisi, S | 1 |
| Purgato, M | 2 |
| Gastaldon, C | 1 |
| Papola, D | 1 |
| Magni, LR | 2 |
| Rossi, G | 1 |
| Barbui, C | 3 |
| Peselow, ED | 1 |
| Tobia, G | 1 |
| Karamians, R | 1 |
| Pizano, D | 1 |
| IsHak, WW | 1 |
| Pehrson, AL | 1 |
| Sanchez, C | 1 |
| Wang, R | 1 |
| Schoenfeld, DA | 1 |
| Hoeppner, B | 1 |
| Evins, AE | 1 |
| Macías-Cortés, Edel C | 1 |
| Llanes-González, L | 1 |
| Aguilar-Faisal, L | 1 |
| McCall, WV | 5 |
| Hong, J | 1 |
| Novick, D | 1 |
| Montgomery, W | 1 |
| Moneta, MV | 1 |
| Dueñas, H | 1 |
| Peng, X | 1 |
| Haro, JM | 2 |
| Yucel, A | 1 |
| Yucel, N | 1 |
| Ozcan, H | 1 |
| Gulec, M | 1 |
| Aydin, A | 1 |
| Uher, R | 1 |
| Ripke, S | 1 |
| Müller-Myhsok, B | 1 |
| Lewis, CM | 1 |
| Perlis, RH | 6 |
| Gougol, A | 1 |
| Zareh-Mohammadi, N | 1 |
| Raheb, S | 1 |
| Farokhnia, M | 1 |
| Salimi, S | 1 |
| Iranpour, N | 1 |
| Yekehtaz, H | 1 |
| Akhondzadeh, S | 6 |
| Almeida Montes, LG | 1 |
| Prado Alcántara, H | 1 |
| Portillo Cedeño, BA | 1 |
| Hernández García, AO | 1 |
| Fuentes Rojas, PE | 1 |
| Heimberg, RG | 1 |
| Vitiello, B | 26 |
| Hayasaka, Y | 1 |
| Ogawa, Y | 1 |
| Takeshima, N | 1 |
| Cipriani, A | 3 |
| Furukawa, TA | 1 |
| Rahn, KA | 1 |
| Cao, YJ | 1 |
| Hendrix, CW | 1 |
| Kaplin, AI | 1 |
| Wells, TG | 1 |
| Melo, A | 1 |
| Kokras, N | 1 |
| Dalla, C | 1 |
| Ferreira, C | 1 |
| Ventura-Silva, AP | 1 |
| Sousa, N | 1 |
| Pêgo, JM | 1 |
| Smagula, SF | 1 |
| Meng, H | 1 |
| Cao, W | 1 |
| Qiu, T | 1 |
| Brown, GK | 1 |
| Borman, PD | 2 |
| Gibbons, AS | 1 |
| Ghosh, R | 1 |
| McOmish, CE | 1 |
| Pavey, G | 1 |
| Hopper, S | 1 |
| Udawela, M | 1 |
| Jakubovski, E | 1 |
| Varigonda, AL | 1 |
| Freemantle, N | 1 |
| Taylor, MJ | 1 |
| Bloch, MH | 1 |
| Peters, AT | 1 |
| Jacobs, RH | 3 |
| Feldhaus, C | 1 |
| Henry, DB | 1 |
| Albano, AM | 4 |
| Langenecker, SA | 1 |
| Cheung, AH | 1 |
| Moore, J | 1 |
| Sahraian, A | 1 |
| Jelodar, S | 1 |
| Javid, Z | 1 |
| Mowla, A | 3 |
| Ahmadzadeh, L | 1 |
| Alboni, S | 1 |
| van Dijk, RM | 1 |
| Milior, G | 1 |
| Perrotta, M | 1 |
| Drenth, T | 1 |
| Brunello, N | 1 |
| Wolfer, DP | 1 |
| Limatola, C | 1 |
| Amrein, I | 1 |
| Maggi, L | 1 |
| Qesseveur, G | 1 |
| Petit, AC | 1 |
| Nguyen, HT | 1 |
| Dahan, L | 1 |
| Rotenberg, S | 1 |
| Seif, I | 1 |
| Robert, P | 1 |
| David, D | 2 |
| Verstuyft, C | 1 |
| Becquemont, L | 1 |
| Carmel, M | 1 |
| Michaelovsky, E | 1 |
| Eilat, T | 1 |
| Yablonski, M | 1 |
| Orpaz, N | 1 |
| Cawkwell, P | 1 |
| Lawler, A | 1 |
| Maneta, E | 1 |
| Coffey, BJ | 1 |
| Liu, SK | 1 |
| Shehab, AA | 1 |
| Brent, D | 3 |
| Maalouf, FT | 1 |
| Guo, X | 1 |
| Li, CS | 1 |
| Manoharan, A | 2 |
| Rajkumar, RP | 2 |
| Shewade, DG | 2 |
| Sundaram, R | 1 |
| Muthuramalingam, A | 1 |
| Paul, A | 1 |
| Salagre, E | 1 |
| Fernandes, BS | 1 |
| Dodd, S | 1 |
| Brownstein, DJ | 1 |
| Yavarian, I | 1 |
| Shayesteh, MR | 1 |
| Erfani, N | 1 |
| Shoushtari, AA | 1 |
| Asadpour, R | 1 |
| Del Giovane, C | 1 |
| Qin, B | 1 |
| Whittington, C | 1 |
| Coghill, D | 1 |
| Hazell, P | 1 |
| Cuijpers, P | 1 |
| Pu, J | 1 |
| Cohen, D | 1 |
| Ravindran, AV | 2 |
| Michael, KD | 1 |
| Yang, L | 1 |
| Xie, P | 1 |
| Nassan, M | 1 |
| Nicholson, WT | 1 |
| Elliott, MA | 1 |
| Rohrer Vitek, CR | 1 |
| Black, JL | 1 |
| Frye, MA | 2 |
| Taguchi, R | 1 |
| Shikata, K | 1 |
| Furuya, Y | 1 |
| Ino, M | 1 |
| Shin, K | 1 |
| Shibata, H | 1 |
| Adithan, S | 1 |
| Arnedt, JT | 1 |
| Swanson, LM | 2 |
| Dopp, RR | 1 |
| Bertram, HS | 1 |
| Mooney, AJ | 1 |
| Huntley, ED | 2 |
| Hoffmann, RF | 1 |
| Armitage, R | 2 |
| Cui, J | 1 |
| Yang, K | 1 |
| Wang, JL | 1 |
| Li, H | 1 |
| Eniola, K | 1 |
| Bacigalupo, A | 1 |
| Mounsey, A | 1 |
| Hung, YY | 1 |
| Lin, CC | 2 |
| Kang, HY | 1 |
| Huang, TL | 2 |
| Das, A | 1 |
| Maiti, A | 1 |
| Sinha, S | 1 |
| DeLucia, V | 1 |
| Kelsberg, G | 1 |
| Safranek, S | 1 |
| Solmi, M | 1 |
| Veronese, N | 1 |
| Zaninotto, L | 1 |
| van der Loos, ML | 1 |
| Gao, K | 1 |
| Schaffer, A | 2 |
| Reis, C | 1 |
| Normann, C | 1 |
| Anghelescu, IG | 1 |
| Correll, CU | 1 |
| Ordóñez, AE | 1 |
| Wang, Z | 3 |
| Liu, X | 2 |
| Nie, G | 2 |
| Jorgenson, K | 1 |
| Sohn, KC | 1 |
| Huang, R | 2 |
| Liu, M | 2 |
| Liu, B | 2 |
| Kong, J | 2 |
| Byun, JS | 1 |
| Liang, Y | 1 |
| Park, J | 1 |
| Rhein, C | 1 |
| Reichel, M | 1 |
| Kramer, M | 1 |
| Rotter, A | 1 |
| Lenz, B | 1 |
| Mühle, C | 1 |
| Kornhuber, J | 1 |
| Zhang, JC | 1 |
| Yao, W | 1 |
| Monteagudo, A | 1 |
| Gueorguieva, R | 2 |
| Krystal, JH | 3 |
| Chandradasa, M | 1 |
| Champika, L | 1 |
| Burgess, HJ | 1 |
| Bertram, H | 1 |
| Mooney, A | 1 |
| Zollars, J | 1 |
| Dopp, R | 1 |
| Hoffmann, R | 1 |
| Todd Arnedt, J | 1 |
| Liu, CC | 2 |
| Liang, KY | 1 |
| Liao, SC | 1 |
| Gau, YT | 1 |
| Hong, CJ | 10 |
| Liou, YJ | 7 |
| Yu, YW | 10 |
| Chen, TJ | 10 |
| Carvalho, LA | 1 |
| Gorenstein, C | 1 |
| Moreno, R | 1 |
| Pariante, C | 1 |
| Markus, RP | 1 |
| Candrian, M | 2 |
| Schwartz, F | 3 |
| Farabaugh, A | 7 |
| Ehlert, U | 1 |
| Fava, M | 55 |
| Gorlyn, M | 1 |
| Keilp, JG | 1 |
| Grunebaum, MF | 1 |
| Taylor, BP | 3 |
| Oquendo, MA | 1 |
| Bruder, GE | 2 |
| Mann, JJ | 5 |
| Preskorn, SH | 1 |
| Katona, C | 1 |
| Salminen, JK | 5 |
| Karlsson, H | 5 |
| Hietala, J | 5 |
| Kajander, J | 5 |
| Aalto, S | 3 |
| Markkula, J | 5 |
| Rasi-Hakala, H | 5 |
| Toikka, T | 1 |
| Garakani, A | 1 |
| Martinez, JM | 1 |
| Marcus, S | 1 |
| Weaver, J | 1 |
| Rickels, K | 1 |
| Hirschowitz, J | 1 |
| Resler, G | 1 |
| Lavie, R | 1 |
| Campos, J | 1 |
| Mata, S | 2 |
| Urbina, M | 4 |
| García, A | 1 |
| Apitz, R | 1 |
| Lima, L | 4 |
| Roobol, TH | 1 |
| Buitelaar, JK | 1 |
| Papakostas, GI | 24 |
| McGrath, P | 2 |
| Stewart, J | 2 |
| Charles, D | 2 |
| Mischoulon, D | 17 |
| Dording, C | 3 |
| Fisar, Z | 1 |
| Kalisová, L | 1 |
| Paclt, I | 1 |
| Anders, M | 1 |
| Vevera, J | 1 |
| Boulton, DW | 1 |
| Balch, AH | 1 |
| Royzman, K | 1 |
| Patel, CG | 1 |
| Berman, RM | 4 |
| Mallikaarjun, S | 1 |
| Reeves, RA | 1 |
| Kongsakon, R | 1 |
| Bunchapattanasakda, C | 1 |
| Kocsis, JH | 4 |
| Ahmed, S | 1 |
| Thase, M | 1 |
| Dunlop, BW | 3 |
| Yan, B | 1 |
| Li, T | 3 |
| Keller, M | 4 |
| Pedrelli, P | 2 |
| Feldman, GC | 1 |
| Vorono, S | 1 |
| Petersen, T | 12 |
| Nightingale-Teresi, J | 3 |
| Hughes, JL | 4 |
| Tao, R | 8 |
| Stewart, SM | 3 |
| Andeweg, J | 1 |
| van Grinsven, M | 1 |
| Sava, FA | 1 |
| Yates, BT | 1 |
| Lupu, V | 1 |
| Szentagotai, A | 1 |
| Nakonezny, P | 1 |
| Hughes, C | 5 |
| Hunter, AM | 8 |
| Ravikumar, S | 1 |
| Cook, IA | 13 |
| Leuchter, AF | 14 |
| Tonev, S | 2 |
| Rohde, P | 13 |
| Reinecke, M | 8 |
| March, J | 12 |
| Brent, DA | 6 |
| Clarke, GN | 2 |
| Asarnow, J | 1 |
| Spirito, A | 2 |
| Ritz, L | 2 |
| Iyengar, S | 3 |
| Ryan, ND | 5 |
| Zelazny, J | 2 |
| Onorato, M | 2 |
| Debar, LL | 1 |
| McCracken, JT | 2 |
| Strober, M | 2 |
| Suddath, R | 2 |
| Leonard, H | 2 |
| Porta, G | 4 |
| Sheehan, DV | 1 |
| Entsuah, R | 3 |
| Lenox-Smith, A | 1 |
| Greenstreet, L | 1 |
| Burslem, K | 1 |
| Knight, C | 1 |
| Hou, SJ | 2 |
| Yen, FC | 2 |
| Henley, DB | 2 |
| Case, M | 4 |
| Watson, SB | 2 |
| Campbell, GM | 1 |
| Corya, SA | 5 |
| Gałecki, P | 2 |
| Szemraj, J | 1 |
| Bieńkiewicz, M | 1 |
| Zboralski, K | 1 |
| Gałecka, E | 2 |
| Cornelius, JR | 6 |
| Bukstein, OG | 5 |
| Wood, DS | 4 |
| Kirisci, L | 1 |
| Douaihy, A | 2 |
| Clark, DB | 5 |
| Becker-Weidman, EG | 1 |
| Martinovich, Z | 1 |
| Harley, J | 1 |
| Roberts, R | 1 |
| Joyce, P | 1 |
| Mulder, R | 1 |
| Luty, S | 1 |
| Frampton, C | 1 |
| Kennedy, M | 1 |
| Filho, AS | 1 |
| Carvalho, DL | 1 |
| Tumas, V | 1 |
| Hetem, LA | 1 |
| Ferrari, MC | 1 |
| Crippa, JA | 1 |
| Foster, EM | 1 |
| Simons, AD | 4 |
| Small, DM | 1 |
| Murakami, JL | 2 |
| High, RR | 1 |
| Kronström, K | 2 |
| Vahlberg, T | 2 |
| Jafari, S | 1 |
| Raisi, F | 3 |
| Nasehi, AA | 3 |
| Ghoreishi, A | 1 |
| Salehi, B | 1 |
| Mohebbi-Rasa, S | 1 |
| Raznahan, M | 2 |
| Kamalipour, A | 1 |
| Dording, CM | 4 |
| Sinicropi-Yao, L | 2 |
| Papakostas, G | 1 |
| Matthews, JD | 4 |
| Nierenberg, AA | 18 |
| Johnstone, JM | 1 |
| Luty, SE | 9 |
| Carter, JD | 3 |
| Mulder, RT | 10 |
| Frampton, CM | 2 |
| Joyce, PR | 10 |
| Rozzini, L | 1 |
| Chilovi, BV | 1 |
| Conti, M | 1 |
| Bertoletti, E | 1 |
| Zanetti, M | 1 |
| Trabucchi, M | 1 |
| Padovani, A | 1 |
| Posner, K | 2 |
| May, DE | 4 |
| Yang, H | 1 |
| Chuzi, S | 2 |
| Johnson, D | 1 |
| Clain, A | 5 |
| Baer, L | 10 |
| McGrath, PJ | 7 |
| de Carvalho, GA | 1 |
| Bahls, SC | 1 |
| Boeving, A | 1 |
| Graf, H | 1 |
| Illi, A | 1 |
| Setälä-Soikkeli, E | 1 |
| Viikki, M | 1 |
| Poutanen, O | 1 |
| Huhtala, H | 1 |
| Mononen, N | 1 |
| Lehtimäki, T | 1 |
| Leinonen, E | 1 |
| Kampman, O | 1 |
| Muthén, BO | 1 |
| Shelton, RC | 3 |
| Sussman, N | 1 |
| Chen, ML | 1 |
| Silva, S | 13 |
| Curry, J | 9 |
| Wells, K | 7 |
| Fairbank, J | 3 |
| Burns, B | 5 |
| Domino, M | 3 |
| Severe, J | 3 |
| Riedal, K | 1 |
| Goldman, M | 1 |
| Feeny, N | 6 |
| Findling, R | 1 |
| Stull, S | 1 |
| Baab, S | 1 |
| Weller, EB | 3 |
| Robbins, M | 1 |
| Weller, RA | 2 |
| Jessani, N | 1 |
| Waslick, B | 4 |
| Sweeney, M | 2 |
| Dublin, R | 1 |
| Walkup, J | 7 |
| Ginsburg, G | 5 |
| Kastelic, E | 3 |
| Koo, H | 1 |
| Kratochvil, C | 8 |
| May, D | 4 |
| LaGrone, R | 1 |
| Vaughan, B | 1 |
| Hirsch, GS | 1 |
| Podniesinki, E | 1 |
| Chu, A | 1 |
| Reincecke, M | 1 |
| Leventhal, B | 1 |
| Rogers, G | 1 |
| Jacobs, R | 3 |
| Pathak, S | 8 |
| Wells, J | 1 |
| Lavanier, SA | 1 |
| Danielyan, A | 1 |
| Simons, A | 6 |
| Grimm, J | 1 |
| Frank, S | 1 |
| Rosenberg, D | 3 |
| Benazon, N | 1 |
| Butkus, M | 1 |
| Bartoi, M | 1 |
| Song, C | 1 |
| Halbreich, U | 2 |
| Han, C | 1 |
| Leonard, BE | 1 |
| Gelenberg, A | 2 |
| Holland, P | 1 |
| Shelton, R | 1 |
| Zajecka, JM | 1 |
| Goldstein, C | 1 |
| Cavanagh, J | 1 |
| Patterson, J | 1 |
| Pimlott, S | 1 |
| Wyper, D | 1 |
| Dewar, D | 1 |
| Başterzi, AD | 1 |
| Yazici, K | 1 |
| Buturak, V | 1 |
| Cimen, B | 1 |
| Yazici, A | 1 |
| Eskandari, G | 1 |
| Tot Acar, S | 1 |
| Taşdelen, B | 1 |
| Madaan, V | 1 |
| Puumala, SE | 1 |
| Kepley, H | 1 |
| Ameral, VE | 2 |
| Brintz, C | 1 |
| Smith, WT | 2 |
| Londborg, PD | 2 |
| Glaudin, V | 2 |
| Painter, JR | 2 |
| Hirvonen, J | 2 |
| Någren, K | 2 |
| Benazzi, F | 3 |
| Barraco, A | 1 |
| Feyissa, AM | 1 |
| Woolverton, WL | 1 |
| Miguel-Hidalgo, JJ | 1 |
| Kyle, PB | 1 |
| Hasler, G | 1 |
| Iyo, AH | 1 |
| Karolewicz, B | 1 |
| Rohmer, JG | 1 |
| Blier, P | 2 |
| Ward, HE | 1 |
| Tremblay, P | 1 |
| Laberge, L | 1 |
| Hébert, C | 1 |
| Bergeron, R | 1 |
| Zou, YF | 2 |
| Liu, P | 2 |
| Feng, XL | 2 |
| Wang, BY | 2 |
| Zang, TH | 2 |
| Wei, J | 2 |
| Tao, M | 3 |
| Li, HC | 2 |
| Li, KQ | 2 |
| Li, M | 3 |
| Zhang, KR | 2 |
| Ye, DQ | 2 |
| Xu, XP | 2 |
| Masi, G | 1 |
| Liboni, F | 1 |
| Brovedani, P | 1 |
| Croxtall, JD | 1 |
| Scott, LJ | 1 |
| Hood, S | 1 |
| Orr, K | 1 |
| Bennett, L | 1 |
| Davies, S | 1 |
| Kingery, JN | 2 |
| Kepley, HO | 1 |
| Ginsburg, GS | 3 |
| Walkup, JT | 2 |
| Hoyle, RH | 2 |
| Feeny, NC | 1 |
| McNulty, S | 5 |
| Pathak, SM | 1 |
| Wells, KC | 1 |
| Robins, M | 4 |
| Rush, AJ | 3 |
| Nguyen, LJ | 1 |
| Reid, MW | 1 |
| Ninan, P | 2 |
| Spittlehouse, JK | 1 |
| Pearson, JF | 1 |
| McKenzie, JM | 6 |
| Abrams, M | 5 |
| Farabaugh, AH | 4 |
| Bitran, S | 3 |
| Witte, J | 2 |
| Alpert, J | 5 |
| Clain, AJ | 3 |
| Maneeton, N | 1 |
| Thongkam, A | 1 |
| Maneeton, B | 1 |
| Yu, ZJ | 1 |
| Mooreville, M | 1 |
| Jazayeri, S | 3 |
| Keshavarz, SA | 2 |
| Tehrani-Doost, M | 3 |
| Djalali, M | 1 |
| Hosseini, M | 3 |
| Amini, H | 3 |
| Chamari, M | 1 |
| Djazayery, A | 3 |
| Amsterdam, JD | 5 |
| Shults, J | 2 |
| Blocker, JN | 2 |
| D'Agostino, R | 2 |
| Kimball, J | 2 |
| Boggs, N | 2 |
| Lasater, B | 2 |
| Rosenquist, PB | 2 |
| Vrijland, P | 1 |
| van Oers, HJ | 1 |
| Schutte, AJ | 1 |
| Simmons, JH | 1 |
| Snedecor, SJ | 1 |
| Botteman, MF | 1 |
| Schaefer, K | 2 |
| Sarocco, P | 1 |
| Barry, N | 1 |
| Pickard, AS | 1 |
| Douaihy, AB | 1 |
| Chung, TA | 1 |
| Daley, DC | 2 |
| Brown, SJ | 1 |
| Michalak, E | 1 |
| Kiss, A | 1 |
| Cruz, D | 1 |
| Hernández, S | 1 |
| Genis, A | 1 |
| Carrillo-Guerrero, MY | 1 |
| Avilés Reyes, R | 1 |
| Sit, D | 2 |
| Perel, JM | 3 |
| Luther, JF | 2 |
| Wisniewski, SR | 2 |
| Helsel, JC | 2 |
| Wisner, KL | 2 |
| Lee, SY | 1 |
| Sonawalla, S | 2 |
| Johnson, DP | 1 |
| Goodness, T | 1 |
| Harley, R | 4 |
| Goodness, TM | 1 |
| Haskett, R | 1 |
| Krystal, A | 2 |
| McDonald, WM | 1 |
| Prukkanone, B | 1 |
| Vos, T | 1 |
| Burgess, P | 1 |
| Chaiyakunapruk, N | 1 |
| Bertram, M | 1 |
| Fischer, K | 1 |
| Goetghebeur, E | 1 |
| Vrijens, B | 1 |
| White, IR | 1 |
| Corral, RM | 1 |
| Mencacci, C | 1 |
| Ruiz, JS | 1 |
| Severo, CA | 1 |
| Gentil, V | 1 |
| Wang, HC | 1 |
| Yeh, TL | 1 |
| Hughes, CW | 4 |
| Sternweis-Yang, KH | 1 |
| Byerly, MJ | 1 |
| Kirchner, J | 2 |
| Lavanier, S | 2 |
| Becker-Weidman, E | 2 |
| Weller, E | 7 |
| Savitz, JB | 1 |
| Nugent, AC | 1 |
| Bogers, W | 1 |
| Roiser, JP | 1 |
| Bain, EE | 1 |
| Neumeister, A | 1 |
| Zarate, CA | 1 |
| Manji, HK | 1 |
| Cannon, DM | 1 |
| Marrett, S | 1 |
| Henn, F | 1 |
| Charney, DS | 5 |
| Drevets, WC | 1 |
| Silk, JS | 1 |
| Forbes, EE | 1 |
| Whalen, DJ | 1 |
| Jakubcak, JL | 1 |
| Thompson, WK | 1 |
| Axelson, DA | 1 |
| Dahl, RE | 1 |
| He, W | 1 |
| Cai, D | 1 |
| Lin, L | 1 |
| Zheng, X | 1 |
| Bernstein, IH | 2 |
| Haley, CL | 1 |
| Sakolsky, DJ | 1 |
| Wagner, KD | 5 |
| Asarnow, JR | 3 |
| Strober, MJ | 1 |
| Huang, H | 2 |
| Wilson, A | 1 |
| Iosifescu, DV | 6 |
| Wessel, TC | 1 |
| LaRocca, RA | 1 |
| Iovieno, N | 1 |
| van Nieuwenhuizen, A | 1 |
| Kardeh, E | 1 |
| Allaman, I | 1 |
| Fiumelli, H | 1 |
| Magistretti, PJ | 1 |
| Martin, JL | 1 |
| Decuyper, M | 1 |
| Lane, HY | 3 |
| Juo, SH | 2 |
| Yen, CF | 2 |
| Abolfazli, R | 1 |
| Ghaleiha, A | 1 |
| Tabrizi, M | 2 |
| Golalizadeh, M | 1 |
| Sidi, H | 3 |
| Asmidar, D | 3 |
| Hod, R | 2 |
| Guan, NC | 3 |
| Wood, SD | 1 |
| Kelly, TM | 2 |
| Salloum, IM | 3 |
| Korb, AS | 1 |
| Posternak, MA | 1 |
| Andjelkovic, M | 1 |
| Jovanovic, DB | 1 |
| Zdravkovic, N | 1 |
| Jankovic, SM | 1 |
| Kondo, DG | 1 |
| Sung, YH | 1 |
| Hellem, TL | 1 |
| Fiedler, KK | 1 |
| Jeong, EK | 1 |
| de la Cerda, P | 1 |
| Cervelló, E | 1 |
| Cocca, A | 1 |
| Viciana, J | 1 |
| Light, SN | 2 |
| Greenwald, SD | 1 |
| Tran, ML | 1 |
| Miyamoto, KN | 1 |
| Scorza, MC | 1 |
| Lladó-Pelfort, L | 1 |
| Oller, S | 1 |
| Cortés, R | 2 |
| Puigdemont, D | 1 |
| Portella, MJ | 1 |
| Pérez-Egea, R | 1 |
| Alvarez, E | 2 |
| Celada, P | 1 |
| Pérez, V | 2 |
| Artigas, F | 2 |
| Koelch, M | 1 |
| Pfalzer, AK | 1 |
| Kliegl, K | 1 |
| Rothenhöfer, S | 1 |
| Ludolph, AG | 1 |
| Fegert, JM | 1 |
| Mehler-Wex, C | 1 |
| Stingl, J | 1 |
| Taurines, R | 1 |
| Egberts, K | 1 |
| Gerlach, M | 1 |
| Jaafar, NR | 1 |
| Isingrini, E | 1 |
| Freslon, JL | 1 |
| Machet, MC | 1 |
| Camus, V | 1 |
| Zhang, ZJ | 1 |
| Ng, R | 1 |
| Man, SC | 1 |
| Li, TY | 1 |
| Wong, W | 1 |
| Wong, HK | 1 |
| Chung, KF | 1 |
| Wong, MT | 1 |
| Tsang, WK | 1 |
| Yip, KC | 1 |
| Ziea, E | 1 |
| Wong, VT | 1 |
| Shamseddeen, W | 1 |
| Clarke, G | 2 |
| Ryan, N | 2 |
| Zhu, L | 1 |
| Croarkin, P | 1 |
| Calley, CS | 1 |
| Hart, J | 1 |
| Lu, H | 1 |
| Tamminga, CA | 1 |
| Gibbons, RD | 4 |
| Brown, CH | 4 |
| Hur, K | 4 |
| Davis, J | 1 |
| McCall, C | 1 |
| Davis, JM | 4 |
| Devi, S | 1 |
| Piwowarska, J | 1 |
| Chimiak, A | 1 |
| Matsumoto, H | 1 |
| Dziklińska, A | 1 |
| Radziwoń-Zaleska, M | 1 |
| Szelenberger, W | 1 |
| Pachecka, J | 1 |
| Dunlap, L | 1 |
| Segal, ZV | 2 |
| Kidner, CL | 1 |
| Mayer, G | 1 |
| Faivel, N | 1 |
| Aviram, S | 1 |
| Walter, G | 1 |
| Bloch, Y | 1 |
| Taneja, C | 1 |
| Jing, Y | 1 |
| Baker, RA | 1 |
| Forbes, RA | 1 |
| Oster, G | 1 |
| Modabbernia, A | 2 |
| Sohrabi, H | 2 |
| Saroukhani, S | 2 |
| Jamshidi, A | 2 |
| Ashrafi, M | 2 |
| Rico-Villademoros, F | 1 |
| Saenz del Burgo, L | 1 |
| Mengod, G | 1 |
| Montaña, M | 1 |
| García del Caño, G | 1 |
| Sallés, J | 1 |
| Chen, CH | 2 |
| Cheng, CY | 3 |
| Chen, SY | 1 |
| Nian, FS | 1 |
| Peñas-Lledó, EM | 1 |
| Trejo, HD | 1 |
| Dorado, P | 1 |
| Ortega, A | 1 |
| Jung, H | 1 |
| Alonso, E | 1 |
| Naranjo, ME | 1 |
| López-López, M | 1 |
| Llerena, A | 1 |
| Lamon-Fava, S | 2 |
| Selhub, J | 1 |
| Katz, J | 1 |
| Yeung, AS | 1 |
| Alpert, JE | 14 |
| Mouillet-Richard, S | 1 |
| Baudry, A | 1 |
| Pietri, M | 1 |
| Kellermann, O | 1 |
| Myung, W | 1 |
| Lim, SW | 2 |
| Kim, S | 2 |
| Kim, H | 2 |
| Chung, JW | 1 |
| Seo, MY | 1 |
| Kim, JW | 2 |
| Carroll, BJ | 4 |
| Kim, DK | 2 |
| Khoraminya, N | 1 |
| Hosseini, A | 1 |
| Midi, M | 1 |
| Kanagasundram, S | 1 |
| Naing, L | 1 |
| Lin, HY | 1 |
| Kashani, L | 1 |
| Mansouri, P | 1 |
| Andrade, C | 1 |
| Spielmans, GI | 1 |
| Jureidini, J | 1 |
| Healy, D | 2 |
| Purssey, R | 1 |
| Siesser, WB | 1 |
| Sachs, BD | 1 |
| Ramsey, AJ | 1 |
| Sotnikova, TD | 1 |
| Beaulieu, JM | 1 |
| Zhang, X | 1 |
| Caron, MG | 1 |
| Gainetdinov, RR | 1 |
| Andreoli, V | 1 |
| Caillard, V | 1 |
| Deo, RS | 1 |
| Rybakowski, JK | 2 |
| Versiani, M | 1 |
| Nierenberg, A | 1 |
| Lagomasino, I | 1 |
| Tedlow, J | 1 |
| Worthington, J | 1 |
| Rosenbaum, JF | 11 |
| Ross, DC | 1 |
| Quitkin, FM | 6 |
| Klein, DF | 2 |
| Levkovitz, Y | 1 |
| Caftori, R | 1 |
| Avital, A | 1 |
| Richter-Levin, G | 1 |
| Scott, LV | 2 |
| Dinan, TG | 2 |
| Davidson, JR | 2 |
| Meoni, P | 1 |
| Haudiquet, V | 1 |
| Cantillon, M | 1 |
| Hackett, D | 1 |
| Sonawalla, SB | 2 |
| Johnson, MW | 1 |
| Morray, M | 1 |
| Delgado, ML | 1 |
| Pingol, MG | 1 |
| Pava, J | 1 |
| Buchin, J | 1 |
| Sickinger, AH | 1 |
| Brunswick, DJ | 2 |
| Eichhorn, M | 1 |
| Eich, P | 1 |
| Novotny, V | 1 |
| Faltus, F | 1 |
| DeLong, GR | 1 |
| Ritch, CR | 1 |
| Burch, S | 1 |
| Rasgon, NL | 1 |
| Carter, MS | 1 |
| Elman, S | 1 |
| Bauer, M | 1 |
| Love, M | 1 |
| Korenman, SG | 1 |
| McCombs, JS | 1 |
| Shi, L | 1 |
| Stimmel, GL | 1 |
| Croghan, TW | 1 |
| Henry, ME | 2 |
| Kaufman, MJ | 2 |
| Hennen, J | 3 |
| Michelson, D | 2 |
| Schmidt, ME | 3 |
| Stoddard, E | 1 |
| Vukovic, AJ | 1 |
| Barreira, PJ | 1 |
| Cohen, BM | 3 |
| Bottonari, KA | 1 |
| Polania, LM | 1 |
| Irvin, R | 1 |
| Romeo, E | 1 |
| Pompili, E | 1 |
| di Michele, F | 1 |
| Pace, M | 1 |
| Bernardi, G | 1 |
| Pasinib, A | 1 |
| Wang, YC | 1 |
| Manev, H | 1 |
| Uz, T | 1 |
| Manev, R | 1 |
| Feiger, AD | 1 |
| Flament, MF | 1 |
| Boyer, P | 2 |
| Gillespie, JA | 1 |
| Mahal, Y | 1 |
| Quitkin, F | 3 |
| Dalery, J | 1 |
| Honig, A | 1 |
| Agid, O | 1 |
| Lerer, B | 1 |
| Sheu, WP | 1 |
| Detweiler, MB | 1 |
| Trinkle, DB | 1 |
| Varley, CK | 1 |
| Frederick, Bd | 1 |
| Villafuerte, RA | 1 |
| Stoddard, EP | 1 |
| Smoller, JW | 1 |
| Wan, YJ | 1 |
| Lin, KM | 1 |
| Miller, AL | 3 |
| Rogers, GR | 1 |
| Kennedy, MA | 4 |
| Corey-Lisle, PK | 1 |
| Birnbaum, H | 1 |
| Greenberg, P | 1 |
| Marynchenko, M | 1 |
| Dube, S | 2 |
| Sullivan, PF | 3 |
| Cloninger, CR | 1 |
| Smith, M | 1 |
| Winokur, A | 1 |
| DeMartinis, NA | 1 |
| McNally, DP | 1 |
| Gary, EM | 1 |
| Cormier, JL | 1 |
| Gary, KA | 1 |
| Chollet, CA | 1 |
| Andreatini, R | 1 |
| Tural, U | 1 |
| Onder, E | 1 |
| Roberts, RL | 1 |
| Perry, EB | 1 |
| Sanacora, G | 3 |
| Anand, A | 2 |
| Lynch-Colonese, K | 1 |
| Cappiello, A | 2 |
| Oren, DA | 1 |
| Kugaya, A | 2 |
| Liu, N | 1 |
| Fasula, D | 1 |
| Bolo, NR | 2 |
| Hodé, Y | 2 |
| Macher, JP | 2 |
| Joliat, MJ | 2 |
| Zhang, S | 1 |
| Trapp, NJ | 1 |
| Miner, CM | 3 |
| Hassman, HA | 1 |
| Glass, SJ | 1 |
| McManus, FC | 1 |
| O'Reardon, JP | 1 |
| Chopra, MP | 1 |
| Bergan, A | 1 |
| Gallop, R | 1 |
| DeRubeis, RJ | 1 |
| Crits-Christoph, P | 1 |
| Hughes, ME | 1 |
| Olié, JP | 1 |
| McIntosh, VV | 1 |
| Carter, FA | 1 |
| Bulik, CM | 1 |
| Young, EA | 2 |
| Altemus, M | 1 |
| Lopez, JF | 1 |
| Schatzberg, AF | 1 |
| DeBattista, C | 1 |
| Zubieta, JK | 2 |
| Williamson, DJ | 2 |
| Tohen, MF | 1 |
| Schatzberg, A | 2 |
| Andersen, SW | 2 |
| Van Campen, LE | 2 |
| Sanger, TM | 4 |
| Tollefson, GD | 2 |
| Shahsavand, E | 1 |
| Mesbahi, M | 1 |
| Kamkar, MZ | 1 |
| Sadeghi, M | 1 |
| Dashti-Khavidaki, S | 1 |
| Hamill, SK | 1 |
| Cassano, P | 2 |
| Soares, CN | 2 |
| Cohen, LS | 2 |
| Lyster, AK | 1 |
| Morgan, M | 3 |
| Dunkin, J | 1 |
| Witte, E | 2 |
| Montoya, HD | 1 |
| Marie-Mitchell, A | 1 |
| Chou, CP | 1 |
| James Gauderman, W | 1 |
| Azen, SP | 1 |
| Pae, CU | 1 |
| Lee, CU | 1 |
| Lee, SJ | 1 |
| Lee, C | 2 |
| Paik, IH | 2 |
| Petrycki, S | 2 |
| Glass, RM | 1 |
| Denninger, JW | 1 |
| Tossani, E | 2 |
| Pava, JA | 1 |
| Wan, GJ | 1 |
| Mallick, R | 1 |
| Casciano, R | 1 |
| Geissler, EC | 1 |
| Panish, JM | 1 |
| Kuenzel, HE | 1 |
| Murck, H | 3 |
| Held, K | 1 |
| Ziegenbein, M | 1 |
| Steiger, A | 1 |
| Burns, AM | 1 |
| Huang, SC | 1 |
| Chang, JC | 1 |
| Staley, JK | 1 |
| Bozkurt, A | 1 |
| Khan, S | 1 |
| Van Dyck, CH | 1 |
| Baldwin, RM | 1 |
| Seibyl, JP | 1 |
| Charney, D | 1 |
| Innis, RB | 1 |
| Otto, MW | 2 |
| Zajecka, J | 2 |
| Mannel, M | 1 |
| Greist, J | 1 |
| McNamara, RK | 1 |
| Mallinckrodt, CH | 3 |
| Rayamajhi, JN | 1 |
| Raskin, J | 1 |
| Möller, HJ | 1 |
| Rifkin, A | 1 |
| Rifkin, W | 1 |
| Antonuccio, D | 1 |
| Burns, D | 1 |
| Bridge, JA | 1 |
| Nilsson, M | 2 |
| Brown, EB | 2 |
| Heiligenstein, JH | 1 |
| Wehmeier, PM | 1 |
| Kluge, M | 1 |
| Maras, A | 1 |
| Riemann, D | 1 |
| Berger, M | 1 |
| Kohnen, R | 1 |
| Dittmann, RW | 1 |
| Gattaz, WF | 1 |
| Doggrell, SA | 1 |
| Wu, SL | 1 |
| Mascarini, A | 2 |
| Blardi, P | 2 |
| de Lalla, A | 2 |
| Auteri, A | 2 |
| Iapichino, S | 2 |
| Dell'Erba, A | 2 |
| Castrogiovanni, P | 2 |
| Brambilla, P | 1 |
| Hotopf, M | 1 |
| Aghayan, S | 1 |
| Jalili, SA | 1 |
| Yahyazadeh, O | 1 |
| Pakravan-Nejad, M | 1 |
| Willner, P | 1 |
| Hale, AS | 1 |
| Argyropoulos, S | 1 |
| Dekker, J | 2 |
| Molenaar, PJ | 1 |
| Kool, S | 2 |
| Van Aalst, G | 1 |
| Peen, J | 2 |
| de Jonghe, F | 1 |
| Porter, RJ | 2 |
| Lebowitz, BD | 1 |
| Ryan, JL | 1 |
| Bottiglieri, T | 1 |
| Cai, W | 1 |
| Khaoustov, VI | 1 |
| Xie, Q | 1 |
| Pan, T | 1 |
| Le, W | 1 |
| Yoffe, B | 1 |
| Nemets, B | 2 |
| Bersudsky, Y | 1 |
| Belmaker, RH | 2 |
| Boggio, PS | 3 |
| Fregni, F | 3 |
| Bermpohl, F | 1 |
| Mansur, CG | 1 |
| Rosa, M | 1 |
| Rumi, DO | 1 |
| Barbosa, ER | 1 |
| Odebrecht Rosa, M | 1 |
| Pascual-Leone, A | 2 |
| Rigonatti, SP | 3 |
| Marcolin, MA | 1 |
| Araujo Silva, MT | 1 |
| Shelton, C | 1 |
| Padmanabhan, SK | 1 |
| Vinall, PE | 1 |
| Lee, TW | 1 |
| Yang, CW | 1 |
| Kronenberg, S | 1 |
| Deliyannides, D | 1 |
| Davies, CA | 1 |
| Cyranowski, JM | 1 |
| Frank, E | 1 |
| Shear, MK | 1 |
| Swartz, H | 1 |
| Fagiolini, A | 1 |
| Scott, J | 1 |
| Kupfer, DJ | 1 |
| Albert, A | 1 |
| Mesters, P | 1 |
| Dewé, W | 1 |
| De Bruyckere, K | 1 |
| Sangeleer, M | 1 |
| Brown, SA | 1 |
| Calarge, C | 1 |
| Kuperman, S | 1 |
| Lee, MS | 1 |
| Ham, BJ | 1 |
| Kee, BS | 1 |
| Kim, JB | 1 |
| Yeon, BK | 1 |
| Oh, KS | 1 |
| Oh, BH | 1 |
| Jung, HY | 1 |
| Chee, IS | 1 |
| Choe, BM | 1 |
| de Swart, H | 1 |
| Friis Andersen, H | 1 |
| Manzano, E | 1 |
| Ortiz, T | 1 |
| Cusin, C | 3 |
| Mansfield, PR | 1 |
| Raven, MK | 1 |
| Jureidini, JN | 1 |
| Briggs, SD | 2 |
| Rogers, GM | 1 |
| Huang, GJ | 1 |
| Herbert, J | 1 |
| Halperin, J | 1 |
| Ehrlichman, H | 1 |
| Clemow, DB | 1 |
| Kim, J | 3 |
| Riggs, KW | 1 |
| Misri, S | 1 |
| Kent, N | 1 |
| Oberlander, TF | 1 |
| Grunau, RE | 1 |
| Fitzgerald, C | 1 |
| Rurak, DW | 1 |
| Serrano-Blanco, A | 1 |
| Gabarron, E | 1 |
| Garcia-Bayo, I | 1 |
| Soler-Vila, M | 1 |
| Caramés, E | 1 |
| Peñarrubia-Maria, MT | 1 |
| Pinto-Meza, A | 1 |
| Gallassi, R | 1 |
| Di Sarro, R | 1 |
| Morreale, A | 1 |
| Amore, M | 1 |
| Spalletta, G | 2 |
| Ripa, A | 1 |
| Bria, P | 1 |
| Caltagirone, C | 2 |
| Robinson, RG | 1 |
| Sackeim, HA | 1 |
| Roose, SP | 2 |
| Lavori, PW | 1 |
| Hammad, TA | 1 |
| Laughren, T | 1 |
| Racoosin, J | 1 |
| Roose, S | 1 |
| Laske, C | 1 |
| Stransky, E | 1 |
| Eschweiler, GW | 1 |
| Klein, R | 1 |
| Wittorf, A | 1 |
| Leyhe, T | 1 |
| Richartz, E | 1 |
| Köhler, N | 1 |
| Bartels, M | 1 |
| Buchkremer, G | 1 |
| Schott, K | 1 |
| Tsao, CW | 1 |
| Lin, YS | 1 |
| Bai, CH | 1 |
| Wu, SR | 1 |
| Pani, A | 1 |
| O'Brien, SM | 1 |
| Williamson, D | 1 |
| Tollefson, G | 1 |
| Lee, KM | 1 |
| Kim, YK | 1 |
| Shapira, B | 1 |
| Trachtenberg, A | 1 |
| Bellino, S | 2 |
| Zizza, M | 2 |
| Rinaldi, C | 2 |
| Bogetto, F | 2 |
| Scalia, M | 1 |
| Miller, KK | 1 |
| Sklarsky, KG | 2 |
| Hilliker, SE | 1 |
| Klibanski, A | 1 |
| Eckert, L | 1 |
| Lançon, C | 1 |
| Morgan, ML | 1 |
| Cookson, J | 1 |
| Gilaberte, I | 2 |
| Desaiah, D | 1 |
| Kajdasz, DK | 1 |
| Epperson, CN | 1 |
| Amin, Z | 1 |
| Naftolin, F | 1 |
| Czarkowski, KA | 1 |
| Stiklus, S | 1 |
| Anderson, GM | 1 |
| Song, Y | 1 |
| Zhou, D | 1 |
| Fan, J | 1 |
| Cheng, J | 1 |
| Petkova, E | 1 |
| Safer, DJ | 1 |
| Moreno, C | 1 |
| Roche, AM | 1 |
| Greenhill, LL | 1 |
| Pier, MP | 1 |
| Hulstijn, W | 2 |
| van Hoof, JJ | 1 |
| Sabbe, BG | 1 |
| Guo, Y | 1 |
| Nilsson, ME | 4 |
| Heiligenstein, J | 1 |
| Wilson, MG | 1 |
| Whelan, F | 2 |
| Deloukas, P | 1 |
| Whittaker, P | 1 |
| Delgado, M | 1 |
| Cantor, RM | 1 |
| McCann, SM | 1 |
| Chang, YH | 1 |
| Pender, M | 1 |
| Kennedy, SE | 1 |
| Koeppe, RA | 1 |
| Leu, HS | 1 |
| Liu, JW | 1 |
| Hughes, J | 1 |
| Casat, C | 3 |
| Jensen, PS | 1 |
| Mao, PX | 1 |
| Tang, YL | 1 |
| Jiang, F | 1 |
| Gu, X | 1 |
| Qian, M | 1 |
| Ma, C | 1 |
| Mitchell, PB | 1 |
| Cai, ZJ | 1 |
| Beasley, CM | 7 |
| Wines, JD | 1 |
| Tamura, RN | 1 |
| Shear, D | 1 |
| Amsterdam, J | 2 |
| Strong, RE | 1 |
| Bremner, JD | 1 |
| Vythilingam, M | 1 |
| Vermetten, E | 1 |
| Prospero-Garcia, KA | 1 |
| Torres-Ruiz, A | 1 |
| Ramirez-Bermudez, J | 1 |
| Velazquez-Moctezuma, J | 1 |
| Arana-Lechuga, Y | 1 |
| Teran-Perez, G | 1 |
| Sernyak, MJ | 1 |
| Rosenheck, RA | 1 |
| Sharma, A | 1 |
| Busnello, JV | 1 |
| Ribeiro, L | 1 |
| Thakur, S | 1 |
| Elashoff, RM | 1 |
| Zhu, F | 1 |
| Xiao, Z | 1 |
| Tang, J | 1 |
| Liu, W | 1 |
| Wu, Y | 1 |
| Cao, Z | 1 |
| Rintelmann, JW | 2 |
| Carmody, T | 3 |
| Tan, ZL | 2 |
| Bao, AM | 2 |
| Zhao, GQ | 1 |
| Liu, YJ | 2 |
| Zhou, JN | 2 |
| Reimherr, FW | 2 |
| Łojko, D | 1 |
| Spring, B | 1 |
| Doran, N | 1 |
| Pagoto, S | 1 |
| McChargue, D | 1 |
| Cook, JW | 1 |
| Bailey, K | 1 |
| Crayton, J | 1 |
| Hedeker, D | 1 |
| Peterson, TJ | 1 |
| Feldman, G | 1 |
| Fresco, DM | 1 |
| Graves, L | 1 |
| Holmes, A | 1 |
| Bogdan, R | 1 |
| Bohn, L | 1 |
| Lury, RA | 1 |
| Bragulat, V | 1 |
| Paillère-Martinot, ML | 1 |
| Artiges, E | 1 |
| Frouin, V | 1 |
| Poline, JB | 1 |
| Martinot, JL | 1 |
| Chen, YC | 1 |
| Shen, YC | 1 |
| Hung, YJ | 1 |
| Chou, CH | 1 |
| Yeh, CB | 1 |
| Perng, CH | 1 |
| Fraguas, R | 1 |
| Marci, C | 1 |
| Bankier, B | 1 |
| Loh, R | 1 |
| Dougherty, DD | 1 |
| Fu, CH | 3 |
| Williams, SC | 3 |
| Brammer, MJ | 2 |
| Suckling, J | 3 |
| Cleare, AJ | 2 |
| Walsh, ND | 3 |
| Mitterschiffthaler, MT | 3 |
| Andrew, CM | 1 |
| Pich, EM | 3 |
| Bullmore, ET | 2 |
| Fountoulakis, KN | 1 |
| Samolis, S | 1 |
| Iacovides, A | 1 |
| St Kaprinis, G | 1 |
| Vaishnavi, S | 1 |
| Connor, K | 1 |
| Meyers, AL | 1 |
| Faries, DE | 1 |
| Detke, MJ | 3 |
| Van, HL | 1 |
| Schoevers, RA | 1 |
| Hendriksen, M | 1 |
| Lai, AL | 1 |
| Zhao, YW | 1 |
| Qi, HY | 1 |
| Zhang, JS | 1 |
| Zhang, LS | 1 |
| Weng, YQ | 1 |
| Rubens, R | 1 |
| Wessel, T | 1 |
| Caron, J | 1 |
| Wilson, P | 1 |
| Roth, T | 1 |
| Mehta, MA | 1 |
| Kedziora, J | 1 |
| Florkowski, A | 1 |
| Edwards, JL | 1 |
| Kirk, KK | 1 |
| Midha, CK | 1 |
| Cardoso, EF | 1 |
| Martins Maia, F | 1 |
| Luis Myczkowski, M | 1 |
| Coracini, K | 1 |
| Lopes Vieira, A | 1 |
| Melo, LM | 1 |
| Sato, JR | 1 |
| Antonio Marcolin, M | 1 |
| Cruz, AC | 1 |
| Reis Barbosa, E | 1 |
| Amaro, E | 1 |
| Jain, S | 1 |
| Carmody, TJ | 1 |
| Morris, DW | 1 |
| Coffey, B | 1 |
| Wieland, N | 1 |
| Benattia, I | 1 |
| Demitrack, M | 1 |
| Sloan, DM | 1 |
| Gourley, SL | 1 |
| Wu, FJ | 1 |
| Kiraly, DD | 1 |
| Ploski, JE | 1 |
| Kedves, AT | 1 |
| Taylor, JR | 1 |
| Herman, KC | 1 |
| Ostrander, R | 1 |
| Arnold, KK | 1 |
| Yager, J | 1 |
| Tauscher-Wisniewski, S | 2 |
| Caldwell, C | 1 |
| Plewes, J | 2 |
| Allen, AJ | 1 |
| Pizzagalli, DA | 1 |
| Ooi, C | 1 |
| Bullmore, E | 1 |
| Pritchett, YL | 1 |
| Ossanna, MJ | 1 |
| Swindle, RW | 1 |
| Xu, J | 1 |
| Ball, SG | 1 |
| Polzer, J | 1 |
| Acharya, N | 1 |
| Myczkowski, ML | 1 |
| Otta, E | 1 |
| Fiquer, JT | 1 |
| Ribeiro, RB | 1 |
| Nitsche, MA | 1 |
| Prentice, ED | 1 |
| Houston, JP | 1 |
| Swindle, R | 1 |
| Rouillon, PF | 1 |
| Parry, BL | 1 |
| Jonsson, GW | 1 |
| Moosa, MY | 1 |
| Jeenah, FY | 1 |
| Jalali, M | 1 |
| Peet, M | 1 |
| Crawford, CM | 1 |
| Scalia, MJ | 1 |
| Lin, KS | 1 |
| Lin, CY | 1 |
| Chung, T | 1 |
| Martin, C | 1 |
| Abebe, K | 1 |
| DeBar, L | 1 |
| McCracken, J | 1 |
| Melhem, N | 1 |
| Pearson, JL | 1 |
| Marcus, RN | 1 |
| McQuade, RD | 1 |
| Carson, WH | 1 |
| Hennicken, D | 1 |
| Simon, JS | 1 |
| Tonev, ST | 1 |
| Mario, J | 1 |
| Norquist, G | 1 |
| McGuire, TG | 1 |
| Essock, SM | 1 |
| Goodyer, IM | 1 |
| Dubicka, B | 1 |
| Wilkinson, P | 1 |
| Kelvin, R | 1 |
| Roberts, C | 1 |
| Byford, S | 1 |
| Breen, S | 1 |
| Ford, C | 1 |
| Barrett, B | 1 |
| Leech, A | 1 |
| Rothwell, J | 1 |
| White, L | 1 |
| Harrington, R | 1 |
| Fazzino, F | 1 |
| Montes, C | 1 |
| Carreira, I | 1 |
| Westenberg, H | 1 |
| Vandoolaeghe, E | 2 |
| Demedts, P | 1 |
| Wauters, A | 1 |
| Neels, H | 1 |
| Meltzer, HY | 1 |
| Goldstein, DJ | 2 |
| Hamilton, SH | 1 |
| Masica, DN | 1 |
| Khouzam, HR | 1 |
| Kissmeyer, P | 1 |
| Uzunova, V | 1 |
| Sheline, Y | 1 |
| Rasmusson, A | 1 |
| Uzunov, DP | 1 |
| Costa, E | 1 |
| Guidotti, A | 1 |
| Blumenfield, M | 1 |
| Levy, NB | 1 |
| Spinowitz, B | 1 |
| Charytan, C | 1 |
| Dubey, AK | 1 |
| Solomon, RJ | 1 |
| Todd, R | 1 |
| Goodman, A | 1 |
| Bergstrom, RF | 1 |
| Verkerk, R | 1 |
| Lin, A | 1 |
| Scharpé, S | 1 |
| Thomas, P | 1 |
| Goudemand, M | 1 |
| Rousseaux, M | 1 |
| Mentré, F | 1 |
| Golmard, JL | 1 |
| Aubin-Brunet, V | 1 |
| Bouhassira, M | 1 |
| Jouvent, R | 1 |
| Chouinard, G | 1 |
| Saxena, B | 1 |
| Bélanger, MC | 1 |
| Ravindran, A | 1 |
| Bakish, D | 1 |
| Beauclair, L | 1 |
| Morris, P | 1 |
| Vasavan Nair, NP | 1 |
| Manchanda, R | 1 |
| Reesal, R | 1 |
| Remick, R | 1 |
| O'Neill, MC | 1 |
| Delgado, PL | 1 |
| Miller, HL | 1 |
| Salomon, RM | 1 |
| Moreno, FA | 1 |
| Heninger, GR | 1 |
| Peretti, CS | 1 |
| Finkel, SI | 1 |
| Richter, EM | 1 |
| Clary, CM | 1 |
| Batzar, E | 1 |
| Bech, P | 1 |
| Raabaek Olsen, L | 1 |
| Jarløv, N | 1 |
| Hammer, M | 1 |
| Schütze, T | 1 |
| Breum, L | 1 |
| Klimke, A | 1 |
| Larisch, R | 1 |
| Janz, A | 1 |
| Vosberg, H | 1 |
| Müller-Gärtner, HW | 1 |
| Gaebel, W | 1 |
| Garcia-España, F | 1 |
| Fawcett, J | 2 |
| Reimherr, F | 1 |
| Rosenbaum, J | 1 |
| Beasley, C | 1 |
| Sabbe, B | 1 |
| van Hoof, J | 1 |
| Tuynman-Qua, HG | 1 |
| Zitman, F | 1 |
| Sechter, D | 1 |
| Troy, S | 1 |
| Paternetti, S | 1 |
| New, AS | 1 |
| Woo-Ming, A | 1 |
| Mitropoulou, V | 1 |
| Silverman, J | 1 |
| Reynolds, D | 1 |
| Schopick, F | 1 |
| Trestman, RL | 1 |
| Siever, LJ | 1 |
| Mullen, LS | 1 |
| Blanco, C | 1 |
| Vaughan, SC | 1 |
| Vaughan, R | 1 |
| Pillay, SS | 1 |
| Bonello, CM | 1 |
| Lafer, BC | 1 |
| Yurgelun-Todd, D | 1 |
| Zaharia, MD | 1 |
| Griffiths, J | 1 |
| Merali, Z | 1 |
| Anisman, H | 1 |
| Flint, AJ | 1 |
| Rifat, SL | 1 |
| Hostetter, A | 1 |
| Stowe, ZN | 1 |
| Strader, JR | 1 |
| McLaughlin, E | 1 |
| Llewellyn, A | 1 |
| Corrigan, MH | 1 |
| Denahan, AQ | 1 |
| Wright, CE | 1 |
| Ragual, RJ | 1 |
| Evans, DL | 1 |
| Lucca, A | 1 |
| Gentilini, G | 1 |
| Lopez-Silva, S | 1 |
| Soldarini, A | 1 |
| Tanum, L | 1 |
| Dunkin, JJ | 1 |
| Kasl-Godley, JE | 1 |
| Rosenberg-Thompson, S | 1 |
| Coppen, A | 1 |
| Bailey, J | 1 |
| Nédélec, JF | 1 |
| Lainé, E | 1 |
| Wagner, G | 1 |
| Montgomery, SA | 1 |
| Judge, R | 2 |
| Shen, JH | 1 |
| Jindal, R | 1 |
| Driver, HS | 1 |
| Shapiro, CM | 1 |
| Martinez, D | 1 |
| Broft, A | 1 |
| Laruelle, M | 1 |
| Mayberg, HS | 1 |
| Brannan, SK | 1 |
| Tekell, JL | 1 |
| Silva, JA | 1 |
| Mahurin, RK | 1 |
| McGinnis, S | 1 |
| Jerabek, PA | 1 |
| Plewes, JM | 1 |
| Kumar, V | 1 |
| Koke, SC | 2 |
| Kopp, JB | 2 |
| Burger, JK | 1 |
| Spillmann, MK | 1 |
| Worthington, JJ | 1 |
| Gonzales, JS | 3 |
| Puiigdemont, D | 1 |
| Ferreri, M | 1 |
| Lavergne, F | 1 |
| Berlin, I | 1 |
| Payan, C | 1 |
| Puech, AJ | 1 |
| Yohannes, AM | 1 |
| Connolly, MJ | 1 |
| Baldwin, RC | 1 |
| Grunhaus, L | 1 |
| Hirschman, S | 1 |
| Dolberg, OT | 1 |
| Schreiber, S | 1 |
| Dannon, PN | 1 |
| Schmitz, JM | 1 |
| Averill, P | 1 |
| Stotts, AL | 1 |
| Moeller, FG | 1 |
| Rhoades, HM | 1 |
| Grabowski, J | 1 |
| Wellington, K | 1 |
| Perry, CM | 1 |
| Gregory, RJ | 1 |
| Jindal, RD | 1 |
| Wu, WH | 1 |
| Huo, SJ | 1 |
| Parow, AM | 1 |
| Hirashima, F | 1 |
| Ke, Y | 1 |
| Moore, CM | 1 |
| Frederick, Bde B | 1 |
| Witte, EA | 1 |
| Entsuah, AR | 1 |
| Bottonari, K | 1 |
| Iacoviello, B | 1 |
| Leo, A | 1 |
| Di Muro, A | 1 |
| Hoog, SL | 1 |
| Judge, RA | 1 |
| Mallinckrodt, C | 1 |
| Demitrack, MA | 1 |
| Munir, R | 1 |
| Bilbao Garay, J | 1 |
| Mesa Plaza, N | 1 |
| Castilla Castellano, V | 1 |
| Dhimes Tejada, P | 1 |
| Pasini, A | 1 |
| Stubbeman, WF | 1 |
| Rosenberg, S | 1 |
| Uijtdehaage, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)[NCT02709746] | Phase 3 | 784 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Assessment of Efficacy and Safety of Anodal Transcranial Direct Current Stimulation (TDCS) in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemics[NCT04780152] | Phase 2/Phase 3 | 172 participants (Anticipated) | Interventional | 2021-10-31 | Recruiting | ||
| A Sequential, Multiple Assignment Randomized Trial (SMART) for Non-specialist Treatment of Common Mental Disorders in Kenya: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research (DAPPER) Project[NCT03466346] | 2,710 participants (Anticipated) | Interventional | 2020-08-31 | Active, not recruiting | |||
| Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause[NCT05346445] | 91 participants (Actual) | Interventional | 2021-01-20 | Completed | |||
| A 8-week, Rater-blind, Active-controlled, Randomized Study to Compare the Effectiveness of Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depressive Disorder[NCT01824433] | Phase 4 | 189 participants (Actual) | Interventional | 2013-03-07 | Completed | ||
| Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine[NCT01075529] | Phase 4 | 140 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Light and Ion Treatment to Enhance Medication Efficacy in Depression[NCT00958204] | Phase 3 | 134 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Treatment for Adolescents With Depression Study (TADS)[NCT00006286] | Phase 3 | 432 participants | Interventional | 1998-09-30 | Completed | ||
| A Randomized Controlled Trial of Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation Associated With Major Depressive Disorder[NCT04502758] | 80 participants (Anticipated) | Interventional | 2022-04-04 | Recruiting | |||
| A Preliminary Clinical Study on the Rapid Antidepressant Effects of Adenosine Triphosphate (ATP) and Phosphocreatine Combinated With Fluoxetine[NCT03138681] | Phase 2 | 42 participants (Anticipated) | Interventional | 2017-05-03 | Recruiting | ||
| Effects of Nutrients Supplementation in Antidepressant Treated Depressive Disorder Patients[NCT04179006] | 120 participants (Anticipated) | Interventional | 2019-11-14 | Recruiting | |||
| A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Effects of a Turmeric and Black Cumin Seed Formulation on Cholesterol Levels Among Generally Healthy Participants[NCT03175757] | 33 participants (Actual) | Interventional | 2017-05-12 | Completed | |||
| Prophylactic Cognitive Therapy for Depression.[NCT00118404] | Phase 3 | 523 participants (Actual) | Interventional | 2000-03-31 | Completed | ||
| Non-Invasive Brain Imaging Techniques That Predict Antidepressant Responsiveness and Provide Insights Into the Mechanism of Action of Venlafaxine ER vs. Fluoxetine[NCT00909155] | 50 participants (Actual) | Interventional | 2002-07-31 | Completed | |||
| An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term[NCT00046020] | Phase 4 | 1,096 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder[NCT00849901] | Phase 3 | 337 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder[NCT00849693] | Phase 3 | 463 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Narrative Therapy for Treatment-Resistant Obsessive-Compulsive Disorder[NCT04154085] | 14 participants (Actual) | Interventional | 2021-01-02 | Completed | |||
| Pediatric MDD: Sequential Treatment With Fluoxetine and Relapse Prevention[NCT00612313] | 144 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| [NCT00265291] | Phase 2 | 700 participants (Actual) | Interventional | 1999-11-30 | Completed | ||
| Role of the Gut Microbiome as Determinant of Depression in Multiple Sclerosis Subjects[NCT05808101] | 120 participants (Anticipated) | Observational | 2022-01-27 | Recruiting | |||
| Efficacy of Individualized Homeopathic Treatment for Moderate to Severe Depression in Peri- and Postmenopausal Women: a Randomized Placebo-controlled, Double-blind, Double-dummy, Study Protocol[NCT01635218] | Phase 2 | 133 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| Can Non-drug Antidepressant Treatments Influence the Way the Human Brain Processes Information?[NCT03688048] | 50 participants (Actual) | Interventional | 2017-02-20 | Completed | |||
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| Effect of Bright Light Therapy on Depression Symptoms in Adult Inpatients With Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD)[NCT04921332] | 4 participants (Actual) | Interventional | 2021-09-07 | Terminated (stopped due to Study was stopped secondary to principal investigator needing to analyze data and present prior to graduating. Target enrollment not able to be reached prior to this.) | |||
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| The Effect of Seven-Day Atorvastatin Administration on Emotional Processing, Reward Processing, and Inflammation in Healthy Volunteers[NCT03966859] | 50 participants (Actual) | Interventional | 2019-06-19 | Completed | |||
| Development and Evaluation of an Ecological Momentary Assessment (EMA) Baseline Screening System for Therapists Who Treat Youths With Depressive Symptoms[NCT04830527] | 60 participants (Actual) | Interventional | 2020-11-24 | Terminated (stopped due to The study was terminated early due to the difficulty in recruiting cases during a pandemic period.) | |||
| A Prospective Interventional Trial of Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation[NCT04727827] | 110 participants (Actual) | Interventional | 2021-02-01 | Completed | |||
| Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression[NCT01545843] | Phase 2 | 68 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Randomized Controlled Study on the Effect of Pharmacogenomics on Individualized Precise Treatment of Patients With Depression[NCT05669391] | 120 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | |||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder[NCT00095758] | Phase 3 | 1,200 participants | Interventional | 2004-09-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder.[NCT00095823] | Phase 3 | 1,200 participants | Interventional | 2004-06-30 | Completed | ||
| Effects of Aripiprazole on the Steady-State Pharmacokinetics of Venlafaxine in Healthy Subjects[NCT00362271] | Phase 1 | 38 participants | Interventional | 2006-08-31 | Completed | ||
| Effects on Aripiprazole on the Steady-State Pharmacokinetics of Escitalopram in Healthy Subjects[NCT00361790] | Phase 1 | 25 participants | Interventional | 2006-08-31 | Completed | ||
| Continuation Phase CBT for Youth With MDD[NCT00158301] | 72 participants (Actual) | Interventional | 2004-09-30 | Completed | |||
| Childhood Depression: Remission and Relapse[NCT00332787] | 200 participants | Interventional | 2000-06-30 | Completed | |||
| Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)[NCT00018902] | Phase 2/Phase 3 | 334 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency[NCT01379469] | Phase 2 | 20 participants (Actual) | Interventional | 2012-01-31 | Terminated | ||
| Pharmacological Intervention Project (Fluoxetine)[NCT00027378] | Phase 2 | 50 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Randomized Trial of KEEP-P, a Preventive Intervention for Foster Preschoolers[NCT03106636] | 442 participants (Actual) | Interventional | 2014-05-20 | Completed | |||
| Salicylic Augmentation in Depression[NCT03152409] | Phase 2 | 74 participants (Anticipated) | Interventional | 2018-11-15 | Recruiting | ||
| Hypnotics in the Treatment of Psychiatric Disorders[NCT00247624] | Phase 4 | 60 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Depression Response to Eszopiclone in Adults With Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety & Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects With Insomnia Relate[NCT00368030] | Phase 3 | 545 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Fluoxetine for Major Depressive Disorder/Cannabis Disorder in Young People[NCT00149643] | Phase 2 | 70 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Antidepressant Use During Pregnancy[NCT00279370] | 283 participants (Actual) | Observational | 1999-09-30 | Completed | |||
| Using Smartphones to Enhance the Treatment of Childhood Anxiety[NCT02259036] | 40 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.[NCT00235508] | Phase 4 | 420 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Prozac Treatment of Major Depression: Discontinuation Study[NCT00427128] | Phase 4 | 627 participants (Actual) | Interventional | 1995-11-30 | Completed | ||
| Creatine Augmentation in Female & Male Veterans With Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder[NCT01175616] | Phase 4 | 0 participants (Actual) | Interventional | 2012-09-30 | Withdrawn (stopped due to Study withdrawn from ClinicalTrials.gov.) | ||
| Adjunctive Creatine Treatment for Adolescent Females With Major Depressive Disorder Who Are Non-Responders to Fluoxetine or Escitalopram: A Magnetic Resonance Spectroscopy Study[NCT00851006] | Phase 2 | 13 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Placebo-Controlled Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder: a Magnetic Resonance Spectroscopy Study[NCT02134808] | Phase 4 | 71 participants (Actual) | Interventional | 2014-11-21 | Completed | ||
| Fluoxetine Versus Fluoxetine Plus DU125530 in Latency of Antidepressant Response Shortening in Major Depressive Disorder[NCT01119430] | Phase 2 | 50 participants (Actual) | Interventional | 2004-05-31 | Terminated (stopped due to interim analysis suggested no differences with whole sample) | ||
| An Assessor-Blinded, Randomised Controlled Trial of Acupuncture to Prevent Chemobrain in Breast Cancer Patients[NCT02457039] | 93 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| A Multisite, Assessor-blinded, Randomized Controlled Trial of Acupuncture for Post-stroke Depression[NCT02644161] | 91 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| Transcutaneous Electrical Acupoint Stimulation (TEAS) and Dense Cranial Electroacupuncture Stimulation (DCEAS) for Psychiatric Sequelae and Related Biomarkers in Women Victims of Domestic Violence: a Randomized Controlled Trial[NCT05102253] | 110 participants (Anticipated) | Interventional | 2022-07-13 | Recruiting | |||
| Combining Acupuncture and Acupressure for Community-dwelling Elderly With Dementia: an Assessor-blinded, Randomized Controlled Trial[NCT04305951] | 248 participants (Anticipated) | Interventional | 2021-10-05 | Recruiting | |||
| Using Telehealth to Improve Outcomes in Veterans at Risk for Suicide[NCT03724370] | 180 participants (Anticipated) | Interventional | 2018-12-14 | Recruiting | |||
| Efficacy Of Switching From SSRI to Desvenlafaxine on Cognitive Function In Patients With an Acute Episode of Major Depression[NCT03432221] | 36 participants (Anticipated) | Observational | 2018-04-03 | Recruiting | |||
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| [NCT00229476] | Phase 4 | 60 participants | Interventional | 2003-12-31 | Completed | ||
| Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior[NCT05390918] | 190 participants (Anticipated) | Interventional | 2022-10-20 | Recruiting | |||
| Study of Web-based Cognitive Behavioral Therapy in Adolescent Depression; Randomized Controlled Trial for Korean Adolescents[NCT02072304] | 164 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Stepped Approach to Reducing Risk of Suicide in Primary Care[NCT06018285] | 4,648 participants (Anticipated) | Interventional | 2023-08-08 | Recruiting | |||
| Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544] | Phase 2 | 236 participants (Anticipated) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Increasing Access to Evidence-based Treatments for Depression: The Development and Evaluation of a Digital Training Platform for Interpersonal Psychotherapy.[NCT04619615] | 44 participants (Actual) | Interventional | 2020-07-27 | Active, not recruiting | |||
| Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment[NCT00296777] | Phase 4 | 28 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Genetics of Self-injurious Behaviour[NCT05563324] | 234 participants (Actual) | Observational | 2014-05-09 | Completed | |||
| Influences on and Prevention of Self-harm Behaviour Among the Most At-risk Adolescents[NCT05765864] | 400 participants (Anticipated) | Observational | 2023-03-23 | Recruiting | |||
| High-definition Transcranial Direct Current Stimulation (HD-tDCS) as Augmentation Therapy in Late-life Depression (LLD) With Suboptimal Response to Treatment - Double-blinded Randomized Sham-controlled Trial[NCT05322863] | 58 participants (Anticipated) | Interventional | 2021-02-22 | Recruiting | |||
| Mood Disorder Cohort Research Consortium (MDCRC) in Korea[NCT03088657] | 500 participants (Anticipated) | Observational [Patient Registry] | 2015-09-30 | Recruiting | |||
| Efficacy of Memantine in the Treatment of Fibromyalgia: a Double-blind Randomized Trial[NCT01653457] | Phase 3 | 60 participants (Anticipated) | Interventional | 2012-09-30 | Not yet recruiting | ||
| Interaction of Estrogen and Serotonin in Modulating Brain Activation in Menopause[NCT01208324] | 47 participants (Actual) | Interventional | 2010-03-04 | Completed | |||
| Attachment Based Family Therapy (ABFT) for Suicidal Adolescents[NCT01537419] | 129 participants (Actual) | Interventional | 2012-03-31 | Completed | |||
| Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2[NCT00519012] | Phase 4 | 200 participants (Anticipated) | Interventional | 2007-08-31 | Recruiting | ||
| Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers[NCT00018174] | Phase 3 | 247 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features[NCT00035321] | Phase 3 | 600 participants | Interventional | 2002-04-30 | Completed | ||
| Evaluation of Blended Stepped-care Mental Well-being Intervention for Adults: A Randomized Controlled Trial[NCT05395312] | 402 participants (Anticipated) | Interventional | 2022-07-30 | Active, not recruiting | |||
| Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial[NCT01080794] | 61 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| A Randomized, Single Blind, Controlled, Longitudinal Study of the Effects of Venlafaxine Hydrochloride Capsules on the Language Function of Stroke Patients With Subcortical Aphasia Using fMRI[NCT03588572] | 43 participants (Actual) | Interventional | 2018-08-01 | Completed | |||
| Home-based Transcranial Direct Current Stimulation in Postpartum Depression: the Feasibility Study and Pilot Study[NCT05046405] | 50 participants (Anticipated) | Interventional | 2022-10-02 | Not yet recruiting | |||
| Real-world Data Collection and Real-world Evidence Clinical Demonstration Study of tDCS for the Treatment of Depression in Perinatal Women[NCT06015425] | 125 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | |||
| The Use of Electronic Communications-based Automated Technologies to Augment Traditional Mental Health Care[NCT03925038] | 100 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | |||
| A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior ADT[NCT00683852] | Phase 3 | 225 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A Phase I Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of HS-10353 in Chinese Adult Subjects[NCT05195203] | Phase 1 | 96 participants (Actual) | Interventional | 2021-01-27 | Completed | ||
| Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel[NCT01957501] | 75 participants (Actual) | Observational | 2013-07-31 | Terminated (stopped due to Funding has been terminated for this study.) | |||
| Investigating the Efficacy of a Top-Down Approach to Cognitive Remediation in Individuals With Affective Disorders[NCT02502604] | 58 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Assesment of Vitamin B6 Level in Patients With Major Depressive Disorder[NCT05649293] | 94 participants (Anticipated) | Observational | 2023-04-01 | Not yet recruiting | |||
| "Response Variability in Treatment Resistant Depression - an Ancillary Study to Sequenced Treatment Alternatives to Relieve Depression (STAR*D)"[NCT00375843] | Phase 4 | 118 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Cerebral Neuroinflammation During Major Depressive Episode: Multicentric Comparative Study.[NCT03314155] | 60 participants (Anticipated) | Interventional | 2018-12-07 | Recruiting | |||
| Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Remission is defined as a CDRS-R total score <= 28. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| Vortioxetine 10 mg/Day | 21 |
| Vortioxetine 20 mg/Day | 24 |
| Fluoxetine 20 mg/Day, | 32 |
| Placebo | 20 |
Children Depression Rating Scale - Response: defined as a >= 50% decrease in CDRS-R total score, calculated as (change from baseline [Randomization])/(baseline value - 17). (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| Vortioxetine 10 mg/Day | 53 |
| Vortioxetine 20 mg/Day | 60 |
| Fluoxetine 20 mg/Day, | 68 |
| Placebo | 49 |
Remission defined as CGI-S score of 1 or 2. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| Vortioxetine 10 mg/Day | 26 |
| Vortioxetine 20 mg/Day | 33 |
| Fluoxetine 20 mg/Day, | 36 |
| Placebo | 24 |
The GBI 10-item mania scale is a parent- and subject-rated scale designed to screen for manic symptoms in children and adolescents. The 10 items are rated on a scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranges from 0 to 30 points, with high scores indicating greater pathology. (NCT02709746)
Timeframe: From randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -5.48 |
| Vortioxetine 20 mg/Day | -5.55 |
| Fluoxetine 20 mg/Day, | -6.30 |
| Placebo | -6.03 |
Change in Children Depression Rating Scale - Revised (CDRS-R): Behaviour. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. behaviour is one of four subscores defined in the CDRS-R:sum of items 1, 2, 3; score ranges from 3 to 21. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -4.32 |
| Vortioxetine 20 mg/Day | -4.90 |
| Fluoxetine 20 mg/Day, | -5.52 |
| Placebo | -4.73 |
Change in Children Depression Rating Scale - Revised (CDRS-R) Mood. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Mood is one of four subscores defined in the CDRS-R: sum of items 8, 11, 14, 15; score range 4 to 28. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -5.05 |
| Vortioxetine 20 mg/Day | -5.47 |
| Fluoxetine 20 mg/Day, | -6.53 |
| Placebo | -5.32 |
Change in Children Depression Rating Scale - Revised (CDRS-R): Somatic. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Somatic is one of four subscores defined in the CDRS-R: sum of items 4, 5, 6, 7, 16, 17; score ranges from 6 to 36. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -5.63 |
| Vortioxetine 20 mg/Day | -6.03 |
| Fluoxetine 20 mg/Day, | -6.79 |
| Placebo | -5.78 |
Change in Children Depression Rating Scale - Revised (CDRS-R): Subjective. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Subjective is one of four subscores defined in the CDRS-R: sum of items 9, 10, 12, 13; score ranges from 4 to 28. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -2.41 |
| Vortioxetine 20 mg/Day | -2.63 |
| Fluoxetine 20 mg/Day, | -3.23 |
| Placebo | -2.66 |
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).Children and parents answer separately. Rater judges and selects 'Best'. (NCT02709746)
Timeframe: At week 2
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -9.58 |
| Vortioxetine 20 mg/Day | -10.15 |
| Fluoxetine 20 mg/Day, | -10.34 |
| Placebo | -8.83 |
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression). (NCT02709746)
Timeframe: At week 4
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -14.32 |
| Vortioxetine 20 mg/Day | -15.03 |
| Fluoxetine 20 mg/Day, | -16.25 |
| Placebo | -13.71 |
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression). (NCT02709746)
Timeframe: At week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -15.43 |
| Vortioxetine 20 mg/Day | -17.78 |
| Fluoxetine 20 mg/Day, | -19.20 |
| Placebo | -16.71 |
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression). (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -17.09 |
| Vortioxetine 20 mg/Day | -18.94 |
| Fluoxetine 20 mg/Day, | -21.95 |
| Placebo | -18.22 |
| Vortioxetine Average (Avg. VOR) | -18.01 |
The Children's Global Assessment Score (CGAS) is a rating scale which measures psychological, social and school functioning for children. The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The items range in value from 1 (most functionally impaired child) to 100 (the healthiest). A total score above 70 indicates normal function. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | 12.24 |
| Vortioxetine 20 mg/Day | 13.89 |
| Fluoxetine 20 mg/Day, | 16.43 |
| Placebo | 14.52 |
The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients). (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -1.23 |
| Vortioxetine 20 mg/Day | -1.38 |
| Fluoxetine 20 mg/Day, | -1.59 |
| Placebo | -1.21 |
Using the 10-item depression subscale, assessed by parent (PGBI-10D). Change from randomization to Week 8 in GBI Total Parent/Guardian Version Depression score. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome. (NCT02709746)
Timeframe: From randomization to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -6.23 |
| Vortioxetine 20 mg/Day | -6.48 |
| Fluoxetine 20 mg/Day, | -8.00 |
| Placebo | -6.62 |
PQ-LES-Q total score (items 1 to 14). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ LES Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning (and item 15 allows subjects to summarize their experience in a global rating). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1-14 (this outcome measurement) is 14 to 70, with higher scores indicating greater satisfaction. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | 7.62 |
| Vortioxetine 20 mg/Day | 7.56 |
| Fluoxetine 20 mg/Day, | 9.26 |
| Placebo | 7.06 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -0.47 |
| Vortioxetine 20 mg/Day | -0.76 |
| Fluoxetine 20 mg/Day, | -0.78 |
| Placebo | -0.71 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -0.93 |
| Vortioxetine 20 mg/Day | -1.09 |
| Fluoxetine 20 mg/Day, | -1.33 |
| Placebo | -1.18 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -1.00 |
| Vortioxetine 20 mg/Day | -1.13 |
| Fluoxetine 20 mg/Day, | -1.33 |
| Placebo | -1.14 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -0.51 |
| Vortioxetine 20 mg/Day | -0.70 |
| Fluoxetine 20 mg/Day, | -1.01 |
| Placebo | -0.59 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -1.12 |
| Vortioxetine 20 mg/Day | -0.97 |
| Fluoxetine 20 mg/Day, | -0.83 |
| Placebo | -0.76 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -1.90 |
| Vortioxetine 20 mg/Day | -1.71 |
| Fluoxetine 20 mg/Day, | -2.45 |
| Placebo | -2.12 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -1.18 |
| Vortioxetine 20 mg/Day | -1.40 |
| Fluoxetine 20 mg/Day, | -1.55 |
| Placebo | -1.27 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | -0.96 |
| Vortioxetine 20 mg/Day | -1.17 |
| Fluoxetine 20 mg/Day, | -0.91 |
| Placebo | -1.33 |
PQ-LES-Q overall evaluation score (item 15). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning and item 15 allows subjects to summarize their experience in a global rating (this outcome measurement). Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good). (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | 0.54 |
| Vortioxetine 20 mg/Day | 0.43 |
| Fluoxetine 20 mg/Day, | 0.67 |
| Placebo | 0.51 |
The Symbol Digit Modalities Test (SDMT) is a cognitive test designed to assess speed of performance requiring visual perception, spatial decision-making and psychomotor skills. The SDMT consists of 110 geometric symbols that the patient has to substitute with a corresponding digit in a 90-second period. Each correct digit is counted, and the total score ranges from 0 (less than normal functioning) to 110 (greater than normal functioning). (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | 3.75 |
| Vortioxetine 20 mg/Day | 2.64 |
| Fluoxetine 20 mg/Day, | 2.69 |
| Placebo | 2.41 |
The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not. (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | 2.81 |
| Vortioxetine 20 mg/Day | 2.69 |
| Fluoxetine 20 mg/Day, | 2.50 |
| Placebo | 2.73 |
The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of change from Baseline symptoms using a 7 point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT02709746)
Timeframe: From Randomization to Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine 10 mg/Day | 2.80 |
| Vortioxetine 20 mg/Day | 2.74 |
| Fluoxetine 20 mg/Day, | 2.49 |
| Placebo | 2.72 |
"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring major depressive disorder) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~The relapse rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)" (NCT00118404)
Timeframe: Measured at month 8
| Intervention | % patients who relapsed (Number) |
|---|---|
| Continuation Phase Fluoxetine | 18 |
| Continuation Phase Cognitive Therapy | 18.3 |
| Continuation Phase Pill Placebo | 32.7 |
"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~Relapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)." (NCT00118404)
Timeframe: Measured at month 32
| Intervention | % patients who relapsed/recurred (Number) |
|---|---|
| Continuation Phase Fluoxetine | 41.1 |
| Continuation Phase Cognitive Therapy | 45.2 |
| Continuation Phase Pill Placebo | 56.3 |
"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~Relapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)" (NCT00118404)
Timeframe: Measured at month 20
| Intervention | % patients who relapsed/recurred (Number) |
|---|---|
| Continuation Phase Fluoxetine | 35.1 |
| Continuation Phase Cognitive Therapy | 35.0 |
| Continuation Phase Pill Placebo | 42.7 |
"Depressed participants were scanned while viewing a sequence of positive and negative images; they were instructed to enhance or supress their emotional response to the image or to continue to attend. To examine brain function when regulating negative affect, we created contrast maps for each participant at all 3 time points by subtracting the attend condition from the suppress condition in response to negative stimuli. Data from all 3 scan sessions were used to assess treatment-induced change in brain activity when regulating emotion. Analyses examining change using difference scores (end vs. starting points), we subtracted initial HAMD score from final HAMD score. For fMRI analyses, in a voxelwise manner, we subtracted initial negative suppress vs attend from final negative suppress vs attend.~Control subjects were not depressed, repeat scans to assess change were not completed.~Reported results are from BA10, one of our areas of interest." (NCT00909155)
Timeframe: At study entry, 2 months and end of study (6 months)
| Intervention | fMRI signal change (Mean) |
|---|---|
| Depressed; Venlafaxine Treatment | -0.042666667 |
| Depressed; Fluoxetine Treatment | 0.0414 |
"Hamilton Depression rating scale is a clinician assessment tool to measure severity of depression symptoms. Minimum score is 0 (no symptoms); maximum score is 52 (severe symptoms of depression).~Hamilton Anxiety rating scale is a clinician assessment tool to measure severity of anxiety symptoms. Minimum score is 0 (no symptoms); maximum score is 56 (severe symptoms of anxiety)." (NCT00909155)
Timeframe: Study entry, 2 months, and at end of study (6 mos)
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| HAMD T0 | HAMA T0 | HAMD 2months | HAMA 2months | HAMD 6months | HAMA 6months | |
| Control (Non-psychiatric Subjects) | 1 | NA | 1.25 | NA | 1.64 | NA |
| Currently Depressed Subjects: Fluoxetine | 21.36 | 15.57 | 10.15 | 8.54 | 7.33 | 5.89 |
| Currently Depressed Subjects: Venlafaxine | 20.07 | 14.07 | 8.86 | 7.5 | 5 | 4.25 |
CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. Least Square (LS) means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Baseline, Week 10
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Duloxetine | -24.3 |
| Fluoxetine | -23.7 |
| Placebo | -24.3 |
CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Baseline, Week 10
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Duloxetine | -1.9 |
| Fluoxetine | -1.8 |
| Placebo | -1.9 |
CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Week 10, Week 36
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Duloxetine/Duloxetine | -7.2 |
| Fluoxetine/Fluoxetine | -9.9 |
| Placebo/Duloxetine | -9.6 |
CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Week 10, Week 36
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Duloxetine/Duloxetine | -0.6 |
| Fluoxetine/Fluoxetine | -1.0 |
| Placebo/Duloxetine | -1.1 |
CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Baseline, Week 10
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Mood (N=113, 113, 103) | Somatic (N=113, 113, 103) | Subjective (N=113, 113, 103) | Behavior (N=113, 112, 103) | |
| Duloxetine | -7.0 | -7.7 | -4.0 | -5.6 |
| Fluoxetine | -7.1 | -7.6 | -3.6 | -5.4 |
| Placebo | -7.0 | -7.7 | -4.0 | -5.7 |
CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Week 10, Week 36
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Mood | Somatic | Subjective | Behavior | |
| Duloxetine/Duloxetine | -1.9 | -2.8 | -0.3 | -1.9 |
| Fluoxetine/Fluoxetine | -2.5 | -3.6 | -1.3 | -2.8 |
| Placebo/Duloxetine | -2.9 | -3.2 | -1.2 | -2.1 |
Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as alanine transaminase (ALT) ≥3 x upper limit of normal (ULN), ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT ≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849901)
Timeframe: Baseline through Week 10
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| ALT≥3 x ULN | ALT≥5 x ULN | ALT≥10 x ULN | ALT≥3 x ULN and Total Bilirubin≥2 x ULN | |
| Duloxetine | 0 | 0 | 0 | 0 |
| Fluoxetine | 0 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 |
Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as alanine transaminase (ALT) ≥3 x upper limit of normal (ULN), ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT ≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849901)
Timeframe: Week 10 through Week 36
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| ALT≥3 x ULN | ALT≥5 x ULN | ALT≥10 x ULN | ALT≥3 x ULN and Total Bilirubin≥2 x ULN | |
| Duloxetine/Duloxetine | 0 | 0 | 0 | 0 |
| Fluoxetine/Fluoxetine | 1 | 1 | 0 | 0 |
| Placebo/Duloxetine | 0 | 0 | 0 | 0 |
"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week -1 - 0)." (NCT00849901)
Timeframe: Baseline through Week 10
| Intervention | participants (Number) | ||
|---|---|---|---|
| Suicidal Ideation | Suicidal Behavior | Treatment Emergent Suicidal Ideation | |
| Duloxetine | 16 | 0 | 8 |
| Fluoxetine | 16 | 1 | 9 |
| Placebo | 15 | 0 | 7 |
"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week 7-10)." (NCT00849901)
Timeframe: Week 10 through Week 36
| Intervention | participants (Number) | ||
|---|---|---|---|
| Suicidal Ideation | Suicidal Behavior | Treatment Emergent Suicidal Ideation | |
| Duloxetine/Duloxetine | 13 | 1 | 9 |
| Fluoxetine/Fluoxetine | 13 | 1 | 13 |
| Placebo/Duloxetine | 8 | 0 | 8 |
PCS increase in systolic and diastolic BP was defined as increase of ≥5 millimeter mercury (mm Hg) from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849901)
Timeframe: Baseline through Week 10
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Diastolic BP Increase (N=102, 106, 93) | Systolic BP Increase (N=100, 106, 90) | Pulse Decrease (N=111, 112, 102) | Pulse Increase (N=113, 114, 103) | Weight Decrease (N=113, 114, 103) | |
| Duloxetine | 8.8 | 7.0 | 0.9 | 0 | 12.4 |
| Fluoxetine | 7.5 | 5.7 | 0.9 | 0 | 11.4 |
| Placebo | 17.2 | 6.7 | 1.0 | 1.0 | 4.9 |
PCS increase in systolic and diastolic BP was defined as increase of ≥ 5mm Hg from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849901)
Timeframe: Week 10 through Week 36
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Diastolic BP Increase (N=65, 76, 61) | Systolic BP Increase (N=64, 80, 69) | Pulse Decrease (N=78, 84, 82) | Pulse Increase (N=81, 91, 84) | Weight Decrease (N=81, 91, 85) | |
| Duloxetine/Duloxetine | 16.9 | 12.5 | 0 | 0 | 6.2 |
| Fluoxetine/Fluoxetine | 11.8 | 12.5 | 0 | 0 | 3.3 |
| Placebo/Duloxetine | 4.9 | 10.1 | 0 | 0 | 9.4 |
CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. Least Square (LS) means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Baseline, Week 10
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Duloxetine 60mg | -23.9 |
| Placebo | -21.6 |
| Duloxetine 30mg | -24.6 |
| Fluoxetine 20mg | -22.6 |
| Placebo | -21.6 |
CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Baseline, Week 10
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Duloxetine 60mg | -1.5 |
| Duloxetine 30mg | -1.5 |
| Fluoxetine 20mg | -1.4 |
| Placebo | -1.4 |
CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Week 10, Week 36
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Duloxetine 60 mg / Duloxetine 60-120 mg | -7.8 |
| Duloxetine 30 mg/Duloxetine 60-120 mg | -7.4 |
| Fluoxetine 20 mg/Fluoxetine 20-40 mg | -10.0 |
| Placebo/Duloxetine 60-120 mg | -9.0 |
CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Week 10, Week 36
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Duloxetine 60 mg / Duloxetine 60-120 mg | -1.1 |
| Duloxetine 30 mg/Duloxetine 60-120 mg | -0.9 |
| Fluoxetine 20 mg/Fluoxetine 20-40 mg | -1.3 |
| Placebo/Duloxetine 60-120 mg | -1.0 |
CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Baseline, Week 10
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Mood | Somatic | Subjective | Behavior | |
| Duloxetine 30mg | -7.2 | -7.9 | -4.0 | -5.6 |
| Duloxetine 60mg | -7.1 | -7.6 | -3.6 | -5.8 |
| Fluoxetine 20mg | -6.6 | -7.1 | -3.5 | -5.6 |
| Placebo | -6.4 | -6.4 | -3.6 | -5.4 |
CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Week 10, Week 36
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Mood | Somatic | Subjective | Behavior | |
| Duloxetine 30 mg/Duloxetine 60-120 mg | -1.9 | -2.4 | -1.3 | -1.8 |
| Duloxetine 60 mg / Duloxetine 60-120 mg | -1.9 | -2.8 | -1.2 | -2.1 |
| Fluoxetine 20 mg/Fluoxetine 20-40 mg | -2.4 | -4.0 | -1.5 | -2.7 |
| Placebo/Duloxetine 60-120 mg | -2.3 | -3.2 | -1.0 | -2.4 |
Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as alanine transaminase (ALT) ≥3 x upper limit of normal (ULN), ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT ≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849693)
Timeframe: Baseline through Week 10
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| ALT≥3 x ULN | ALT≥5 x ULN | ALT≥10 x ULN | ALT≥3 x ULN and Total Bilirubin≥2 x ULN | |
| Duloxetine 30mg | 0 | 0 | 0 | 0 |
| Duloxetine 60mg | 0 | 0 | 0 | 0 |
| Fluoxetine 20mg | 0 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 |
Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as ALT ≥3 x ULN, ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849693)
Timeframe: Week 10 through Week 36
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| ALT≥3 x ULN | ALT≥5 x ULN | ALT≥10 x ULN | ALT≥3 x ULN and Total Bilirubin≥2 x ULN | |
| Duloxetine 30 mg/Duloxetine 60-120 mg | 0 | 0 | 0 | 0 |
| Duloxetine 60 mg / Duloxetine 60-120 mg | 0 | 0 | 0 | 0 |
| Fluoxetine 20 mg/Fluoxetine 20-40 mg | 0 | 0 | 0 | 0 |
| Placebo/Duloxetine 60-120 mg | 0 | 0 | 0 | 0 |
"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week -1 to 0)." (NCT00849693)
Timeframe: Baseline through Week 10
| Intervention | participants (Number) | ||
|---|---|---|---|
| Suicidal Ideation | Suicidal Behavior | Treatment Emergent Suicidal Ideation | |
| Duloxetine 30mg | 11 | 0 | 6 |
| Duloxetine 60mg | 16 | 0 | 7 |
| Fluoxetine 20mg | 13 | 1 | 9 |
| Placebo | 15 | 1 | 11 |
"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week 7-10)." (NCT00849693)
Timeframe: Week 10 through Week 36
| Intervention | participants (Number) | ||
|---|---|---|---|
| Suicidal Ideation | Suicidal Behavior | Treatment Emergent Suicidal Ideation | |
| Duloxetine 30 mg/Duloxetine 60-120 mg | 12 | 3 | 8 |
| Duloxetine 60 mg / Duloxetine 60-120 mg | 6 | 2 | 5 |
| Fluoxetine 20 mg/Fluoxetine 20-40 mg | 8 | 0 | 7 |
| Placebo/Duloxetine 60-120 mg | 8 | 1 | 6 |
PCS increase in systolic and diastolic BP was defined as increase of ≥5 millimeter mercury (mm Hg) from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849693)
Timeframe: Baseline through Week 10
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Diastolic BP Increase (N=93, 100, 99, 110) | Systolic BP Increase (N=88, 95, 93, 98) | Pulse Decrease (N=100, 108, 108, 112) | Pulse Increase (N=105, 114, 112, 117) | Weight Decrease (N=105, 114, 112, 117) | |
| Duloxetine 30mg | 7.0 | 12.6 | 0 | 0 | 8.8 |
| Duloxetine 60mg | 11.8 | 9.1 | 0 | 0 | 13.3 |
| Fluoxetine 20mg | 10.1 | 12.9 | 0 | 0 | 11.6 |
| Placebo | 4.5 | 10.2 | 0 | 0 | 5.1 |
PCS increase in systolic and diastolic BP was defined as increase of ≥5 mm Hg from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849693)
Timeframe: Week 10 through Week 36
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Diastolic BP Increase (N=55, 65, 64, 69) | Systolic BP Increase (N=53, 62, 57, 57) | Pulse Decrease (N=68, 75, 76, 73) | Pulse Increase (N=71, 78, 81, 79) | Weight Decrease (N=71, 78, 81, 79) | |
| Duloxetine 30 mg/Duloxetine 60-120 mg | 4.6 | 6.5 | 0 | 0 | 9.0 |
| Duloxetine 60 mg / Duloxetine 60-120 mg | 14.5 | 9.4 | 0 | 1.4 | 2.8 |
| Fluoxetine 20 mg/Fluoxetine 20-40 mg | 20.3 | 7.0 | 0 | 0 | 3.7 |
| Placebo/Duloxetine 60-120 mg | 11.6 | 10.5 | 0 | 1.3 | 13.9 |
"K-Life interview was conducted at Weeks 6, 12, 18, 24, and 30, with ratings for depressive illness for each week throughout the study.~Ratings definitions: 1=Normal, no residual symptoms; 2=Presence of 1 or more symptosm in no more than mild degree; 3=Considerably less psychopathology than full criteria, but still obvious evidence of disorder with no more than moderate impairment; 4=Does not meet full criteria, but has major symptoms or impairment from the disorder; 5=Meets full criteria, but no extreme impairment; 6=Meets full criteria, and either has prominent psychotic symptoms or extreme impairment.~Time well is defined as each week the depression rating was a 1 or 2. Percent time well was defined as each week the depression rating was a 1 or 2 divided by the total number of weeks in the study.~Statistic: anova" (NCT00612313)
Timeframe: 30 weeks
| Intervention | Weeks spent well (Mean) |
|---|---|
| Continued Medication Alone | 12.8 |
| Continued Medication Plus CBT | 16.0 |
Remission is defined as CDRS-R <=28. Timing of remission is based on clinical assessment using the CDRS-R and K-Life to identify the week at which point the patient remitted. (NCT00612313)
Timeframe: 30 weeks
| Intervention | weeks (Mean) |
|---|---|
| Continued Medication Alone | 13.67 |
| Continued Medication Plus CBT | 11.33 |
"Relapse was defined as:~1) CDRS-R score >=40 with a history of 2 weeks of clinical deterioration or 2) CDRS-R<40, but with a 2 week history of significant clinical deterioration." (NCT00612313)
Timeframe: Measured at Weeks 12, 18, 24, and 30
| Intervention | probability of relapse (%) (Number) | |||
|---|---|---|---|---|
| Week 12 | Week 18 | Week 24 | Week 30 | |
| Continued Medication Alone | 3 | 10 | 20.5 | 26.5 |
| Continued Medication Plus CBT | 1 | 3.5 | 7 | 9 |
"Up through week 30, relapse was defined as:~1) CDRS-R score >=40 with a history of 2 weeks of clinical deterioration or 2) CDRS-R<40, but with a 2 week history of significant clinical deterioration.~From week 31-78, relapse was assessed using the K-Life. Relapse was defined as at least 2 weeks of a K-Life rating of 5 or 6; participants may also be identified as relapsing with a K-Life rating of 4 if the rating was for several weeks and not strictly related to stressful life events." (NCT00612313)
Timeframe: Weeks 52 and 78
| Intervention | Probability of Relapse (%) (Number) | |
|---|---|---|
| Week 52 | Week 78 | |
| Continued Medication Alone | 49 | 62 |
| Continued Medication Plus CBT | 27 | 36 |
Remission is defined as CDRS-R <=28 (up through week 30) or at least 8 consecutive weeks of a K-Life rating of 1 or 2. Timing of remission is based on clinical assessment using the CDRS-R and K-Life to identify the week at which point the patient remitted. (NCT00612313)
Timeframe: Weeks 52 and 78
| Intervention | Probability of remission (%) (Number) | |
|---|---|---|
| Week 52 | Week 78 | |
| Continued Medication Alone | 89 | 92 |
| Continued Medication Plus CBT | 94 | 96 |
Remission is defined as CDRS-R <=28. (NCT00612313)
Timeframe: Measured at Weeks 12, 18, 24, and 30
| Intervention | probability of remitting (%) (Number) | |||
|---|---|---|---|---|
| Week 12 | Week 18 | Week 24 | Week 30 | |
| Continued Medication Alone | 59 | 71 | 80 | 84 |
| Continued Medication Plus CBT | 68 | 79 | 86 | 90 |
17-item Hamilton Rating Scale for Depression (HRSD) is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in HRSD was assessed at baseline and after six weeks of treatment. For this study the change was calculated as the later time point (total score in 17- HRSD at 6 weeks) minus the earlier time point (total score at baseline). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks
| Intervention | Units in Hamilton Scale (Mean) |
|---|---|
| Individualized Homeopathic Treatment | 9.9 |
| Fluoxetine | 11.7 |
| Placebo | 15 |
Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory that assess severity of depression. A total score range was assessed at baseline and after six weeks of treatment. A score 0 (without depression) up to 63 (most severe depression). For this study the change was calculated as the later time point (total score in BDI at 6 weeks) minus the earlier time point (total score in BDI at baseline). A score 0 - 8 is considered normal, 9 - 18 (mild to moderate depression), 19 - 28 (moderate to severe depression), > 29 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks
| Intervention | Units in Beck Depression Inventory (Mean) |
|---|---|
| Individualized Homeopathic Treatment | 12 |
| Fluoxetine | 14.2 |
| Placebo | 15.5 |
Greene Climacteric Scale (GS) is intended to be a standard measure of core climacteric symptoms. For this study a total range was assessed at baseline and after six weeks of treatment. A total score 0 (without climacteric symptoms) up to 63 (most severe climacteric symptoms). The change was calculated as the later time point (total score in GS at 6 weeks) minus the earlier time point (total score at baseline).The scale measures four separate sub-scales (anxiety, depression, somatic symptoms and sexual function). The score of the four sub-scales was summed. A total score of 0 -10 is considered without symptoms, 11 - 29 (mild symptoms), 30 - 49 (moderate symptoms) and > 50 (severe symptoms). (NCT01635218)
Timeframe: Baseline and 6 weeks
| Intervention | Units in Green Scale (Mean) |
|---|---|
| Individualized Homeopathic Treatment | 18.1 |
| Fluoxetine | 23.1 |
| Placebo | 26.8 |
17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Remission rate definition: 17-item Hamilton Rating Scale for Depression score < 7 points after 6 weeks of treatment. (NCT01635218)
Timeframe: 6 weeks
| Intervention | participants with a score of < 7 in HS (Number) |
|---|---|
| Individualized Homeopathic Treatment | 7 |
| Fluoxetine | 7 |
| Placebo | 2 |
17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Responder rate definition: a decrease of 50% or more from baseline score using 17-item Hamilton Rating Scale for Depression after six weeks treatment. (NCT01635218)
Timeframe: 6 weeks
| Intervention | participants with a decrease >50% in HS (Number) |
|---|---|
| Individualized Homeopathic Treatment | 24 |
| Fluoxetine | 19 |
| Placebo | 5 |
Change between pre-intervention and post-intervention self-reported answer totals to the 21 scored items on BDI-II (minimum score obtainable=0 (absent symptoms); maximum score obtainable=63 (most severe symptoms). (NCT04921332)
Timeframe: First at time of admission, second at end of 7 day goal or upon discharge.
| Intervention | score on a scale (Mean) |
|---|---|
| Bright Light Therapy (BLT) | 8.750 |
The RN will sign a daily log indicating what time therapy was initiated and if therapy was refused. These logs will be collected from patient doors at the end of each week by the principal investigator (PI) in order to measure compliance with completion of therapy on a daily basis. (NCT04921332)
Timeframe: Daily for duration of intervention period (goal/maximum of 7 days).
| Intervention | days (Mean) |
|---|---|
| Bright Light Therapy Compliance (Secondary Outcome) | 4.5 |
Total score on a clinician-rated measure of depressive symptoms, minus 3 sleep items Total score range: 0-46. Higher scores represent more severe depression. (NCT01545843)
Timeframe: Post-treatment (8 weeks)
| Intervention | units on a scale (Mean) |
|---|---|
| No Sleep Deprivation | 6.1 |
| Late Bedtime Sleep Deprivation | 8.1 |
| Early Risetime Sleep Deprivation | 6.3 |
Patient-reported depression symptom severity at post-treatment, total score. Total scores range from 0 to 27. Higher scores represent more severe depression. (NCT01545843)
Timeframe: Post-treatment (8 weeks)
| Intervention | units on a scale (Mean) |
|---|---|
| No Sleep Deprivation | 5.3 |
| Late Bedtime Sleep Deprivation | 6.9 |
| Early Risetime Sleep Deprivation | 6.7 |
Measurement of EEG activity during sleep using polysomnography: Total Sleep Time is the length of time from sleep onset to final wake up minus any wakefulness during the night. It reflects the total amount of time asleep during the night. (NCT01545843)
Timeframe: Baseline, 2 weeks, 8 weeks
| Intervention | minutes (Mean) | ||
|---|---|---|---|
| Baseline | Week 2 | Week 8 | |
| Early Risetime Sleep Deprivation | 444.040 | 332.909 | 433.333 |
| Late Bedtime Sleep Deprivation | 439.208 | 337.75 | 428.264 |
| No Sleep Deprivation | 430.132 | 435.382 | 439.6 |
Measurement of EEG activity during sleep using polysomnography: Sleep efficiency [(total sleep time/time in bed)*100] (NCT01545843)
Timeframe: Baseline, 2 weeks, 8 weeks
| Intervention | percent of sleep time (Mean) | ||
|---|---|---|---|
| Baseline | Week 2 | Week 8 | |
| Early Risetime Sleep Deprivation | 92.8248 | 92.9082 | 90.3838 |
| Late Bedtime Sleep Deprivation | 91.6829 | 93.3322 | 88.9224 |
| No Sleep Deprivation | 89.7005 | 90.7824 | 91.6153 |
Reaction Time is measured using a modified Go/No-go test of inhibitory control (NCT01545843)
Timeframe: 0, 2, 8 weeks
| Intervention | milliseconds (Mean) | ||
|---|---|---|---|
| Week 0 (Baseline) | Week 2 | Week 8 | |
| Early Risetime Sleep Deprivation | 470.2942 | 472.7244 | 500.1197 |
| Late Bedtime Sleep Deprivation | 528.3513 | 519.8196 | 557.1635 |
| No Sleep Deprivation | 499.1545 | 493.2579 | 483.7349 |
Change in different aspects of thinking (e.g., memory, attention, executive functioning) (NCT01545843)
Timeframe: Baseline, 2 weeks, 8 weeks
| Intervention | words (Mean) | ||
|---|---|---|---|
| Baseline | Week 2 | Week 8 | |
| Early Risetime Sleep Deprivation | 76.095 | 77.400 | 81.200 |
| Late Bedtime Sleep Deprivation | 74.938 | 81.529 | 79.733 |
| No Sleep Deprivation | 77.118 | 76.647 | 73.923 |
Emotional Perception is measured based on the percent of faces whose emotions are correctly identified using the Facial Emotion Perception Test (FEPT) (NCT01545843)
Timeframe: 0 weeks, 2 weeks, 8 weeks
| Intervention | percentage of emotions accurately ID'ed (Mean) | ||
|---|---|---|---|
| 0 weeks (Baseline) | Week 2 | Week 8 | |
| Early Risetime Sleep Deprivation | 88.83 | 88.75 | 87.74 |
| Late Bedtime Sleep Deprivation | 86.24 | 88.15 | 89.15 |
| No Sleep Deprivation | 83.54 | 83.08 | 85.95 |
Self-report measure of sleep quality. The Pittsburgh Sleep Quality Index is a validated scale which measures self-reported sleep quality based on a wide variety of questions (duration, quality, disturbances, medication, etc.) and converts them to a scale which ranges from 0 to 21 where 6 or higher denotes poor sleep quality. (NCT01545843)
Timeframe: Baseline, 2 weeks and 8 weeks post-treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 2 | Week 8 | |
| Early Risetime Sleep Deprivation | 6.85 | 5.50 | 6.33 |
| Late Bedtime Sleep Deprivation | 8.67 | 6.07 | 6.23 |
| No Sleep Deprivation | 6.00 | 5.23 | 4.86 |
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
Alcohol use behaviors measured by drinks per week. (NCT00027378)
Timeframe: Average number of drinks as recorded on the Timeline Follow-Back (subject-reported) measure daily over the 12-week acute phase.
| Intervention | standard drink (14 gr. alcohol) (Mean) |
|---|---|
| Fluoxetine Plus Treatment As Usual (TAU) | 1.56 |
| Placebo Plus Treatment as Usual (TAU) | 1.73 |
Beck Depression Inventory (BDI) Scores measured at Weeks 1-4, 6, 8, 10, 12. The BDI is a subject reported measure that has a minimum score of 0 and a maximum score of 63. A better outcome would consist of values near the minimum end of the scale (0) and a worse outcome would consist of values near the maximum end of the scale (63). (NCT00027378)
Timeframe: Average score as measured by participant's report on the Beck Depression Inventory (BDI).
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine Plus Treatment As Usual (TAU) | 6.79 |
| Placebo Plus Treatment as Usual (TAU) | 10.46 |
"The FOI-adapted Parenting Sense of Competence (PSOC) questionnaire is filled out by the caregiver to assess parents' sense of competence and enjoyment of parenting. This is an adapted version of the PSOC (original PSOC has 17 items, Johnston & Mash, 1989), with 18 items and simplified language for lower reading levels.~Items are answered on a 4-point Likert scale ranging from strongly agree to strongly disagree. Nine items (#s 2,3,4,5,8,9,13,15 and 17) are reverse coded so that, for all items, higher scores indicate greater parenting self-esteem.~Total score of parent's perceived sense of competency is calculated by summing up scores of all the 18 items, ranging from 18 to 72." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 49.42 | 51.6 | 2.14 |
| KEEP-P+ | 49.82 | 50.15 | 0.3 |
"The Attachment Diary (ADRY) is a 47-item measure in which caregivers report how the child reacts when hurt, frightened, or separated from the caregiver by placing check marks on a behavior list. All the checked behaviors are coded into three categories, proximity seeking/contact maintenance, avoidance, and resistance, to assess individual differences in child's attachment behaviors. Thus, there are no total scores for the ADRY, only subscale scores for the three categories.~Outcomes include scores for proximity seeking/contact maintenance (range from 0 to 14), scores for avoidance (range from 0 to 18), and scores for resistance (range from 0 to 6), which are generated by counting the number of checked behaviors in corresponding subscales. Higher scores indicate higher levels of behaviors correspondingly." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline Proximity | Endpoint Proximity | Change Proximity | Baseline Avoidance | Endpoint Avoidance | Change Avoidance | Baseline Resistance | Endpoint Resistance | Change Resistance | |
| KEEP-P | 7.53 | 7.75 | 0.22 | 1.84 | 1.78 | -0.03 | 0.72 | 0.57 | -0.08 |
| KEEP-P+ | 8.42 | 7.87 | -0.49 | 1.95 | 2.06 | -0.04 | 0.88 | 0.70 | -0.21 |
"The Kansas Reflection-Impulsivity Scale for Preschoolers (KRISP) presents children with a target picture and 4-6 similar pictures. Children were asked to identify an exact match of the target picture.~Fifteen test trials were administered following a single practice trial. Each item was scored based on the number of incorrect responses, up to 3 errors. Final score is calculated as the number of errors subtracted from the total errors possible (45), ranging from 0 to 45. Higher score indicates better executive functioning." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 35.76 | 37.81 | 2.16 |
| KEEP-P+ | 33.52 | 35.8 | 3.96 |
"The Child Behavior Checklist (CBCL) is a 100-item questionnaire to assess emotional and behavioral problems in children. Caregivers are asked to rate how often their child displayed certain behaviors in the past two months on a 3-point Likert scale (0 = Not True, 1 = Somewhat/Sometimes True, 2 = Very True/Often True).~Subscales include: Internalizing symptoms - Emotionally Reactive: 21, 46, 82, 83, 92, 97, 99; Anxious/Depressed: 10, 33, 37, 43, 47, 68, 87, 90; Somatic Complaints: 1, 7, 39, 45, 78, 86, 93; Withdrawn: 2, 4, 12, 19, 23, 62, 67, 70, 71, 98 Externalizing symptoms - Attention Problems: 5, 6, 24, 48, 51, 56, 59, 64, 95; Aggressive Behavior: 8, 14, 15, 16, 17, 18, 20, 22, 27, 28, 29, 35, 40, 42, 44, 53, 58, 66, 69, 74, 81, 84, 85, 88, 96 Raw scores for each subscale were calculated by summing up item scores correspondingly and then normalized to T-scores. The means are anchored to 50, with a standard deviation of 10 points. Higher T score indicates more behavior problems." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | T-score (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 59.6 | 57.18 | -3.24 |
| KEEP-P+ | 61.65 | 57.47 | -3.76 |
"The Ages and Stages Questionnaires: Social-Emotional Development Screening Tool (ASQ:SE) is a caregiver-report questionnaire about children's social-emotional development.~The ASQ:SE has 29 questions, of which 26 questions are scored from 0-15, the others are open-ended. Therefore the total score (the sum of the 26 item scores) ranges from 0 to 390. Lower scores indicate more pocitive outcomes, i.e. better social-emotional development." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 121.35 | 105 | -14.33 |
| KEEP-P+ | 125.81 | 119.13 | -2.39 |
The total number of phases passed in the DCCS. A phase was passed if 4/6 trials were correct. Children only proceeded to the next phase if they passed the previous phase. 5 phases total. Higher score indicates better executive functioning. (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | number of phases passed (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 1.76 | 2.12 | 0.48 |
| KEEP-P+ | 1.61 | 2.05 | 0.43 |
"The Family Routines Questionnaire (FRQ) is a 28-item measure of the frequency and rated importance of family routines. Scores are calculated based on the how frequent the family's routines are and how important the routines are to them. The frequency of family routines construct was reported in the results.~To rate each endorsed routine by the frequency of its performance by the family, daily performance is assigned a weight of 3, a somewhat less frequency performance of 3-5 times a week is assigned a weight of 2; and an even less frequent performance of l-2 times a week is assigned a weight of 1. The 'almost never' category is taken to mean that the family does not participate in the particular routine, and it is therefore assigned a value of 0 in computing the total inventory score. By summing up frequency scores of all the 28 items, the total frequency score ranges from 0 to 84. Higher scores indicate higher frequency of family routines." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 51.66 | 52.63 | 1.37 |
| KEEP-P+ | 50.43 | 52.09 | 1.3 |
"The Interpersonal Mindfulness in Parenting (IEMP) scale is a 10-item measure to investigate the quality of interpersonal mindfulness in parenting.~Items are answered on a 5-point Likert scale ranging from never true to always true. Four items (#s 1,5,9, and 10) are reverse coded.~Total score is the sum of all the item scores, ranging from 10 to 50. Higher scores indicate higher quality of Mindful parenting." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 37.87 | 38.8 | 0.81 |
| KEEP-P+ | 37.17 | 37.56 | 0.69 |
"In the Bear/Dragon Task, children were presented with a nice bear and a mean dragon and instructed to do what the bear says (e.g., touch your nose), but not to do what the dragon says.~Children's compliance was scored on a 4-point scale on 5 bear trials (0 = failure to move; 1 = a wrong movement; 2 = a partial movement; 3 = a full correct movement) and 5 dragon trials (0 = a full commanded movement; 1 = a partial commanded movement; 2 = a flinch or wrong movement; 3 = no movement). Scores of each trial are summed up to produce a total score ranging from 0 to 30. A higher score indicates better inhibitory control." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | total score (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 21.52 | 23.6 | 1.56 |
| KEEP-P+ | 20.42 | 22.42 | 3.24 |
"In the Delay Choice Paradigm, children were asked to make choices between getting one penny/sticker/treat now or four (or more) to bring home for nine times.~Total score is the total times when the child chooses the bring home option (ranges from 0 to 9). Higher score indicates better ability for child to delay gratification, i.e. better inhibitory control." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 4.86 | 5.24 | 0.19 |
| KEEP-P+ | 5.55 | 4.54 | -0.89 |
"In the Spin the Pots Task, several visually distinct boxes were arranged on a rotating tray (2.5-year -olds: 8 boxes; 3-year-olds: 9 boxes; 3.5 year olds: 10 boxes; 4-year-olds; 11 boxes). Children watched the experimenter hide colourful stickers inside all but two boxes, cover the boxes with a cloth, and rotate a tray for a few seconds to mark the beginning of a search trial. The cloth was removed and children were instructed to select a box to find a sticker. If a sticker was found, children were allowed to keep it. After each search attempt, the tray was covered and rotated again to mark the beginning of the next search trial. The task was completed once children found all hidden stickers or after the allotted number of trials (2.5-year -olds: 12 trials; 3-year-olds: 14 trials; 3.5 year olds: 16 trials; 4-year-olds; 18 trials).~Ratio of stickers found to number of trials ranges from 0 to 1. A higher score indicates better working memory." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | Ratio of stickers found to trials (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 0.58 | 0.62 | 0.05 |
| KEEP-P+ | 0.55 | 0.59 | 0.06 |
"The Parenting Interactions with Children: Checklist of Observations Linked to Outcomes (PICCOLO) is an observational measure which rates developmentally-supportive parenting across four domains: affection, responsiveness, encouragement, and teaching.~It is a checklist of 29 items reflecting positive parent-child interaction behaviors. Each behavior is rated according to their frequency as 0 (absent, no behavior observed), 1 (barely, minor or emerging behavior) and 2 (clearly, definitive, strong and frequent behavior). Higher scores indicating higher levels of positive parenting.~PICCOLO total score is calculated by summing up scores of all the 29 items, ranging from 0 to 58. " (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 42.58 | 42.85 | 0.14 |
| KEEP-P+ | 43.36 | 43.08 | -0.76 |
"The Parent Daily Report (PDR) is a caregiver-report measure assessing child behaviour problems and associated parental stress occurring in the past 24 hours. The measure has several versions. The version used in the present research is the Oregon Social Learning Center Community Programs PDR which has 39 questions with only negative child behaviors, targeting to children from 3 to 6 years.~Caregivers rate each child behavior as 0 = Did Not Occur, 1 = Occurred & Not Stressful, 2 = Occurred & Stressful. The PDR was administered 3 times per wave. For each response, total score of stressful behaviors was calculated by counting the number of behaviors rated as 2 = Occurred & Stressful. Then the three total scores was averaged to get the mean of stressful behaviors (ranges from 0 to 39) as a indicator of parental stress. Higher score indicates higher level of parental stress." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 6.56 | 4.48 | -1.9 |
| KEEP-P+ | 7.26 | 4.58 | -2.8 |
"The Parenting Stress Index IV (PSI-IV) Short Form evaluates the magnitude of stress in the parent-child relationship based on the parent's perception of the child's characteristics, the personal characteristics of the parent, and the interaction between the parent and child.~It is a 5-point Likert scale ranging from strongly agree to strongly disagree with 36 items. Item 32 is the only item which is reverse coded. For all the other items, higher scores indicate higher levels of stress.~Total parenting stress score is calculated by summing up scores of all the 36 items, ranging from 36 to 180." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 80.87 | 74.62 | -5.29 |
| KEEP-P+ | 86.18 | 80.8 | -5.72 |
"Caregivers perception of their child's behaviors via the Preschool and Kindergarten Behavior Scales (PKBS). Items are on a 4-point scale ranging from never to often. Higher scores indicate more behavior problems.~PKBS total score (76 items) sum score ranging between 0-228." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | total score on scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 55.86 | 50.6 | -3.44 |
| KEEP-P+ | 54.63 | 52.39 | -3.09 |
Proportion of animals sorted correctly after rule switch. Higher score indicates better executive functioning. (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)
| Intervention | proportion correct (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change | |
| KEEP-P | 0.64 | 0.67 | 0.05 |
| KEEP-P+ | 0.61 | 0.71 | 0.1 |
"The BASIS 32 psychometric includes several subscales, including daily living and role functioning (DLRF). These subscales are rated from 0-4, with higher scores indicating a greater deal of difficulty in this dimension and lower scores denoting better outcomes. Measured weekly for 9 weeks. Reported as mean of 9 weeks." (NCT00247624)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine (FLX) Plus Eszopiclone (ESZ) | 0.81 |
| FLX Plus Placebo | 1.2 |
The Insomnia Severity Index has seven questions. The seven answers are added up to get a total score, range 0-28. Lower scores represent better outcomes. Total score categories: 0-7 = No clinically significant insomnia, 8-14 = Subthreshold insomnia, 15-21 = Clinical insomnia (moderate severity), 22-28 = Clinical insomnia (severe). (NCT00247624)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine (FLX) Plus Eszopiclone (ESZ) | 21.1 |
| FLX Plus Placebo | 20.2 |
The Q-LES-Q is scored from 0-100, with higher scores better than lower. Measured weekly for 9 weeks. Reported as mean of 9 weeks. (NCT00247624)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine (FLX) Plus Eszopiclone (ESZ) | 50.2 |
| FLX Plus Placebo | 46.9 |
"The BASIS 32 psychometric includes several subscales, including relation to self and others (RSO). These subscales are rated from 0-4, with higher scores indicating a greater deal of difficulty in this dimension. Measured weekly for 9 weeks. Reported as mean of 9 weeks." (NCT00247624)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine (FLX) Plus Eszopiclone (ESZ) | 0.74 |
| FLX Plus Placebo | 1.04 |
The number days out of the last seven days that cannabis was used. (NCT00149643)
Timeframe: 12 Weeks
| Intervention | Days of cannabis use per week (Mean) |
|---|---|
| Fluoxetine | 3.88 |
| Placebo | 3.1 |
Average of Beck Depression Inventory (BDI) Scores measured at Weeks 1-4, 6, 8, 10 and 12. The BDI is a subject reported measure that has a minimim score of 0 and a maximum score of 63. A better outcome would consist of values near the minimum end of the scale (0) and a worse outcome would consist of values near the maximum end of the scare (63). Each DSM-IV criteron asses a different depressive symptom. (NCT00149643)
Timeframe: 12 Weeks
| Intervention | BDI Total (Mean) |
|---|---|
| Fluoxetine | 7.79 |
| Placebo | 7.31 |
Criterion used in this study was the number of DSM-IV cannabis use disorder symptoms (criteria) that were met. (NCT00149643)
Timeframe: 12 Weeks
| Intervention | Number of DSM-IV criterion (Mean) |
|---|---|
| Fluoxetine | 0.59 |
| Placebo | 0.47 |
Phosphocreatine Metabolite is a phosphorylated creatine molecule that plays a role in the production of the energy in the body. Phosphocreatine (PCr) metabolite was quantified by calculating the ratio of PCr over total phosphorus resonance from 31-Phosphorus Magnetic Resonance Spectroscopy. (NCT00851006)
Timeframe: 8 weeks
| Intervention | ratio of PCr and total phosphorus (Mean) | |
|---|---|---|
| Baseline | After 8 weeks | |
| Healthy Control Group | 0.1556 | 0.1558 |
| Open Label Creatine Treatment | 0.1513 | 0.1610 |
The CDRS-R is a 17-item scale, with items ranging from 1 to 5 or 1 to 7 (possible total score from 17 to 113), rated by a clinician via interviews with the child or parent. Scores ≥40 are indicative of depression, whereas scores ≤28 is often used to define remission (NCT00851006)
Timeframe: 8 weeks
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | After 8 week Creatine treatment | |
| Open Label Creatine Treatment | 69 | 30.6 |
To replicate and extend our previous behavioral findings of an interaction between estrogen therapy (ET) and tryptophan depletion on verbal memory in a group of early menopausal women randomized to receive ET. Blood-oxygen-level dependent or BOLD signal is the outcome of BOLD imaging, which is a technique used in functional MRI. BOLD signal reflects changes in regional cerebral blood flow which delineate regional activity. A positive BOLD signal marks an increase in regional blood flow, while a negative BOLD signal marks a decrease in regional blood flow. A positive percent change means that between scans the BOLD signal i.e. blood flow in that region has increased, a negative percent change means that the BOLD signal has decreased between scans. (NCT01208324)
Timeframe: 8 weeks
| Intervention | percentage of BOLD signal changes (Mean) |
|---|---|
| High Ace | -.43 |
| Low Ace | .20 |
The Self-Report of Family Functioning consists of 10 items selected from a number of well-known family assessment measures (Family Environment Scale, Family Concept Q-Sort, Family Adaptability and Cohesion Scale, and Family Assessment Measure). The scale ranges from 10 to 40, with a score of 10 being representative of no family conflict and a score of 40 being representative of the greatest magnitude of family conflict. Therefore, a decrease in score represents and decrease in self-reported family conflict. (NCT01537419)
Timeframe: 16 weeks (end of treatment)
| Intervention | units on a scale (Mean) |
|---|---|
| Family-Enhanced Non-directive Supportive Therapy | -1.058 |
| Attachment-Based Family Therapy | -1.2538 |
The Suicidal Ideation Questionnaire-JR is a 15-item self-report assessment. It is based on Reynolds' theoretical notion of suicidality forming a continuum ranging from thoughts of death, thoughts of wanting to be dead, general and specific suicidal plans, preparations for carrying out plans, and actual suicide attempts. The scale ranges from 0 to 90, with a score of 0 being representative of no suicidal ideation, and a score of 31 or greater indicating severe suicidal ideation. (NCT01537419)
Timeframe: 16 weeks (end of treatment)
| Intervention | units on a scale (Mean) |
|---|---|
| Family-Enhanced Non-directive Supportive Therapy | -27.42 |
| Attachment-Based Family Therapy | -31.55 |
Beck Depression Inventory-II. The second edition of the BDI is a widely-used, 21-item self-report instrument designed to assess the severity of depressive symptoms in adults and adolescents. The BDI-II has 21 items and takes approximately 5 minutes to complete. The scale ranges from 0 to 63, with a higher score being representative of a greater clinical magnitude of depression: a total score of 0-13 is considered minimal depression, 14-19 is mild depression, 20-28 is moderate depression, and 29-63 is severe depression. (NCT01537419)
Timeframe: 16 weeks (end of treatment)
| Intervention | units on a scale (Mean) |
|---|---|
| Family-Enhanced Non-directive Supportive Therapy | -4.87 |
| Attachment-Based Family Therapy | -5.40 |
To establish the safety and tolerability of rTMS in Parkinson's Disease. (NCT01080794)
Timeframe: Baseline through Month 6
| Intervention | incidents of an adverse event (Number) |
|---|---|
| Double rTMS | 18 |
| M1 Active rTMS + DLPFC Sham rTMS | 14 |
| DLPFC Active rTMS + M1 Sham rTMS | 1 |
| Double Sham rTMS | 1 |
To evaluate apathy in Parkinson's Disease. The AES mean scores were reported for each group at each time point. The AES Score Range is 0-42, where higher the score indicates greater severity of the apathy symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 18.7 | 18.1 | 19.0 | 19.3 | 15.8 |
| Double rTMS | 15.6 | 16.2 | 17 | 16.9 | 17.8 |
| Double Sham rTMS | 16.3 | 15.5 | 15.0 | 16.1 | 16.2 |
| M1 Active rTMS + DLPFC Sham rTMS | 15.9 | 16.9 | 14.6 | 15.1 | 12.4 |
To assess mood symptoms in Parkinson's Disease. The BDI-II mean scores were reported for each group at each time point. The BDI-II Score Range is 0 - 63, where higher the score indicates greater severity of the mood symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.7 | 18.2 | 20.2 | 19.0 | 15.7 |
| Double rTMS | 23.2 | 20.7 | 16.4 | 17.9 | 20.1 |
| Double Sham rTMS | 18.8 | 13.7 | 13.1 | 14.7 | 16.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 18.5 | 16.5 | 16.7 | 19.1 | 16.3 |
To evaluate anxiety in Parkinson's Disease. The CAS mean scores were reported for each group at each time point. The CAS Score Range is 0 - 100, where higher the score indicates greater severity of the anxiety symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 33.4 | 27.6 | 30.8 | 31.4 | 24.8 |
| Double rTMS | 36.3 | 34.2 | 31.7 | 33.1 | 33.4 |
| Double Sham rTMS | 37.5 | 32.4 | 28.2 | 28.5 | 35.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 34.3 | 31.0 | 30.8 | 27.3 | 28.1 |
To assess symptom severity and treatment response in Parkinson's Disease. The CGI mean scores were reported for each group at each time point. The CGI Score Range is 1 - 8, where higher the score indicates greater severity of illness or worsening of illness. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-Treatment): Severity | Week 1 Post Treatment: Severity | Week 1 Post Treatment: Improvement | Month 1 Post Treatment: Severity | Month 1 Post Treatment: Improvement | Month 3 Post Treatment: Severity | Month 3 Post Treatment: Improvement | Month 6 Post Treatment: Severity | Month 6 Post Treatment: Improvement | |
| DLPFC Active rTMS + M1 Sham rTMS | 4.3 | 4.7 | 3.5 | 4.4 | 3.7 | 4.4 | 3.6 | 4.3 | 3.7 |
| Double rTMS | 4.9 | 4.8 | 3.6 | 4.4 | 3.5 | 4.6 | 3.7 | 4.2 | 3.5 |
| Double Sham rTMS | 3.6 | 3.9 | 3.0 | 4.1 | 3.5 | 4.4 | 3.6 | 4.6 | 3.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 4.7 | 4.9 | 3.5 | 4.8 | 3.8 | 3.8 | 3.4 | 5.0 | 4.2 |
"To evaluate the depressive mood symptoms in PD.~The HAM-D mean scores were reported for each group at each time point. The HAM-D Score Range is 0 - 56, where higher the score indicates greater severity of depressive mood symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 13.8 | 9.4 | 12.4 | 10.4 | 10.4 |
| Double rTMS | 15.2 | 11.3 | 10.6 | 10.7 | 10.4 |
| Double Sham rTMS | 14.1 | 9.3 | 8.0 | 11.1 | 10.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 16.7 | 11.2 | 10.1 | 10.1 | 8.6 |
To screen and follow cognitive function in Parkinson's Disease. The MoCA mean scores were reported for each group at each time point. The MoCA Score Range is 0 - 30, where 26-30 indicates normal cognition. (NCT01080794)
Timeframe: pre-treatment; 0,1,3, and 6 months post-treatment
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 27.3 | 26.3 | 26.8 | 26.7 | 26.6 |
| Double rTMS | 28.2 | 26.8 | 28.8 | 26.5 | 28.0 |
| Double Sham rTMS | 26.2 | 27.8 | 28.7 | 24.9 | 28.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.6 | 27.1 | 27.2 | 25.3 | 27.9 |
"To evaluate the motor symptoms in Parkinson's Disease.~The UPDRS-III mean scores were reported for each group at each time point. The UPDRS-III Score Range is 0 - 56, where higher the score indicates greater severity of the motor symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 32.8 | 30.3 | 29.3 | 31.5 | 28.8 |
| Double rTMS | 32.3 | 31.2 | 30.1 | 29.6 | 30.5 |
| Double Sham rTMS | 28.9 | 28.2 | 28.6 | 28.6 | 29.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 33.1 | 27.4 | 28.1 | 33.2 | 30.6 |
To assess the quality of life (QOL) in Parkinson's Disease. The PDQ-39 mean scores were reported for each group at each time point. The PDQ-39 Score Range is 0 - 156, where higher the score indicates greater impact on quality of life. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 51.9 | 46.8 | 49.4 | 49.4 | 49 |
| Double rTMS | 57.6 | 51.2 | 49.9 | 51.7 | 50.5 |
| Double Sham rTMS | 55.5 | 43.1 | 40.9 | 43.1 | 47.5 |
| M1 Active rTMS + DLPFC Sham rTMS | 61.5 | 60.7 | 56.8 | 53.1 | 48.3 |
"To assess apathy, cognition, depression, activities of daily living (ADL), quality of life (QOL), and motor symptoms in Parkinson's Disease.~The UPDRS I, II, IV total mean scores were reported for each group at each time point. The UPDRS I, II, IV scores were added together for each patient, with a total score range of 0 - 91, where higher the score indicates greater severity of the symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.5 | 19.3 | 19.9 | 18.9 | 20.2 |
| Double rTMS | 25.4 | 23.3 | 21.8 | 21.1 | 23.8 |
| Double Sham rTMS | 19.6 | 15.5 | 16.5 | 16.9 | 18.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.1 | 23.2 | 23.0 | 23.2 | 22.7 |
This test mainly assesses the ability of picture name of participants.we used a program for displaying named pictures on a computer screen (60 photos in total, of which 20 were Chinese celebrity faces). Each image was displayed in 3 seconds, and 1 point was correctly named for an image.The faces of celebrities were selected from the picture database of Chinese celebrities in the State Key Laboratory of Cognitive Neuroscience and Learning at Beijing Normal University.Score fluctuation is 0-60 points, the higher the score, the better the ability of picture name. (NCT03588572)
Timeframe: This is an outcome measure to assess the improvement of language function from onset to 3 months after treatment. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Visitation 1 | Visitation 2 | Visitation 3 | |
| Controlled Group | 38.31 | 43.31 | 48.31 |
| Venlafaxine Group | 39.19 | 46.75 | 52.25 |
This test mainly assesses spontaneous speech fluency of participants.It requires participants name as many food names as possible within one minute, and each correct one to give one point.The higher the score, the better the language function. (NCT03588572)
Timeframe: This is an outcome measure to assess the improvement of language function from onset to 3 months after treatment. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Visitation 1 | Visitation 2 | Visitation 3 | |
| Controlled Group | 5.75 | 8.13 | 10.81 |
| Venlafaxine Group | 5.31 | 9.31 | 12.69 |
The main outcome measure for this scale is Aphasia Quotient(AQ) which mainly tests the ability of spontaneous speech, oral comprehension, repetition, and naming, and reflects the severity of aphasia, and can be used as a reliable indicator to evaluate the improvement and deterioration of aphasia. Score fluctuation is 0-100 points, the normal value is 98.4-100 points, AQ<93.8 can be judged as language dysfunction. (NCT03588572)
Timeframe: This is an outcome measure to assess the improvement of language function from onset to 3 months after treatment. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Visitation 1 | Visitation 2 | Visitation 3 | |
| Controlled Group | 78.60 | 83.51 | 88.55 |
| Venlafaxine Group | 78.16 | 88.24 | 94.23 |
The Hamilton Anxiety Rating Scale (HAMA) is a widely used and well-validated tool for measuring the severity of a patient's anxiety. The HAMA is composed of 14 items and takes 15-20 minutes to complete the interview and score the results. Each item is scored on a 5-point scale, ranging from 0=not present to 4=severe.HAMA Scoring Instructions:0-8=Normal, 8-13= Possible Anxiety, 14-17 = Mild Anxiety, 18-24 = Moderate Anxiety, 25-30 = Severe Anxiety(i.e.,the higher the score, the greater the likelihood of anxiety). (NCT03588572)
Timeframe: We must determine that the participant is not in anxiety at each follow-up. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Visitation 1 | Visitation 2 | Visitation 3 | |
| Controlled Group | 4.63 | 4.00 | 3.25 |
| Venlafaxine Group | 4.88 | 4.13 | 3.56 |
The Hamilton Depression Rating Scale (HAMD) has proven useful for many years as a way of determining a patient's level of depression before, during, and after treatment. It generally takes 15-20 minutes to complete the interview and score the results. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine items are scored from 0-2. HAMD Scoring Instructions:0-7=Normal, 8-13 = Mild Depression, 14-18 = Moderate Depression, 19-22 = Severe Depression, ≥ 23 = Very Severe Depression(i.e.,Minimum 0 points and maximum 50 points, the higher the score, the greater the likelihood of depression). (NCT03588572)
Timeframe: We must determine that the participant is not in depression at each follow-up. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Visitation 1 | Visitation 2 | Visitation 3 | |
| Controlled Group | 5.25 | 4.63 | 3.88 |
| Venlafaxine Group | 5.63 | 4.94 | 4.06 |
The Mini-Mental State Examination (MMSE) is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. Administration of the test takes between 5 and 10 minutes. The MMSE test includes simple questions and problems in a number of areas: the time and place of the test, repeating lists of words, arithmetic such as the serial sevens, language use and comprehension, and basic motor skills. Any score greater than or equal to 24 points (out of 30) indicates a normal cognition. Below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.The raw score may also need to be corrected for educational attainment and age. (NCT03588572)
Timeframe: We must determine that the participant is not in moderate or more cognitive impairment at each follow-up. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Visitation 1 | Visitation 2 | Visitation 3 | |
| Controlled Group | 23.88 | 25.00 | 26.19 |
| Venlafaxine Group | 23.81 | 25.38 | 26.38 |
MADRS readmission rate is defined as MADRS score<11. The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 1 Drug | 4 |
| Phase 1 Placebo Non-Responders on Drug in Phase 2 | 8 |
| Phase I Placebo | 16 |
| Phase 1 Placebo Non-Responders on Placebo in Phase 2 | 4 |
The primary outcome was the difference in response rate (decrease in MADRS total score of at least 50%) using the SPCD (sequential parallel comparison design). The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 1 Drug | 10 |
| Phase 1 Placebo Non-Responders on Drug in Phase 2 | 11 |
| Phase I Placebo | 29 |
| Phase 1 Placebo Non-Responders on Placebo in Phase 2 | 5 |
The CGI-S scale was administered by clinicians based on assessment of the patient's clinical status. They measured, based on history and scores on other instruments, depressive severity. It consists of one question scored on a seven-point scale (1 = normal to 7 = among the most severe), so a higher total score indicates greater depressive severity. The minimum score is 1, and the maximum score is 7. (NCT00683852)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Phase 1 Drug | -0.81 |
| Phase 1 Placebo Non-Responders on Drug in Phase 2 | -0.64 |
| Phase I Placebo | -0.84 |
| Phase 1 Placebo Non-Responders on Placebo in Phase 2 | -0.43 |
The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: Baseline and 12 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Phase 1 Drug | -8.54 |
| Phase 1 Placebo Non-Responders on Drug in Phase 2 | -5.80 |
| Phase I Placebo | -8.09 |
| Phase 1 Placebo Non-Responders on Placebo in Phase 2 | -3.32 |
Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. This analysis compared AEs between the arms that received exclusively drug throughout the study or placebo throughout the study. (NCT00683852)
Timeframe: 12 Weeks
| Intervention | Patients (Number) |
|---|---|
| ADAPT Drug/Drug Group | 39 |
| ADAPT Placebo/Placebo Group | 60 |
Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. This analysis focused on placebo non-responders in phase 1 and presented them by their treatment assignment in phase 2. (NCT00683852)
Timeframe: 12 Weeks
| Intervention | Patients (Number) |
|---|---|
| Phase 1 Placebo Non-Responders on Drug in Phase 2 | 40 |
| Phase 1 Placebo Non-Responders on Placebo in Phase 2 | 44 |
Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. In this analysis, AEs were summarized according to person-phase of occurrence. Each AE was attributed to the person and then to phase 1 or phase 2, depending on the initial date of onset. (NCT00683852)
Timeframe: 12 Weeks
| Intervention | adverse events (Number) |
|---|---|
| ADAPT Drug Group | 58 |
| ADAPT Placebo Group | 110 |
The SQ, a 92-item (yes/no) self-rating questionnaire, includes 4 distress and 4 well-being subscales. There are 68 items for the distress subscales and 24 items for the well-being subscales. Each item has either a Yes/No or True/False answer. For the distress symptom score, add together the following items and score 1 when the answer is Yes/True: 1, 2, 3, 5, 6, 8, 11, 12, 15, 18, 20, 22, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 36, 37, 39, 41, 42, 44, 45, 47, 48, 49, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 72, 73, 74, 75, 76, 77, 79, 80, 81, 82, 84, 85, 86, 87, 88, 90, 91, 92. Minimum score is 0 and maximum score is 68. A higher score indicates more distress symptoms. For the well-being subscale score, add together the following items and score 1 when the answer is No/False: 4, 7, 9, 10, 13, 14, 16, 17, 19, 21, 23, 29, 31, 35, 38, 40, 43, 46, 50, 51, 71, 78, 83, 89. Minimum score is 0 and maximum score is 24. A higher score indicates more well-being. (NCT00683852)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Sum of 4 subscaled distress scores | Sum of 4 subscaled well-being scores | |
| Phase 1 Drug | -9.44 | 3.71 |
| Phase 1 Placebo Non-Responders on Drug in Phase 2 | -6.78 | 3.34 |
| Phase 1 Placebo Non-Responders on Placebo in Phase 2 | -4.52 | 1.98 |
| Phase I Placebo | -9.70 | 2.75 |
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BDI-II score (Mean) |
|---|---|
| Paroxetine | -9.7 |
| Venlafaxine Extended Release | -9.6 |
| Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BPRS score (Mean) |
|---|---|
| Paroxetine | -9.0 |
| Venlafaxine Extended Release | -9.8 |
| Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in GDS score (Mean) |
|---|---|
| Paroxetine | -6.9 |
| Venlafaxine Extended Release | -6.9 |
| Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in HAM-D score (Mean) |
|---|---|
| Paroxetine | -13.0 |
| Venlafaxine Extended Release | -11.0 |
| Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in MADRS score (Mean) |
|---|---|
| Paroxetine | -13.6 |
| Venlafaxine Extended Release | -10.9 |
| Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 Emotional score (Mean) |
|---|---|
| Paroxetine | -21.4 |
| Venlafaxine Extended Release | -20.7 |
| Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 score (Mean) |
|---|---|
| Paroxetine | -8.0 |
| Venlafaxine Extended Release | -8.4 |
| Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PQSI score (Mean) |
|---|---|
| Paroxetine | -2.1 |
| Venlafaxine Extended Release | -2.6 |
| Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 mental score (Mean) |
|---|---|
| Paroxetine | 11.4 |
| Venlafaxine Extended Release | 9.5 |
| Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Mental Health score (Mean) |
|---|---|
| Paroxetine | 16.7 |
| Venlafaxine Extended Release | 17.4 |
| Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Role score (Mean) |
|---|---|
| Paroxetine | 39.5 |
| Venlafaxine Extended Release | 26.9 |
| Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 vitality score (Mean) |
|---|---|
| Paroxetine | 13.5 |
| Venlafaxine Extended Release | 9.1 |
| Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in CAS score (Mean) |
|---|---|
| Paroxetine | -3.6 |
| Venlafaxine Extended Release | -3.2 |
| Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS score (Mean) |
|---|---|
| Paroxetine | -8.7 |
| Venlafaxine Extended Release | -7.0 |
| Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-Bulbar score (Mean) |
|---|---|
| Paroxetine | -1.4 |
| Venlafaxine Extended Release | -1.4 |
| Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-motor score (Mean) |
|---|---|
| Paroxetine | -4.3 |
| Venlafaxine Extended Release | -2.0 |
| Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-tremor score (Mean) |
|---|---|
| Paroxetine | 0.4 |
| Venlafaxine Extended Release | 0.5 |
| Placebo | -0.6 |
63 reviews available for fluoxetine and Depressive Disorder, Major
| Article | Year |
|---|---|
Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis.
Topics: Cytokines; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Interleukin-1beta; Interleuki | 2022 |
Effect of antidepressants on functioning and quality of life outcomes in children and adolescents with major depressive disorder: a systematic review and meta-analysis.
Topics: Adolescent; Antidepressive Agents; Antidepressive Agents, Second-Generation; Child; Depressive Disor | 2022 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine | 2023 |
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Dul | 2022 |
Stroke, depression, and self-harm in later life.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Stroke; Su | 2023 |
Pharmacological and non-pharmacological treatments for major depressive disorder in adults: A systematic review and network meta-analysis.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral The | 2019 |
How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxetine; Humans; Patients | 2020 |
Inflammatory modulation of fluoxetine use in patients with depression: A systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major | 2020 |
New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxi | 2021 |
Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule | 2017 |
Model-based comparing efficacy of fluoxetine between elderly and non-elderly participants with major depressive disorder.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Depressive Di | 2018 |
Adolescent depression: clinical features and therapeutic strategies.
Topics: Adolescent; Cognitive Behavioral Therapy; Depressive Disorder, Major; Fluoxetine; Humans | 2013 |
Comparative efficacies of fluoxetine and paroxetine in major depression across varying acute-phase treatment periods: a meta-analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Fluoxetine; Humans; Par | 2014 |
Drug safety evaluation of olanzapine/fluoxetine combination.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Di | 2014 |
Treatment of bipolar depression: making sensible decisions.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; De | 2014 |
Drug dose as mediator of treatment effect in antidepressant drug trials: the case of fluoxetine.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Depressive Disorder, Major; Dose-Resp | 2015 |
Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Evidence-Based Medicine; Fluoxeti | 2015 |
Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; H | 2016 |
Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials.
Topics: Antidepressive Agents; Atorvastatin; Citalopram; Depressive Disorder, Major; Double-Blind Method; Fl | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine.
Topics: Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitor | 2016 |
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bip | 2016 |
Pharmacological treatment of children and adolescents with depression.
Topics: Adolescent; Antidepressive Agents; Child; Clinical Trials as Topic; Data Interpretation, Statistical | 2016 |
New antidepressants for older people: a critical review of the evidence base.
Topics: Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; F | 2008 |
Treatment of adolescent depression: what we have come to know.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2009 |
Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Depressive Disorder | 2009 |
Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Delayed-Act | 1999 |
Clinical messages from the Treatment for Adolescents With Depression Study (TADS).
Topics: Adolescent; Adolescent Behavior; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive | 2009 |
Pharmacotherapy of major depressive disorder in adolescents.
Topics: Adolescent; Adolescent Behavior; Adult; Antidepressive Agents; Cognitive Behavioral Therapy; Combine | 2010 |
Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder.
Topics: Benzodiazepines; Clinical Trials as Topic; Databases, Factual; Depressive Disorder, Major; Fluoxetin | 2010 |
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder.
Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Fluox | 2010 |
From TADS and SOFTADS to TORDIA and beyond: what's new in the treatment of adolescent depression?
Topics: Adolescent; Antidepressive Agents; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined | 2010 |
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive | 2010 |
Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.
Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic | 2012 |
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.
Topics: Adolescent; Adult; Aged; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized C | 2012 |
Drug interactions in the treatment of depression in patients with ischemic heart disease.
Topics: Aged; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Comorbidity; Cytoc | 2012 |
Vasopressin as a target for antidepressant development: an assessment of the available evidence.
Topics: Adrenocorticotropic Hormone; Antidepressive Agents; Corticotropin-Releasing Hormone; Depressive Diso | 2002 |
Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Ma | 2002 |
Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Therapy, Combinati | 2002 |
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.
Topics: Adult; Anxiety; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; F | 2004 |
A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Control | 2002 |
Fluoxetine--do the benefits outweigh the risks in adolescent major depression?
Topics: Adolescent; Depressive Disorder, Major; Fluoxetine; Humans; Risk Factors; Suicide | 2005 |
Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Drug Tolerance; Fluoxetine; Gastrointe | 2005 |
Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review.
Topics: Adolescent; Alcohol Drinking; Alcoholism; Antidepressive Agents, Second-Generation; Combined Modalit | 2005 |
Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy.
Topics: Adolescent; Age Factors; Age of Onset; Antidepressive Agents; Child; Controlled Clinical Trials as T | 2005 |
Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study.
Topics: Adolescent; Adolescent Behavior; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Mo | 2005 |
Suicidality in pediatric patients treated with antidepressant drugs.
Topics: Adolescent; Age Factors; Antidepressive Agents; Child; Depressive Disorder, Major; Female; Fluoxetin | 2006 |
Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, | 2006 |
Pharmacotherapy of child and adolescent depression.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder, Major; Fluoxetine; Humans | 2006 |
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; F | 2008 |
Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo.
Topics: Adolescent; Aggression; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; | 2007 |
Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; | 2007 |
Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials.
Topics: Adverse Drug Reaction Reporting Systems; Data Collection; Depressive Disorder, Major; Dose-Response | 2007 |
Perimenopausal depression.
Topics: Administration, Cutaneous; Combined Modality Therapy; Comorbidity; Depression, Postpartum; Depressiv | 2008 |
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Maj | 2008 |
[Therapeutic action lag time and resistance to treatment].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv | 1999 |
Reboxetine: tolerability and safety profile in patients with major depression.
Topics: Adrenergic Uptake Inhibitors; Age Factors; Antidepressive Agents; Cytochrome P-450 Enzyme System; De | 2000 |
Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluo | 2000 |
Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies.
Topics: Animals; Brain; Cerebrovascular Circulation; Clinical Trials as Topic; Depressive Disorder, Major; D | 2000 |
Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive | 2000 |
Venlafaxine extended-release: a review of its use in the management of major depression.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depre | 2001 |
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Dis | 2001 |
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Dis | 2001 |
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Dis | 2001 |
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Dis | 2001 |
[Serotonin syndrome: report of a fatal case and review of the literature].
Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism | 2002 |
326 trials available for fluoxetine and Depressive Disorder, Major
| Article | Year |
|---|---|
Functional outcomes with bright light in monotherapy and combined with fluoxetine in patients with major depressive disorder: Results from the LIFE-D trial.
Topics: Cognition; Depressive Disorder, Major; Double-Blind Method; Efficiency; Fluoxetine; Humans; Treatmen | 2022 |
Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
Topics: Adolescent; Adult; Child; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Piper | 2022 |
Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
Topics: Adolescent; Adult; Child; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Piper | 2022 |
Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
Topics: Adolescent; Adult; Child; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Piper | 2022 |
Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
Topics: Adolescent; Adult; Child; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Piper | 2022 |
Acute neural effects of fluoxetine on emotional regulation in depressed adolescents.
Topics: Adolescent; Brain; Brain Mapping; Depressive Disorder, Major; Emotional Regulation; Emotions; Fluoxe | 2023 |
Predictors of response to pharmacotherapy in children and adolescents with psychiatric disorders: A combined post hoc analysis of four clinical trial data.
Topics: Adolescent; Child; Depressive Disorder, Major; Female; Fluoxetine; Humans; Selective Serotonin Reupt | 2022 |
Sequenced treatment alternatives to relieve adolescent depression (STAR-AD): a multicentre open-label randomized controlled trial protocol.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Depressive D | 2023 |
Is sleep disturbance linked to short- and long-term outcomes following treatments for recurrent depression?
Topics: Adult; Antidepressive Agents; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluo | 2020 |
Implementation research for public sector mental health care scale-up (SMART-DAPPER): a sequential multiple, assignment randomized trial (SMART) of non-specialist-delivered psychotherapy and/or medication for major depressive disorder and posttraumatic st
Topics: Adult; Ambulatory Care; Ambulatory Care Facilities; Antidepressive Agents, Second-Generation; Combin | 2019 |
Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
Topics: Adolescent; Bayes Theorem; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressiv | 2020 |
A placebo prognostic index (PI) as a moderator of outcomes in the treatment of adolescent depression: Could it inform risk-stratification in treatment with cognitive-behavioral therapy, fluoxetine, or their combination?
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Depressive Disorder | 2021 |
Quality of Life Impacts of Bright Light Treatment, Fluoxetine, and the Combination in Patients with Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Fluoxetine; Humans; Quality of Life; Treatment Ou | 2021 |
Quality of life after response to acute-phase cognitive therapy for recurrent depression.
Topics: Adult; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Fluoxetine; Follow-Up S | 2021 |
Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people.
Topics: Adolescent; Australia; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Fluoxet | 2021 |
Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
Topics: Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Postmeno | 2021 |
Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
Topics: Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Postmeno | 2021 |
Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
Topics: Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Postmeno | 2021 |
Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
Topics: Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Postmeno | 2021 |
Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disorder, | 2017 |
Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression.
Topics: Acetamides; Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma | 2017 |
Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxetine; Humans; Inpatients; Ma | 2017 |
Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose | 2018 |
Nitrous oxide (N
Topics: Adolescent; Child; Data Interpretation, Statistical; Depressive Disorder, Major; Drug Therapy, Combi | 2017 |
Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression.
Topics: Adult; Appetitive Behavior; Combined Modality Therapy; Depressive Disorder, Major; Female; Fluoxetin | 2018 |
Using acute tryptophan depletion to investigate predictors of treatment response in adolescents with major depressive disorder: study protocol for a randomised controlled trial.
Topics: Adolescent; Adolescent Behavior; Affect; Age Factors; Amino Acids; Antidepressive Agents, Second-Gen | 2018 |
Treating a broader range of depressed adolescents with combined therapy.
Topics: Adolescent; Adolescent Behavior; Antidepressive Agents, Second-Generation; Child; Cognitive Behavior | 2018 |
Changes in cognitive distortions and affectivity levels in adolescent depression after acute phase fluoxetine treatment.
Topics: Adolescent; Affect; Cognitive Dissonance; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up | 2019 |
Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
Topics: Adenosine Triphosphate; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Affect | 2019 |
Inflammatory Profiles in Depressed Adolescents Treated with Fluoxetine: An 8-Week Follow-up Open Study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cytokines; Depression; Depressive Disor | 2018 |
Trajectories of Symptom Change in the Treatment for Adolescents With Depression Study.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Dia | 2019 |
Estimating patient-specific treatment advantages in the 'Treatment for Adolescents with Depression Study'.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined | 2019 |
The long-term effect of trauma history on adolescent depression treatment.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depressive Disorde | 2019 |
Latent Profiles of Cognitive and Interpersonal Risk Factors for Adolescent Depression and Implications for Personalized Treatment.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Cognitive | 2019 |
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
Topics: Adolescent; Adult; Anxiety; Australia; Cognitive Behavioral Therapy; Combined Modality Therapy; Como | 2019 |
A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Dr | 2013 |
Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adjuvants, Pharmaceutic; Antidepressive Agents; Ascorbic Acid; Child; Depressive Disorder, Major; Do | 2013 |
Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cyclohexanols; | 2013 |
Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brain-derived neurotrophic factor in patients with major depression.
Topics: Adolescent; Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cytokines; | 2014 |
The change of insulin levels after six weeks antidepressant use in drug-naïve major depressive patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Mass | 2013 |
Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial.
Topics: Adult; Antidepressive Agents; Curcumin; Depressive Disorder, Major; Double-Blind Method; Drug Therap | 2014 |
Health-related quality of life and symptom severity in Chinese patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Asian People; China; Depressive Disorder, M | 2013 |
Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.
Topics: Adult; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; P | 2013 |
The structure of the Montgomery-Åsberg depression rating scale over the course of treatment for depression.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; D | 2013 |
Neurocognitive changes in depressed patients in psychodynamic psychotherapy, therapy with fluoxetine and combination therapy.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognition; Combined Modality Therapy; Depressive Di | 2013 |
Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial.
Topics: Adult; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; F | 2013 |
Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depression; De | 2013 |
Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; | 2014 |
Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.
Topics: Adult; Antidepressive Agents; Catechol O-Methyltransferase; Depressive Disorder, Major; Diagnostic a | 2012 |
Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind | 2014 |
Mental health service use among adolescents following participation in a randomized clinical trial for depression.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj | 2015 |
Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder, Major; Dose-Response Relationship, Drug; | 2014 |
Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Depressive Disorder, Trea | 2014 |
A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Dose-Response Relationship, Dr | 2014 |
A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Dose-Response Relationship, Dr | 2014 |
Sequential treatment with fluoxetine and relapse--prevention CBT to improve outcomes in pediatric depression.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj | 2014 |
Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depres | 2014 |
Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period.
Topics: Adult; Benzodiazepines; Depressive Disorder, Major; Drug Administration Schedule; Drug Combinations; | 2014 |
Latent classes of nonresponders, rapid responders, and gradual responders in depressed outpatients receiving antidepressant medication and psychotherapy.
Topics: Adult; Aged; Antidepressive Agents; Bayes Theorem; Cognitive Behavioral Therapy; Combined Modality T | 2015 |
Childhood depression subscales using repeated sessions on Children's Depression Rating Scale - revised (CDRS-R) scores.
Topics: Adolescent; Child; Depressive Disorder, Major; Factor Analysis, Statistical; Female; Fluoxetine; Hum | 2014 |
Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Gene | 2014 |
Comparison of physician-rating and self-rating scales for patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum | 2014 |
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.
Topics: Adolescent; Adolescent Behavior; Adult; Age Factors; Antidepressive Agents, Second-Generation; Clini | 2014 |
Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial.
Topics: Adult; Carotenoids; Citalopram; Crocus; Depressive Disorder, Major; Double-Blind Method; Female; Flu | 2015 |
Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxeti | 2015 |
A rest-activity biomarker to predict response to SSRIs in major depressive disorder.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Biomarkers; Depressive Disorder, Major; Female; Fluox | 2015 |
Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial.
Topics: Adult; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetin | 2015 |
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Double-Blind Method; Duloxetin | 2015 |
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Double-Blind Method; Duloxetin | 2015 |
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Double-Blind Method; Duloxetin | 2015 |
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Double-Blind Method; Duloxetin | 2015 |
Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder.
Topics: Adult; Age Factors; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral | 2015 |
Improved cognitive content endures for 2 years among unstable responders to acute-phase cognitive therapy for recurrent major depressive disorder.
Topics: Adult; Attitude; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Follo | 2015 |
Assessing cognitive therapy skills comprehension, acquisition, and use by means of an independent observer version of the Skills of Cognitive Therapy (SoCT-IO).
Topics: Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Comprehension; Depression; D | 2016 |
Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Desvenl | 2015 |
Trajectories of Functioning Into Emerging Adulthood Following Treatment for Adolescent Depression.
Topics: Adolescent; Adolescent Development; Brief Psychiatric Rating Scale; Cognitive Behavioral Therapy; Co | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj | 2016 |
Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.
Topics: Adolescent; Child; Cognition; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Di | 2015 |
Study the effects of saffron on depression and lipid profiles: A double blind comparative study.
Topics: Adolescent; Adult; Crocus; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Huma | 2016 |
Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care.
Topics: Acute Disease; Adult; Aged; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; | 2016 |
Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder.
Topics: Adult; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Studi | 2016 |
Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Alleles; Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxet | 2016 |
Effects of Restricted Time in Bed on Antidepressant Treatment Response: A Randomized Controlled Trial.
Topics: Actigraphy; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Flu | 2016 |
PURLs: Light therapy for nonseasonal major depressive disorder?
Topics: Adult; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Female; Fluoxet | 2016 |
Defined symptom-change trajectories during acute-phase cognitive therapy for depression predict better longitudinal outcomes.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality The | 2016 |
Acupuncture treatment modulates the corticostriatal reward circuitry in major depressive disorder.
Topics: Acupuncture Therapy; Adult; Antidepressive Agents, Second-Generation; Cerebral Cortex; Combined Moda | 2017 |
Repeated acupuncture treatments modulate amygdala resting state functional connectivity of depressive patients.
Topics: Acupuncture Therapy; Adult; Amygdala; Antidepressive Agents, Second-Generation; Brain; Brain Mapping | 2016 |
Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxeti | 2017 |
Relationships between circadian measures, depression, and response to antidepressant treatment: A preliminary investigation.
Topics: Adult; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Female; Fluoxetine; Huma | 2017 |
Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients.
Topics: Adult; Asian People; Catechol O-Methyltransferase; Depressive Disorder, Major; Diagnostic and Statis | 2009 |
Effect of antidepressants on melatonin metabolite in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxeti | 2009 |
Personality disorders and perceived stress in major depressive disorder.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Comorbidity; Depressive Disorder, Major; Diagnostic and St | 2008 |
Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study.
Topics: Adult; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Admin | 2008 |
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Depressive | 2008 |
Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes.
Topics: Adult; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Down-Regulation; Drug Syner | 2008 |
Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depress | 2008 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed | 2010 |
Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depress | 2008 |
Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined | 2008 |
Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Behavior Therapy; Cognitive B | 2009 |
Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression.
Topics: Brain; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disord | 2009 |
Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Fem | 2009 |
Assessment of safety and long-term outcomes of initial treatment with placebo in TADS.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj | 2009 |
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross- | 2009 |
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross- | 2009 |
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross- | 2009 |
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross- | 2009 |
Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.
Topics: Adult; Antidepressive Agents; Blood Pressure; Constipation; Cyclohexanols; Depressive Disorder, Majo | 2009 |
Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder.
Topics: Adolescent; Adolescent Behavior; Alcohol-Related Disorders; Cognitive Behavioral Therapy; Comorbidit | 2009 |
Predictors of hopelessness among clinically depressed youth.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2009 |
Orosomucoid influences the response to antidepressants in major depressive disorder.
Topics: Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Female; Fluoxetine; Genotype; | 2010 |
Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response.
Topics: Adult; Aged; Alleles; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Case-Control Studies | 2009 |
Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined | 2009 |
Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined | 2009 |
Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined | 2009 |
Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined | 2009 |
The role of readiness to change in response to treatment of adolescent depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined | 2009 |
Does defense style or psychological mindedness predict treatement response in major depression?
Topics: Adult; Cognition; Defense Mechanisms; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; | 2009 |
The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Dis | 2009 |
Childhood neglect and abuse as predictors of antidepressant response in adult depression.
Topics: Adult; Age of Onset; Antidepressive Agents; Child; Child Abuse; Child Abuse, Sexual; Chronic Disease | 2009 |
Suicidal events in the Treatment for Adolescents With Depression Study (TADS).
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Depressive Disorder, Major; Diagnostic and Statisti | 2009 |
Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
Topics: Adolescent; Adult; Aged; Checklist; Depressive Disorder, Major; Double-Blind Method; Drug Administra | 2010 |
Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function.
Topics: Adult; Aged; Autoantibodies; Depressive Disorder, Major; Fluoxetine; Humans; Hypothyroidism; Iodide | 2009 |
Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.
Topics: Antidepressive Agents; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method | 2010 |
Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Gene Frequ | 2009 |
The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj | 2009 |
Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cytokines; Depressive Disorde | 2009 |
Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.
Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; | 2009 |
Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Antigens, CD; Cyclohexanols; Depressive Disorder, M | 2010 |
Personality disorders improve in patients treated for major depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Comorbidity; Depressive Disorder, Major; Dose-Respon | 2010 |
Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Clonazepam; Depressive Disorder, Major; | 2010 |
Research letter: Psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain; Brain Chemistry; Depre | 2010 |
Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
Topics: Adult; Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met | 2010 |
Factor structure and psychometric properties of the Children's Negative Cognitive Error Questionnaire with a clinically depressed adolescent sample.
Topics: Adolescent; Affect; Child; Cognition; Cognitive Behavioral Therapy; Depressive Disorder, Major; Fact | 2009 |
Cognitive measures of adolescent depression: unique or unitary constructs?
Topics: Adolescent; Child; Cognition Disorders; Cognitive Behavioral Therapy; Culture; Depressive Disorder, | 2009 |
An exploratory analysis of the impact of family functioning on treatment for depression in adolescents.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Depressive Disorder, Major; Double-Blind Method; Fa | 2009 |
Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Brain-Derived Neurotrophic Factor; China; Cohort S | 2010 |
Correlation between patient and clinician assessments of depression severity in the PREVENT study.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluox | 2010 |
Measures of temperament and character are differentially impacted on by depression severity.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognitive | 2010 |
Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Brain; | 2010 |
Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder, Major; Female; Fluoxe | 2010 |
Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Dep | 2010 |
Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Eicosapentaenoic Aci | 2010 |
Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode.
Topics: Adult; Affect; Aged; Aged, 80 and over; Bipolar Disorder; Depressive Disorder, Major; Female; Fluoxe | 2010 |
Insomnia severity is an indicator of suicidal ideation during a depression clinical trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive | 2010 |
Personality traits and recovery from major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Comparative Effectiveness Research; Cooperative Beh | 2011 |
Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
Topics: Absenteeism; Algorithms; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Cost of Ill | 2010 |
Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined | 2010 |
Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum | 2010 |
Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder.
Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; | 2010 |
Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome.
Topics: Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Prevalence; Selective Serotonin | 2010 |
Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression.
Topics: Activities of Daily Living; Affect; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; | 2010 |
Effects of antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D2/3 receptors in major depressive disorder studied with [11C]raclopride PET.
Topics: Adult; Antidepressive Agents, Second-Generation; Carbon Radioisotopes; Corpus Striatum; Depressive D | 2011 |
Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic a | 2010 |
TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients.
Topics: Adult; Asian People; Case-Control Studies; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxe | 2011 |
A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Drug Monito | 2010 |
A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Drug Monito | 2010 |
A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Drug Monito | 2010 |
A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Drug Monito | 2010 |
Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder.
Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major | 2010 |
Recovery and recurrence following treatment for adolescent major depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2011 |
Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Double-B | 2010 |
Clinical studies on event-related potentials (ERPs) N400 and the related factors in patients with poststroke depression (PSD).
Topics: Aged; Antidepressive Agents, Second-Generation; Blood Platelets; Cerebral Hemorrhage; Cerebral Infar | 2010 |
Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study.
Topics: Adolescent; Age Factors; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Fluo | 2011 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
Topics: Acute Disease; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorde | 2011 |
Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial.
Topics: Adult; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders | 2011 |
Does personality disorder co-morbidity impact treatment outcome for patients with major depression? A multi-level analysis.
Topics: Antidepressive Agents; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; | 2011 |
Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder.
Topics: Adult; Aged; Asian People; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged | 2011 |
Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Central Nervous System Stimul | 2011 |
Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents.
Topics: Adolescent; Alcohol-Related Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Como | 2011 |
Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Brain Mapping; Cyclohexanols; Depressive Disorde | 2011 |
Response rates to fluoxetine in subjects who initially show no improvement.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; | 2011 |
Gallbladder emptying in patients with major depression: a case series.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Case-Control Studies; Depressive Diso | 2011 |
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female | 2011 |
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female | 2011 |
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female | 2011 |
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female | 2011 |
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female | 2011 |
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female | 2011 |
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female | 2011 |
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female | 2011 |
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female | 2011 |
Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Femal | 2011 |
Effect of an aerobic training program as complementary therapy in patients with moderate depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Complementary Therapies; | 2011 |
Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder.
Topics: Adult; Anhedonia; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met | 2011 |
The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Chi-Square Distribution; Depressive Disorder, Major | 2011 |
Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist DU-125530 for antidepressant treatment.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adult; Animals; Antidepressive Agents; Brain; Depressive Dis | 2012 |
Therapeutic drug monitoring of children and adolescents treated with fluoxetine.
Topics: Adolescent; Age Factors; Child; Cohort Studies; Depressive Disorder, Major; Dose-Response Relationsh | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde | 2012 |
Onset of alcohol or substance use disorders following treatment for adolescent depression.
Topics: Adolescent; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressi | 2012 |
Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Cytochrome P-450 | 2012 |
Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth.
Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major | 2012 |
Brain activity in adolescent major depressive disorder before and after fluoxetine treatment.
Topics: Adolescent; Adolescent Behavior; Brain; Child; Depressive Disorder, Major; Facial Expression; Female | 2012 |
Objective vs. subjective measurements of sleep in depressed insomniacs: first night effect or reverse first night effect?
Topics: Actigraphy; Adult; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disord | 2012 |
Serum cortisol concentration in patients with major depression after treatment with fluoxetine.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Chromatography, High Pressure Liquid; Depress | 2012 |
Does prior antidepressant treatment of major depression impact brain function during current treatment?
Topics: Adult; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder, Major; Diagnostic | 2012 |
Cognitive reactivity, dysfunctional attitudes, and depressive relapse and recurrence in cognitive therapy responders.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents, Second-Generation; Attitude; Cognitive Behav | 2012 |
Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Crocus; Depressive Disorder, Major; Double-Blind Method; Erectile Dysfunction; Fl | 2012 |
Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Calcifediol; Cholecalciferol; Depressive Disorder, Major; Double-Blind Meth | 2013 |
Relationships between changes in sustained fronto-striatal connectivity and positive affect in major depression resulting from antidepressant treatment.
Topics: Affect; Antidepressive Agents; Biological Availability; Brain Mapping; Cyclohexanols; Depressive Dis | 2013 |
Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study.
Topics: Adolescent; Adult; Crocus; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Huma | 2013 |
Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distrib | 2002 |
Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyc | 2002 |
The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression.
Topics: Acute Disease; Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Depressive Disorder, M | 2002 |
Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality The | 2002 |
Site variability in treatment outcome in antidepressant trials.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chi-Square Distribution; Controlled Clinical Trials | 2002 |
Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind | 2002 |
Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment.
Topics: Adult; Caudate Nucleus; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; | 2003 |
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Depressive Disord | 2002 |
Effects of fluoxetine, indomethacine and placebo on 3 alpha, 5 alpha tetrahydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal.
Topics: Adult; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Ethanol; F | 2000 |
Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj | 2003 |
Switching to bupropion in fluoxetine-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Drug Resista | 2003 |
Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Fluvox | 2003 |
Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation.
Topics: Adult; Aged; Algorithms; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Synergis | 2003 |
Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Female; | 2003 |
Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study.
Topics: Adult; Brain Mapping; Choline; Depressive Disorder, Major; Female; Fluoxetine; Gyrus Cinguli; Humans | 2003 |
Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.
Topics: Adult; Age Factors; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyc | 2003 |
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disord | 2003 |
Fluoxetine once every third day in the treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Demography; Depressive Disorder, Major; Dose-Respon | 2003 |
No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
Topics: Adolescent; Adult; Antidepressive Agents; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Femal | 2004 |
Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Connecticut; Cross-Over Studies; Depressive Disorder, Majo | 2004 |
Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antidepressive Agents; Depressive Disorder, M | 2004 |
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.
Topics: Adult; Anxiety; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; F | 2004 |
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2004 |
Response to tryptophan depletion in major depression treated with either cognitive therapy or selective serotonin reuptake inhibitor antidepressants.
Topics: Cognitive Behavioral Therapy; Cross-Over Studies; Depressive Disorder, Major; Diagnostic and Statist | 2004 |
Bipolar II disorder: personality and outcome in two clinical samples.
Topics: Adrenergic Uptake Inhibitors; Adult; Bipolar Disorder; Bulimia; Cognitive Behavioral Therapy; Depres | 2004 |
HPA axis activation in major depression and response to fluoxetine: a pilot study.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Antidepressive Agents, Second-Generation; Circadian | 2004 |
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.
Topics: Adult; Analysis of Variance; Benzodiazepines; Chi-Square Distribution; Depressive Disorder, Major; D | 2004 |
Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Blood Glucose; Depressive Disorder, Major; Double-Bli | 2004 |
Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder.
Topics: Adult; Cholesterol; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged | 2004 |
Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
Topics: Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cohort Studie | 2004 |
Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression.
Topics: Adult; Brain; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Mid | 2004 |
Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disorder, | 2004 |
Predictors of improved mood over time in clinical trials for major depression.
Topics: Adult; Affect; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalograph | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2004 |
Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.
Topics: Activities of Daily Living; Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Antima | 2004 |
Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Depressive Disorder, Major; Electroencephalography; Femal | 2004 |
Obesity among outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Body Mass Index; Body Weight; Depr | 2005 |
Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors.
Topics: Adult; Analysis of Variance; Brain Mapping; Cocaine; Depressive Disorder, Major; Diencephalon; Femal | 2004 |
Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo.
Topics: Analysis of Variance; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Hypericum | 2005 |
Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agent | 2004 |
Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents.
Topics: Adolescent; Child; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Single-Blind | 2004 |
Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; | 2005 |
The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety; D | 2005 |
Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
Topics: Adolescent; Adult; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders | 2005 |
Dopaminergic mechanism of antidepressant action in depressed patients.
Topics: Adult; Affect; Case-Control Studies; Citalopram; Depressive Disorder, Major; Dopamine Antagonists; F | 2005 |
Dose-effect relations in time-limited combined psycho-pharmacological treatment for depression.
Topics: Adolescent; Adult; Combined Modality Therapy; Depressive Disorder, Major; Diagnostic and Statistical | 2005 |
Reversed diurnal variation in depression: associations with a differential antidepressant response, tryptophan: large neutral amino acid ratio and serotonin transporter polymorphisms.
Topics: Adult; Affect; Alleles; Amino Acids; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Depr | 2005 |
The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Femal | 2005 |
Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder.
Topics: Adult; Age of Onset; Anticonvulsants; Depressive Disorder, Major; Double-Blind Method; Drug Administ | 2005 |
Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Fe | 2005 |
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Dis | 2005 |
Tryptophan and tyrosine availability and response to antidepressant treatment in major depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Amino Acids, Neutral; Antidepressive Agents, Tricyclic; Circadi | 2005 |
Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression.
Topics: Acoustic Stimulation; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; China; | 2005 |
Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Clinical Protocols; Depressive Disorder, Major; Doubl | 2005 |
Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder, Major; | 2005 |
A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Doubl | 2005 |
Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Topics: Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Female; Fluoxetine; H | 2005 |
Escitalopram in the treatment of depressed elderly patients.
Topics: Aged; Aged, 80 and over; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxe | 2005 |
Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum | 2005 |
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical | 2005 |
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Depressive Disorder, | 2005 |
Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders.
Topics: Adult; Asian People; Asparagine; Depressive Disorder, Major; Female; Fluoxetine; Glycine; Humans; Li | 2006 |
Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine.
Topics: Adult; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Depressive Disorder, Major; Double-B | 2006 |
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl | 2006 |
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl | 2006 |
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl | 2006 |
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl | 2006 |
Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy.
Topics: Adolescent; Adult; Age of Onset; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Memor | 2006 |
Response of emotional unawareness after stroke to antidepressant treatment.
Topics: Activities of Daily Living; Affective Symptoms; Aged; Agnosia; Antidepressive Agents; Awareness; Cog | 2006 |
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
Topics: Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Cyclohexanols; Demography; Depressi | 2006 |
Cytokines and serotonin transporter in patients with major depression.
Topics: Adult; Cytokines; Depressive Disorder, Major; DNA Primers; Female; Fluoxetine; Humans; Male; Middle | 2006 |
A comparison of effects of fluoxetine and nortriptyline on the symptoms of major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder, Major; Female; Fluoxetine; Humans; Iran; M | 2006 |
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
Topics: Benzodiazepines; Brief Psychiatric Rating Scale; Cyclohexanols; Depressive Disorder, Major; Double-B | 2006 |
The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; | 2006 |
Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis.
Topics: Adult; Cognition; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Placebo | 2006 |
Phenytoin as an augmentation for SSRI failures: a small controlled study.
Topics: Adult; Aged; Anticonvulsants; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug | 2006 |
Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy.
Topics: Adult; Antidepressive Agents, Second-Generation; Borderline Personality Disorder; Combined Modality | 2006 |
Problem-solving ability and comorbid personality disorders in depressed outpatients.
Topics: Adult; Antidepressive Agents, Second-Generation; Aptitude; Comorbidity; Depressive Disorder, Major; | 2006 |
Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine.
Topics: Adult; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hyperprolactinemia; Male; Middle Aged | 2006 |
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
Topics: Adult; Biomarkers; Brain; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met | 2006 |
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
Topics: Adult; Biomarkers; Brain; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met | 2006 |
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
Topics: Adult; Biomarkers; Brain; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met | 2006 |
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
Topics: Adult; Biomarkers; Brain; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met | 2006 |
Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Doubl | 2006 |
Effects of electroacupuncture and fluoxetine on the density of GTP-binding-proteins in platelet membrane in patients with major depressive disorder.
Topics: Adult; Antibodies; Combined Modality Therapy; Depressive Disorder, Major; Electroacupuncture; Female | 2007 |
Predictors of relapse in a prospective study of fluoxetine treatment of major depression.
Topics: Adult; Chronic Disease; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Female; Fl | 2006 |
Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Aged; Antidepressive Agents; Cyclic Nucleotide Phosphodi | 2006 |
Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD.
Topics: Adult; Antidepressive Agents, Second-Generation; Attitude; Cognition Disorders; Cognitive Behavioral | 2007 |
Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women.
Topics: Adrenocorticotropic Hormone; Adult; Brain; Carbon Radioisotopes; Depressive Disorder, Major; Emotion | 2006 |
The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Dia | 2006 |
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Demography; Depressive Disorder | 2006 |
Acute time to response in the Treatment for Adolescents with Depression Study (TADS).
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj | 2006 |
Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS).
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Dia | 2006 |
Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Dia | 2006 |
Treatment for Adolescents with Depression Study (TADS): safety results.
Topics: Adolescent; Algorithms; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive D | 2006 |
Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
Topics: Adolescent; Adult; Aged; Asian People; China; Citalopram; Depressive Disorder, Major; Diagnostic and | 2008 |
Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Drug Administration Schedule; | 2007 |
Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combinati | 2006 |
Effect of fluoxetine on circadian rhythm of melatonin in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Circadian Rhythm; Depressive Disorder, Major; Femal | 2007 |
Fluoxetine, smoking, and history of major depression: A randomized controlled trial.
Topics: Adolescent; Adult; Depressive Disorder, Major; Fluoxetine; Follow-Up Studies; Humans; Middle Aged; S | 2007 |
Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment.
Topics: Acute Disease; Adult; Chronic Disease; Cognitive Behavioral Therapy; Depressive Disorder, Major; Dos | 2007 |
Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Blood Glucose; Body M | 2007 |
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Double-B | 2007 |
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
Topics: Adult; Azabicyclo Compounds; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Admi | 2007 |
[Copper-zinc superoxide dismutase activity in platelets in patients with depressive disorder treated by fluoxetine--preliminary study].
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Platelets; Depressive Disorder, Major; Female | 2007 |
rTMS treatment for depression in Parkinson's disease increases BOLD responses in the left prefrontal cortex.
Topics: Affect; Aged; Antidepressive Agents, Second-Generation; Brain Mapping; Combined Modality Therapy; De | 2008 |
A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children.
Topics: Child; Depression; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Psychometrics; Sele | 2007 |
Empirically derived subtypes of adolescent depression: latent profile analysis of co-occurring symptoms in the Treatment for Adolescents with Depression Study (TADS).
Topics: Adolescent; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; | 2007 |
The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
Topics: Adolescent; Clinical Protocols; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive | 2007 |
Perceived stress and cognitive vulnerability mediate the effects of personality disorder comorbidity on treatment outcome in major depressive disorder: a path analysis study.
Topics: Acute Disease; Adolescent; Adult; Ambulatory Care; Cognition Disorders; Comorbidity; Depressive Diso | 2007 |
Transcranial direct stimulation and fluoxetine for the treatment of depression.
Topics: Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Pers | 2008 |
Transcranial direct stimulation and fluoxetine for the treatment of depression.
Topics: Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Pers | 2008 |
Transcranial direct stimulation and fluoxetine for the treatment of depression.
Topics: Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Pers | 2008 |
Transcranial direct stimulation and fluoxetine for the treatment of depression.
Topics: Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Pers | 2008 |
Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS).
Topics: Adolescent; Cognitive Behavioral Therapy; Depressive Disorder, Major; Diagnostic and Statistical Man | 2007 |
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Dr | 2007 |
Dimensional personality traits and treatment outcome in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Cognitive Behavioral Therapy; Depressive Disorder, Major; Diagnostic and St | 2008 |
Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Menta | 2008 |
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine.
Topics: Adult; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Hypericum; Male; | 2007 |
Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.
Topics: Adolescent; Age Factors; Child; Depressive Disorder, Major; Double-Blind Method; Drug Administration | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr | 2008 |
Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy.
Topics: Achievement; Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Thera | 2008 |
Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy.
Topics: Anxiety Disorders; Borderline Personality Disorder; Cognitive Behavioral Therapy; Combined Modality | 2007 |
Cost-effectiveness of treatments for adolescent depression: results from TADS.
Topics: Adolescent; Child; Combined Modality Therapy; Cost-Benefit Analysis; Depressive Disorder, Major; Dru | 2008 |
Maternal depressive symptoms in pediatric major depressive disorder: relationship to acute treatment outcome.
Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Child; Child of Impaired Parent | 2008 |
A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined | 2008 |
Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antigens, CD; CD4-Positive T-Lymphocyte | 2008 |
Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Rel | 1997 |
Fluoxetine in medically stable, depressed geriatric patients: effects on weight.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Body Mass Index; Depressive Disor | 1997 |
Fluoxetine in depressed patients on dialysis.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Meth | 1997 |
Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.
Topics: Adult; Aged; Alanine; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arginine; Asparagine; | 1998 |
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
Topics: Adult; Anxiety; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Fluoxetine; Hu | 1999 |
Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action.
Topics: Adult; Aged; Amino Acids; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepres | 1999 |
Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Cognition; Depressive Disorder, Major; Double-Blind | 1999 |
A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Double-Blind Method; Drug Tole | 1999 |
Serotonin and the prediction of response time to fluoxetine in patients with mild depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Fe | 1999 |
A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity.
Topics: Adult; Antidepressive Agents, Second-Generation; Caudate Nucleus; Corpus Striatum; Depressive Disord | 1998 |
Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dysthymi | 2000 |
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.
Topics: Adult; Benzothiazoles; Depressive Disorder, Major; Dopamine Agonists; Dose-Response Relationship, Dr | 2000 |
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum | 2000 |
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum | 2000 |
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum | 2000 |
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum | 2000 |
Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Dr | 2000 |
Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Dru | 2000 |
Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression.
Topics: Adult; Aged; Anxiety; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug | 2000 |
Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression.
Topics: Adult; Anemia, Macrocytic; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dru | 2000 |
Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors.
Topics: Adrenergic beta-Antagonists; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind | 2001 |
Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Dr | 2001 |
A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Depre | 2001 |
Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT.
Topics: Aged; Bipolar Disorder; Combined Modality Therapy; Depressive Disorder, Major; Dose-Response Relatio | 2001 |
Fluoxetine treatment of cocaine-dependent patients with major depressive disorder.
Topics: Adolescent; Adult; Analysis of Variance; Cocaine-Related Disorders; Depressive Disorder, Major; Diag | 2001 |
Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depress | 2001 |
Changes in brain function of depressed subjects during treatment with placebo.
Topics: Adult; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencep | 2002 |
Changes in brain function of depressed subjects during treatment with placebo.
Topics: Adult; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencep | 2002 |
Changes in brain function of depressed subjects during treatment with placebo.
Topics: Adult; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencep | 2002 |
Changes in brain function of depressed subjects during treatment with placebo.
Topics: Adult; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencep | 2002 |
NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Dose-Response Relationship, Dr | 2002 |
Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.
Topics: Acute Disease; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Depressive Disorder, | 2002 |
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Blood Pressure; Body Weight; Depressive | 2002 |
Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Drug Admini | 2002 |
Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial.
Topics: Adult; Aged; Analysis of Variance; Anxiety; Comorbidity; Depressive Disorder, Major; Fluoxetine; Hum | 2002 |
Early changes in prefrontal activity characterize clinical responders to antidepressants.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Cyclohexanols; Depressi | 2002 |
Early changes in prefrontal activity characterize clinical responders to antidepressants.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Cyclohexanols; Depressi | 2002 |
Early changes in prefrontal activity characterize clinical responders to antidepressants.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Cyclohexanols; Depressi | 2002 |
Early changes in prefrontal activity characterize clinical responders to antidepressants.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Cyclohexanols; Depressi | 2002 |
Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedu | 2002 |
311 other studies available for fluoxetine and Depressive Disorder, Major
| Article | Year |
|---|---|
Discovery of Novel and Potent
Topics: Action Potentials; Allosteric Regulation; Animals; Antidepressive Agents; Binding Sites; Cell Surviv | 2021 |
Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders.
Topics: Adult; Alcoholism; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Fluoxetine; Humans; Middle A | 2021 |
Fluoxetine-induced hepatic lipid accumulation is mediated by prostaglandin endoperoxide synthase 1 and is linked to elevated 15-deoxy-Δ
Topics: Cyclooxygenase 2; Depressive Disorder, Major; Fluoxetine; Humans; Non-alcoholic Fatty Liver Disease; | 2022 |
Fluoxetine inhibited the activation of A1 reactive astrocyte in a mouse model of major depressive disorder through astrocytic 5-HT
Topics: Animals; Astrocytes; beta-Arrestin 2; Depressive Disorder, Major; Fluoxetine; Mice; Serotonin | 2022 |
Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants.
Topics: Adolescent; Antidepressive Agents; Artificial Intelligence; Child; Depressive Disorder, Major; Doubl | 2022 |
Oridonin relieves depressive-like behaviors by inhibiting neuroinflammation and autophagy impairment in rats subjected to chronic unpredictable mild stress.
Topics: Animals; Antidepressive Agents; Autophagy; Autophagy-Related Proteins; Cytokines; Depression; Depres | 2022 |
Octopamine mediates sugar relief from a chronic-stress-induced depression-like state in Drosophila.
Topics: 5-Hydroxytryptophan; Animals; Depression; Depressive Disorder, Major; Dopaminergic Neurons; Drosophi | 2022 |
Chronic Fluoxetine Treatment of Socially Isolated Rats Modulates Prefrontal Cortex Proteome.
Topics: Animals; Antidepressive Agents; Calcium; Calcium-Binding Proteins; Cytochromes c; Depression; Depres | 2022 |
Fluoxetine Decreases Phagocytic Function via REV-ERBα in Microglia.
Topics: ARNTL Transcription Factors; Circadian Rhythm; Depressive Disorder, Major; Fluoxetine; Humans; Infla | 2023 |
Physical exercise prevents behavioral alterations in a reserpine-treated zebrafish: A putative depression model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents; Behavior, Animal; COVID-19; Depressi | 2022 |
Multispectral and Molecular Docking Studies Reveal Potential Effectiveness of Antidepressant Fluoxetine by Forming π-Acceptor Complexes.
Topics: Adolescent; Antidepressive Agents; Benzoic Acid; Child; Depressive Disorder, Major; Dinitrobenzenes; | 2022 |
Delineation of biomarkers and molecular pathways of residual effects of fluoxetine treatment in juvenile rhesus monkeys by proteomic profiling.
Topics: Animals; Biomarkers; Depressive Disorder, Major; Fluoxetine; Macaca mulatta; Proteomics; Selective S | 2023 |
Fluoxetine Enhances Synaptic Vesicle Trafficking and Energy Metabolism in the Hippocampus of Socially Isolated Rats.
Topics: Animals; Depressive Disorder, Major; Energy Metabolism; Fluoxetine; Hippocampus; Proteomics; Rats; S | 2022 |
Fluoxetine Enhances Synaptic Vesicle Trafficking and Energy Metabolism in the Hippocampus of Socially Isolated Rats.
Topics: Animals; Depressive Disorder, Major; Energy Metabolism; Fluoxetine; Hippocampus; Proteomics; Rats; S | 2022 |
Fluoxetine Enhances Synaptic Vesicle Trafficking and Energy Metabolism in the Hippocampus of Socially Isolated Rats.
Topics: Animals; Depressive Disorder, Major; Energy Metabolism; Fluoxetine; Hippocampus; Proteomics; Rats; S | 2022 |
Fluoxetine Enhances Synaptic Vesicle Trafficking and Energy Metabolism in the Hippocampus of Socially Isolated Rats.
Topics: Animals; Depressive Disorder, Major; Energy Metabolism; Fluoxetine; Hippocampus; Proteomics; Rats; S | 2022 |
Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Fluoxetine; Mice; Paroxeti | 2023 |
Case Report: Performing a Medication Safety Review Assisted by Pharmacogenomics to Explain a Prescribing Cascade Resulting in a Patient Fall.
Topics: Antidepressive Agents; Depressive Disorder, Major; Fluoxetine; Humans; Hydrocodone; Pharmacogenetics | 2023 |
Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane.
Topics: Animals; Citalopram; Depressive Disorder, Major; Endoplasmic Reticulum; Escitalopram; Fluoxetine; Hu | 2023 |
Inflammatory Factors Predicted the Resilient Phenotype in Social Defeat-induced Depression of Male Mouse.
Topics: Animals; Depressive Disorder, Major; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Minocycline; Phenot | 2023 |
Right-side frontal-central cortical hyperactivation before the treatment predicts outcomes of antidepressant and electroconvulsive therapy responsivity in major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Electroconvulsive Therapy; Fluoxetine; Frontal Lo | 2023 |
Intrahippocampal injection of a selective blocker of NMDA receptors containing the GluN2B subunit, Ro25-6981, increases glutamate neurotransmission and induces antidepressant-like effects.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Fluox | 2023 |
Chronic fluoxetine treatment in socially-isolated rats modulates the prefrontal cortex synaptoproteome.
Topics: Adenosine Triphosphatases; Animals; Antidepressive Agents; Cation Transport Proteins; Cell Adhesion | 2023 |
Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept?
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Fluox | 2023 |
Organic cation transporter 2 contributes to SSRI antidepressant efficacy by controlling tryptophan availability in the brain.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain; Corticosterone; Depressive Disorder, Major; Fluoxe | 2023 |
Role of Tyrosine Nitrosylation in Stress-Induced Major Depressive Disorder: Mechanisms and Implications.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Fluoxetine; Glucocorticoids; Hippocampus | 2023 |
Developmental fluoxetine exposure affects adolescent and adult bone depending on the dose and period of exposure in mice.
Topics: Animals; Bone and Bones; Depressive Disorder, Major; Female; Fluoxetine; Humans; Mice; Prenatal Expo | 2023 |
Time-to-effect of fluoxetine in children with depression.
Topics: Adolescent; Child; Depressive Disorder, Major; Fluoxetine; Humans; Practice Guidelines as Topic; Ris | 2019 |
Activating newborn neurons suppresses depression and anxiety-like behaviors.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Dentate Gyrus; Depression; Depressive Dis | 2019 |
Applying the inclusion/exclusion criteria in placebo-controlled studies to a clinical sample: A comparison of medications.
Topics: Adult; Antidepressive Agents; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Femal | 2020 |
Alterations in the Levels of Growth Factors in Adolescents with Major Depressive Disorder: A Longitudinal Study during the Treatment with Fluoxetine.
Topics: Adolescent; Adult; Depressive Disorder, Major; Female; Fibroblast Growth Factor 2; Fluoxetine; Granu | 2019 |
Increased circulatory IL-6 during 8-week fluoxetine treatment is a risk factor for suicidal behaviors in youth.
Topics: Adolescent; Child; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interleukin-6; Male; Risk | 2020 |
Simultaneous determination of fluoxetine, venlafaxine, vortioxetine and their active metabolites in human plasma by LC-MS/MS using one-step sample preparation procedure.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Child; Chromatography, High Pressure Liquid; Depress | 2020 |
Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study.
Topics: Antidepressive Agents; Anxiety; Citalopram; Depressive Disorder, Major; Fluoxetine; Fluvoxamine; Fol | 2020 |
Electroconvulsive Therapy Versus Fluoxetine in Suicidal Resolution for Patients With Major Depressive Disorder.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Electroconvulsive Therapy; Fem | 2020 |
Higher dose weekly fluoxetine in hemodialysis patients: A case series report.
Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxetine; Humans; Psychiatric Status Ra | 2021 |
The impact of repetitive transcranial magnetic stimulation and fluoxetine on the brain lipidome in a rat model of chronic unpredictable stress.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain Chemistry; Chronic Disease; Depressive Disor | 2020 |
Long-term use of fluoxetine accelerates bone loss through the disruption of sphingolipids metabolism in bone marrow adipose tissue.
Topics: Adipose Tissue; Animals; Bone Marrow; Depressive Disorder, Major; Fluoxetine; Mice; Sphingolipids | 2020 |
Key role of the 5-HT1A receptor addressing protein Yif1B in serotonin neurotransmission and SSRI treatment.
Topics: Animals; Autopsy; Behavior, Animal; Depressive Disorder, Major; Disease Models, Animal; Female; Fluo | 2020 |
What next? A Bayesian hierarchical modeling re-examination of treatments for adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Bayes Theorem; Cyclohexanols; Depression; Depressive Disorder, Major; Fluoxetine; Humans | 2020 |
An increase in IL-6 levels at 6-month follow-up visit is associated with SSRI-emergent suicidality in high-risk children and adolescents treated with fluoxetine.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Stud | 2020 |
Do Cognitive Therapy Skills Neutralize Lifetime Stress to Improve Treatment Outcomes in Recurrent Depression?
Topics: Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Recurrence | 2020 |
Developing a data-driven algorithm for guiding selection between cognitive behavioral therapy, fluoxetine, and combination treatment for adolescent depression.
Topics: Adolescent; Algorithms; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; | 2020 |
Neural effects of a single dose of fluoxetine on resting-state functional connectivity in adolescent depression.
Topics: Adolescent; Cerebral Cortex; Connectome; Default Mode Network; Depressive Disorder, Major; Female; F | 2020 |
Can the Risk of Severe Depression-Related Outcomes Be Reduced by Tailoring the Antidepressant Therapy to Patient Characteristics?
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Cohort Studies; Databases, Factual; Depressive Disor | 2021 |
Ketamine treatment protects against oxidative damage and the immunological response induced by electroconvulsive therapy.
Topics: Animals; Antidepressive Agents; Bupropion; Combined Modality Therapy; Depressive Disorder, Major; El | 2021 |
Joy Journal: A Behavioral Activation Technique Used in the Treatment of Late-Life Depression Associated With Hopelessness During the COVID-19 Pandemic.
Topics: Aged; Antidepressive Agents; Aripiprazole; Cognitive Behavioral Therapy; COVID-19; Depressive Disord | 2021 |
Dentate gyrus activin signaling mediates the antidepressant response.
Topics: Activins; Animals; Antidepressive Agents; Dentate Gyrus; Depressive Disorder, Major; Fluoxetine; Hum | 2021 |
Standardised ginseng extract G115® potentiates the antidepressant-like properties of fluoxetine in the forced swim test.
Topics: Animals; Anxiety; Autopsy; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depressive Disorder, | 2021 |
Stress Resilience is Associated with Hippocampal Synaptoprotection in the Female Rat Learned Helplessness Paradigm.
Topics: Animals; Depressive Disorder, Major; Disease Models, Animal; Female; Fluoxetine; Helplessness, Learn | 2021 |
Moderators and Predictors of Response After 36 Weeks of Treatment in the Treatment for Adolescents with Depression Study (TADS).
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Depressive D | 2021 |
Postpartum corticosterone and fluoxetine shift the tryptophan-kynurenine pathway in dams.
Topics: Animals; Corticosterone; Depression, Postpartum; Depressive Disorder, Major; Female; Fluoxetine; Hum | 2021 |
Sex-Based Impact of Creatine Supplementation on Depressive Symptoms, Brain Serotonin and SSRI Efficacy in an Animal Model of Treatment-Resistant Depression.
Topics: Animals; Brain; Creatine; Depressive Disorder, Major; Dietary Supplements; Drug Synergism; Energy Me | 2021 |
Prenatal fluoxetine modifies the behavioral and hormonal responses to stress in male mice: role for glucocorticoid insensitivity.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Animal; Corticosterone; Depres | 2017 |
Fluoxetine induces paradoxical effects in C57BL6/J mice: comparison with BALB/c mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder, Major; Disease Mo | 2017 |
A Case of Fluoxetine-Induced Lower Extremity Ecchymosis.
Topics: Adult; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Diso | 2017 |
Glucocorticoid Receptor Genetic Variants and Response to Fluoxetine in Major Depressive Disorder.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Femal | 2018 |
Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine.
Topics: Administration, Oral; Amino Acids; Animals; Antidepressive Agents; Brain; Depressive Disorder, Major | 2017 |
Heterogeneous stock rats: a model to study the genetics of despair-like behavior in adolescence.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder, Major; Disease Models, Animal | 2018 |
Patients' comprehension and skill usage as a putative mediator of change or an engaged target in cognitive therapy: Preliminary findings.
Topics: Adult; Cognitive Behavioral Therapy; Comprehension; Depression; Depressive Disorder, Major; Female; | 2018 |
Behavioural and computational methods reveal differential effects for how delayed and rapid onset antidepressants effect decision making in rats.
Topics: Acoustic Stimulation; Amphetamine; Analgesics; Animals; Antidepressive Agents; Association Learning; | 2017 |
ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis.
Topics: Adult; Age Factors; Antidepressive Agents, Second-Generation; Cost of Illness; Depressive Disorder, | 2018 |
FGF21 Is Associated with Metabolic Effects and Treatment Response in Depressed Bipolar II Disorder Patients Treated with Valproate.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Drug Therapy, Co | 2018 |
Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Desvenlafaxine Succinate; Fluo | 2018 |
Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, M | 2018 |
Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzofurans; Citalopram; Depression; Depr | 2018 |
Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Female; Fluoxetine; Genetic Va | 2018 |
Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Comorbidity; Depressi | 2019 |
Preliminary evidence of an association between increased cortical inhibition and reduced suicidal ideation in adolescents treated for major depression.
Topics: Adolescent; Adolescent Behavior; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; De | 2019 |
Major depression model induced by repeated and intermittent lipopolysaccharide administration: Long-lasting behavioral, neuroimmune and neuroprogressive alterations.
Topics: Animals; Behavior, Animal; Depressive Disorder, Major; Disease Models, Animal; Female; Fluoxetine; L | 2018 |
Early improvement in HAMD-17 and HAMD-6 scores predicts ultimate response and remission for depressed patients treated with fluoxetine or ECT.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Electroconvulsive Thera | 2019 |
Do baseline WAIS-III subtests predict treatment outcomes for depressed inpatients receiving fluoxetine?
Topics: Adult; Aged; Depressive Disorder, Major; Female; Fluoxetine; Humans; Inpatients; Male; Middle Aged; | 2019 |
Precuneus and psychiatric manifestations: Novel neurobiological formulations through lesion based connectivity mapping of psychopathology.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brain Mapping; Brai | 2019 |
A single dose of fluoxetine reduces neural limbic responses to anger in depressed adolescents.
Topics: Adolescent; Amygdala; Anger; Brain Mapping; Depressive Disorder, Major; Facial Expression; Female; F | 2019 |
Adolescent fluoxetine history impairs spatial memory in adult male, but not female, C57BL/6 mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Depressive Disorder, Major; Dos | 2019 |
Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Topics: Adolescent; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Fluoxe | 2019 |
Re: "Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research" by Strawn JR and Croarkin PE
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Desvenlafaxine Succinate; Fluo | 2019 |
A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression.
Topics: Adult; Aged; Aged, 80 and over; Animals; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; | 2020 |
A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy.
Topics: Anxiety; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hydroxyzine; Paroxetine; Selective | 2020 |
Early improvement in HAMD-17 and HAMD-7 scores predict response and remission in depressed patients treated with fluoxetine or electroconvulsive therapy.
Topics: Adult; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Combined Modality Therapy | 2019 |
Could Treatment Matching Patients' Beliefs About Depression Improve Outcomes?
Topics: Adult; Chronic Disease; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Female | 2019 |
Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression.
Topics: Animals; Aripiprazole; Behavior, Animal; Depression; Depressive Disorder, Major; Disease Models, Ani | 2019 |
Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depression; Depressive Disorder, Major; | 2019 |
A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressiv | 2013 |
Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Brain; Brain-Derived Neurotrophic Facto | 2013 |
Comparing effects of citalopram with fluoxetine on sleep quality in patients with major depressive disorder.
Topics: Adolescent; Adult; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Ment | 2013 |
Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables.
Topics: Adult; Alleles; Amino Acid Substitution; Antidepressive Agents; Catechol O-Methyltransferase; Depres | 2013 |
An adolescent with nonsuicidal self-injury: a case and discussion of neurobiological research on emotion regulation.
Topics: Adaptation, Psychological; Adolescent; Allosteric Regulation; Antidepressive Agents; Autonomic Nervo | 2013 |
Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation.
Topics: Adult; Affect; Antidepressive Agents; Behavioral Symptoms; Benzodiazepines; Depressive Disorder, Maj | 2013 |
Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum | 2013 |
When depression doesn't lead with depression.
Topics: Anger; Bipolar Disorder; Cyclohexanols; Depression; Depressive Disorder, Major; Emotions; Female; Fl | 2013 |
Angioedema probably related to fluoxetine in a preadolescent being followed up for major depressive disorder.
Topics: Angioedema; Child; Depressive Disorder, Major; Fluoxetine; Follow-Up Studies; Humans; Male; Selectiv | 2013 |
Frontal-subcortical volumetric deficits in single episode, medication-naïve depressed patients and the effects of 8 weeks fluoxetine treatment: a VBM-DARTEL study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Brain; Case-Control Studies; Cerebral C | 2014 |
Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disord | 2014 |
Continuation-phase cognitive therapy and fluoxetine are effective in reducing the risk of relapse/recurrence in major depression after incomplete remission.
Topics: Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Secondar | 2014 |
Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Body Weight; Depressive Disorder, | 2014 |
The 25th anniversary of the launch of Prozac gives pause for thought: where did we go wrong?
Topics: Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disor | 2014 |
"The ickiness factor:" case study of an unconventional psychotherapeutic approach to pediatric OCD.
Topics: Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Defense Mechanisms; Depressive Disor | 2014 |
An aripiprazole discontinuation syndrome.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressiv | 2013 |
The role of patient expectancy in placebo and nocebo effects in antidepressant trials.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Administration Sch | 2014 |
Fluoxetine-induced pancreatic beta cell dysfunction: New insight into the benefits of folic acid in the treatment of depression.
Topics: Animals; Cell Line; Depressive Disorder, Major; Female; Fluoxetine; Folic Acid; Humans; Insulin-Secr | 2014 |
Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Arginine Vasopressin; Depressive Disord | 2014 |
Improving remission and preventing relapse in youths with major depression.
Topics: Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male | 2014 |
Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain; Chronic Disease; Depress | 2014 |
Impact of antidepressant therapy on cognitive aspects of work, condom use, and psychosocial well-being among HIV clients in Uganda.
Topics: Adult; Antidepressive Agents; Cognition Disorders; Condoms; Depressive Disorder, Major; Developing C | 2014 |
Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
Topics: Adult; Citalopram; Cognitive Behavioral Therapy; Cohort Studies; Combined Modality Therapy; Depressi | 2015 |
Effects of remission speed and improvement of cognitive functions of depressed patients.
Topics: Adult; Antidepressive Agents; Cognition; Depressive Disorder, Major; Executive Function; Female; Flu | 2015 |
Detecting treatment-covariate interactions using permutation methods.
Topics: Adolescent; Analysis of Variance; Antidepressive Agents, Second-Generation; Bias; Clinical Decision- | 2015 |
Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
Topics: Adult; Asia, Eastern; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluo | 2016 |
Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; | 2015 |
Association of a brain methylation site with clinical outcomes in depression does not replicate across populations.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Desipramine; F | 2015 |
Response to Uher et al.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Desipramine; F | 2015 |
Persistent decrease in alpha current density in fully remitted subjects with major depressive disorder treated with fluoxetine: A prospective electric tomography study.
Topics: Adolescent; Adult; Alpha Rhythm; Antidepressive Agents, Second-Generation; Brain Mapping; Chi-Square | 2015 |
Relative efficacy of psychological and pharmacological treatments for social anxiety disorder.
Topics: Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male | 2015 |
Improving outcome of paediatric depression with cognitive-behavioural therapy (CBT) after initial improvement on antidepressant medication.
Topics: Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male | 2015 |
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose | 2015 |
The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Child; Depr | 2015 |
The relationship between symptom relief and functional improvement during acute fluoxetine treatment for patients with major depressive disorder.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Humans; Ma | 2015 |
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Behavior, Animal; Brain; Depression; Depress | 2015 |
What's in a delayed bathyphase?
Topics: Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Rest; Selective Serotonin Reuptake Inh | 2015 |
MiR-335 is involved in major depression disorder and antidepressant treatment through targeting GRM4.
Topics: Adolescent; Antidepressive Agents; Case-Control Studies; Child; Citalopram; Depressive Disorder, Maj | 2015 |
Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants.
Topics: Animals; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cerebral Cortex; Depressive Diso | 2016 |
Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Comorbidity; Depressive Disorder, Major; Female; Fl | 2015 |
Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia.
Topics: Amino Acids; Animals; Antidepressive Agents; Bipolar Disorder; Brain; Depressive Disorder, Major; Ex | 2016 |
Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment.
Topics: Affect; Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; CA1 Region, Hippocampal | 2017 |
Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach.
Topics: Adolescent; Adult; Aged; Animals; Antidepressive Agents; Cell Survival; Citalopram; Depressive Disor | 2016 |
The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders.
Topics: Adolescent; Anxiety Disorders; Child; Cytokines; Depressive Disorder, Major; Enzyme-Linked Immunosor | 2016 |
Staying Up at Night: Overlapping Bipolar and Obsessive-Compulsive Disorder Symptoms in an Adolescent with Autism Spectrum Disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder | 2016 |
Melancholic features in inpatients with major depressive disorder associate with differential clinical characteristics and treatment outcomes.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Diagnostic and Statisti | 2016 |
Neurocognitive Changes in Selective Serotonin Reuptake Inhibitors-Treated Adolescents with Depression.
Topics: Adolescent; Attention; Case-Control Studies; Child; Cognition; Depressive Disorder, Major; Executive | 2016 |
The symptom trajectories to clinical remission in Chinese patients with unipolar major depressive disorder.
Topics: Adult; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Outcome Assessment | 2016 |
Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine.
Topics: Adolescent; Adult; Aged; Biomarkers; Case-Control Studies; Chromatography, Liquid; Depressive Disord | 2016 |
Selective corticotropin-releasing factor 1 receptor antagonist E2508 has potent antidepressant-like and anxiolytic-like properties in rodent models.
Topics: Acetylcholine; Administration, Oral; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Di | 2016 |
One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms.
Topics: Adolescent; ATP Binding Cassette Transporter, Subfamily B, Member 1; Depressive Disorder, Major; Fem | 2016 |
Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Gen | 2016 |
Chronic Fluoxetine Treatment Upregulates the Activity of the ERK1/2-NF-κB Signaling Pathway in the Hippocampus and Prefrontal Cortex of Rats Exposed to Forced-Swimming Stress.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Blotting, | 2016 |
TNFAIP3, a negative regulator of the TLR signaling pathway, is a potential predictive biomarker of response to antidepressant treatment in major depressive disorder.
Topics: Adult; Animals; Antidepressive Agents; Biomarkers; Cell Line; Depressive Disorder, Major; Female; Fl | 2017 |
Antidepressant Prescription in the Geriatric Population: A Teachable Moment.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnosis, Differential; Female; Fluoxetine | 2016 |
Which SSRIs most effectively treat depression in adolescents?
Topics: Adolescent; Adolescent Behavior; Antidepressive Agents; Behavior Therapy; Citalopram; Depressive Dis | 2016 |
Alternative splicing of SMPD1 coding for acid sphingomyelinase in major depression.
Topics: Adult; Aged; Alternative Splicing; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Fe | 2017 |
Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling.
Topics: Animals; Antidepressive Agents; Azepines; Behavior, Animal; Benzamides; Brain-Derived Neurotrophic F | 2016 |
Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Depressive Disorder, | 2017 |
Fluoxetine-Induced Severe Oral Ulceration in a 13-Year-Old Girl.
Topics: Adolescent; Depressive Disorder, Major; Female; Fluoxetine; Humans; Oral Ulcer; Selective Serotonin | 2017 |
Antidepressant-associated mania: soon after switch from fluoxetine to mirtazapine in an elderly woman with mixed depressive features.
Topics: Adrenergic alpha-Antagonists; Aged; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Rela | 2009 |
Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects.
Topics: Adult; Depressive Disorder, Major; Female; Fluoxetine; Humans; Intelligence Tests; Male; Memory, Sho | 2008 |
Flat dose-response curves for efficacy: what do they mean to the clinician?
Topics: Attitude of Health Personnel; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; D | 2008 |
[A place for SSRIs in the treatment of severely depressed children and adolescents].
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cyclohexanols; Depressive Disorder, Maj | 2008 |
Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Citalopram; Depressive Disorder, Major; Female; | 2008 |
Platelet serotonin uptake in drug-naïve depressive patients before and after treatment with citalopram.
Topics: Adult; Blood Platelets; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Studie | 2008 |
The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Decision | 2008 |
Dysfunctional attitudes and perceived stress predict depressive symptoms severity following antidepressant treatment in patients with chronic depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Attitude; Depressive Disorder, Major; Female; Fluox | 2008 |
[A place for SSRIs in the treatment of severely depressed children and adolescents].
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Fluoxetine; | 2008 |
Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.
Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Maj | 2009 |
Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cost-Bene | 2009 |
Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Gene Frequ | 2009 |
An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Cyclohexanol | 2009 |
Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Antioxidan | 2009 |
Trismus induced by fluoxetine.
Topics: Anxiety Disorders; Depressive Disorder, Major; Fluoxetine; Humans; Male; Middle Aged; Selective Sero | 2009 |
Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.
Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Depressive Disorder, Major; Diagnostic and Statistica | 2009 |
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depr | 2010 |
5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression.
Topics: Adolescent; Adult; Aged; Citalopram; Depressive Disorder, Major; Fluoxetine; Humans; Middle Aged; Pa | 2009 |
SSRI antidepressants do not confound single photon emission computed tomography (SPECT) imaging studies using the alpha4beta2 nicotinic acetylcholine receptor [123I]5-I-A85380 ligand: in vivo and in vitro evidence.
Topics: Adult; Antidepressive Agents, Second-Generation; Autoradiography; Azetidines; Brain; Citalopram; Dep | 2010 |
The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
Topics: Adolescent; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Thera | 2009 |
Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cognitive Behavioral Therapy; Comb | 2009 |
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Diso | 2009 |
Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression.
Topics: Adult; Aged; Animals; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; | 2010 |
[Further evidence of the efficacy of the antidepressant Valdoxan (agomelatine) compared with conventional antidepressive drugs (from the ECNP held in Istanbul, 15 September 2009)].
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Flu | 2009 |
Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Asian People; Brain-Derived Neurotrophic Factor; De | 2010 |
Altered function of the serotonin 1A autoreceptor and the antidepressant response.
Topics: Animals; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Fluoxetine; Humans; M | 2010 |
Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Depressive Disorder, Major; Drug Interactions; Drug Thera | 2010 |
Combining antidepressant medications: a good idea?
Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Dr | 2010 |
Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS).
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Child Abuse; Child Abuse, Sexual; Cogni | 2010 |
Cognitive-behavioral therapy added to fluoxetine in major depressive disorder after 4 weeks of fluoxetine-treatment: 16-week open label study.
Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Female; | 2010 |
Anxiety as a predictor of treatment outcome in children and adolescents with depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Depressive Disorder, | 2010 |
The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder.
Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Anxiety Disorders; Attention; Comorbidity; | 2010 |
Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
Topics: Adult; Anger; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder, Majo | 2010 |
Adherence to antidepressant therapy for major depressive patients in a psychiatric hospital in Thailand.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Femal | 2010 |
Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Di | 2011 |
A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments.
Topics: Algorithms; Bias; Computer Simulation; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; | 2011 |
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Brain Mappin | 2011 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Psychometric properties of the Children's Depression Rating Scale-Revised in adolescents.
Topics: Adolescent; Depressive Disorder; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Studies; | 2010 |
Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.
Topics: Depressive Disorder, Major; Fluoxetine; Humans; Hypericum; Logistic Models; Outpatients; Phytotherap | 2011 |
Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes.
Topics: Animals; Animals, Newborn; Astrocytes; Brain-Derived Neurotrophic Factor; Cells, Cultured; Depressiv | 2011 |
Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine.
Topics: Adult; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Dose-Response Relationship, | 2012 |
Mother-infant antidepressant concentrations, maternal depression, and perinatal events.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Res | 2011 |
Hypoactive sexual desire among depressed female patients treated with selective serotonin reuptake inhibitors: a comparison between escitalopram and fluoxetine.
Topics: Adolescent; Adult; Aged; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Dose-Respo | 2012 |
Fluoxetine effect on aortic nitric oxide-dependent vasorelaxation in the unpredictable chronic mild stress model of depression in mice.
Topics: Acetylcholine; Animals; Aorta; Atherosclerosis; Biological Factors; Depressive Disorder, Major; Dise | 2012 |
Antidepressant-suicide link in children questioned.
Topics: Adolescent; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Drug Prescriptions | 2012 |
Imaging adolescent depression treatment.
Topics: Adolescent Behavior; Brain; Depressive Disorder, Major; Female; Fluoxetine; Humans; Magnetic Resonan | 2012 |
Repetitive transcranial magnetic stimulation in depressed adolescents: experience, knowledge, and attitudes of recipients and their parents.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine | 2012 |
Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; D | 2012 |
On the interpretation of odds ratios.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Humans; In | 2012 |
Chronic effects of corticosterone on GIRK1-3 subunits and 5-HT1A receptor expression in rat brain and their reversal by concurrent fluoxetine treatment.
Topics: Animals; Autoradiography; Corticosterone; Dentate Gyrus; Depressive Disorder, Major; Fluoxetine; G P | 2013 |
Convergent evidence from mouse and human studies suggests the involvement of zinc finger protein 326 gene in antidepressant treatment response.
Topics: Adult; Aged; Animals; Antidepressive Agents; Behavior, Animal; Brain; Case-Control Studies; Depressi | 2012 |
CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.
Topics: Amitriptyline; Antidepressive Agents; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Dose-Resp | 2013 |
Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Femal | 2012 |
Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16.
Topics: Adult; Animals; Behavior, Animal; Depressive Disorder, Major; Female; Fluoxetine; Hippocampus; Human | 2011 |
Serotonin transporter genotype and function in relation to antidepressant response in Koreans.
Topics: Adult; Aged; Asian People; Blood Platelets; Case-Control Studies; Depressive Disorder, Major; Female | 2013 |
Sexual arousal difficulties in women treated with antidepressants: a comparison between escitalopram and fluoxetine.
Topics: Adult; Antidepressive Agents; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Dose- | 2012 |
Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: dose-related phenomenon?
Topics: Aripiprazole; Bipolar Disorder; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship, | 2012 |
Inappropriate data and measures lead to questionable conclusions.
Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic | 2013 |
Inappropriate data and measures lead to questionable conclusions--reply.
Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic | 2013 |
Suicide risk and efficacy of antidepressant drugs.
Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic | 2013 |
Suicide risk and efficacy of antidepressant drugs--reply.
Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic | 2013 |
Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice.
Topics: Animals; Depressive Disorder, Major; Fluoxetine; Humans; Mice; Mice, Mutant Strains; Polymorphism, G | 2013 |
A typological model for estimation of drug and placebo effects in depression.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Fluoxetine; Humans; Imi | 2002 |
Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Disorder | 2002 |
[Dextromethorphane intoxication under co-medication with cytochrome P450-inhibitor fluoxetin: prolonged and accentuated signs of intoxication].
Topics: Adult; Antitussive Agents; Cytochrome P-450 Enzyme Inhibitors; Depressive Disorder, Major; Dextromet | 2002 |
Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement.
Topics: Autistic Disorder; Bipolar Disorder; Child; Child, Preschool; Cluster Analysis; Depressive Disorder, | 2002 |
The brain tells: early signs of depression recovery.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxet | 2002 |
A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder.
Topics: Adult; California; Depressive Disorder, Major; Drug Costs; Drug Utilization Review; Female; Fluoxeti | 2002 |
Serotonin transporter modulation in blood lymphocytes from patients with major depression.
Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Second-Generation; Brain; Carrier Protei | 2002 |
Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response.
Topics: Adult; Antipsychotic Agents; Depressive Disorder, Major; Female; Fluoxetine; Gene Expression; Gene F | 2003 |
Glia as a putative target for antidepressant treatments.
Topics: Animals; Depressive Disorder, Major; Fluorescent Antibody Technique; Fluoxetine; Hippocampus; Male; | 2003 |
Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder, Major; Doub | 2003 |
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depressive Disorder, Major; Dose-Respo | 2003 |
Psychopharmacological treatment of major depressive disorder in children and adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine | 2003 |
Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment.
Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Carrier Proteins; Depressive Disorder, Maj | 2003 |
Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response.
Topics: Adult; Aged; Alleles; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Chromosomes, Human, | 2003 |
Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study.
Topics: Adolescent; Adult; Aged; Benzodiazepines; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Th | 2003 |
Temperament, childhood environment and psychopathology as risk factors for avoidant and borderline personality disorders.
Topics: Adolescent; Adult; Borderline Personality Disorder; Child; Demography; Depressive Disorder, Major; F | 2003 |
The impact of medical comorbidity on acute treatment in major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Comorbidity; Cost of Illness; Depr | 2003 |
Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Drug Interac | 2003 |
Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: a fluorine magnetic resonance spectroscopy study in vivo.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bone Marrow; Brain; Chromatography, High Pres | 2004 |
Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation.
Topics: Adolescent; Adult; Alcohol-Related Disorders; Depressive Disorder, Major; Diagnosis, Dual (Psychiatr | 2004 |
Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.
Topics: Adult; Anxiety; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Prospective Studies; S | 2004 |
Fluoxetine-induced mania in an Asian patient.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder, Major; Diagn | 2004 |
Treatment of adolescents with major depression: contributions of a major trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disor | 2004 |
Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Topics: Activities of Daily Living; Acute Disease; Ambulatory Care; Cost-Benefit Analysis; Cyclohexanols; De | 2004 |
Fluoxetine-induced memory impairment in four family members.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Depressive Disorder, Major; Fe | 2004 |
SSRIs: are the accusations justified?
Topics: Adolescent Psychiatry; Child Psychiatry; Depressive Disorder, Major; Fluoxetine; Humans; Selective S | 2004 |
Adolescents with depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disor | 2004 |
Adolescents with depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disor | 2004 |
Adolescents with depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disor | 2004 |
Adolescents with depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disor | 2004 |
Pharmacological management of treatment-resistant pediatric depression.
Topics: Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Drug Res | 2005 |
Plasma catecholamine levels after fluoxetine treatment in depressive patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Catecholamines; Depressive Disord | 2005 |
Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antiviral Agents; Cell C | 2005 |
Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response.
Topics: Adolescent; Adult; Aged; Alleles; Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxet | 2005 |
Turning darkness into light. A new landmark study on the treatment of adolescent depression. Comments on the TADS study.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Dru | 2005 |
Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study.
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interpersonal | 2005 |
What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Data Interpretation, Statistical; Depressive Disorde | 2005 |
Fluoxetine for depression relapse prevention.
Topics: Adolescent; Child; Depressive Disorder, Major; Fluoxetine; Humans; Secondary Prevention; Selective S | 2005 |
Noradrenaline transporter and its turnover rate are decreased in blood lymphocytes of patients with major depression.
Topics: Adult; Blood Platelets; Cell Membrane; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hydro | 2005 |
Depressed youth, suicidality and antidepressants.
Topics: Adolescent; Child; Depressive Disorder, Major; Drug Evaluation; Fluoxetine; Humans; Selective Seroto | 2005 |
Stimulation of neurogenesis in the hippocampus of the adult rat by fluoxetine requires rhythmic change in corticosterone.
Topics: Age Factors; Aging; Animals; Cell Proliferation; Corticosterone; Dentate Gyrus; Depressive Disorder, | 2006 |
Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Dopamine; Female; Fluoxetine; | 2006 |
Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Dopamine; Female; Fluoxetine; | 2006 |
Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Dopamine; Female; Fluoxetine; | 2006 |
Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Dopamine; Female; Fluoxetine; | 2006 |
Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding.
Topics: Adult; Aging; Antidepressive Agents, Second-Generation; Breast Feeding; Depressive Disorder, Major; | 2006 |
Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD).
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relationship, Dr | 2006 |
Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants.
Topics: Amitriptyline; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depressive Disorder, | 2007 |
Antidepressant therapy and C-reactive protein levels.
Topics: Adult; Aged; C-Reactive Protein; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middl | 2006 |
The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings.
Topics: Adult; Affect; Cognition; Depressive Disorder, Major; Drug Therapy, Combination; Estradiol; Female; | 2007 |
Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety disorders?
Topics: Adolescent; Age Factors; Anxiety Disorders; Child; Clinical Trials as Topic; Depressive Disorder, Ma | 2006 |
[Psychomotor retardation in depression assessed by visuomotor tasks. Overview and achievements of ten years' research].
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetin | 2006 |
An exploratory factor analysis of the children's depression rating scale-revised.
Topics: Adolescent; Age Factors; Analysis of Variance; Antidepressive Agents, Second-Generation; Child; Clin | 2006 |
Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
Topics: Adult; Aged; Antidepressive Agents; Asian People; Depressive Disorder, Major; Female; Fluoxetine; Hu | 2006 |
Lymphocyte subsets and viral load in male AIDS patients with major depression: naturalistic study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antidepressive Agents, Second-Generation; Antiretroviral | 2006 |
After TADS, can we measure up, catch up, and ante up?
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Flu | 2006 |
Glad for what TADS adds, but many TADS grads still sad.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Flu | 2006 |
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Anger; Anxiety Disorders; Depressive Disorder, Major; Diagnostic and Statis | 2007 |
Effects of antidepressant treatment on neural correlates of emotional and neutral declarative verbal memory in depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dose-Res | 2007 |
Generic fluoxetine and choice of antidepressant medication.
Topics: Choice Behavior; Depressive Disorder, Major; Drugs, Generic; Fluoxetine; Humans; Selective Serotonin | 2007 |
Suicidality scores during double-blind fluoxetine and desipramine treatment in Mexican Americans.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Fluo | 2007 |
Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders.
Topics: Adult; Antidepressive Agents; Brain; China; Corticotropin-Releasing Hormone; Depressive Disorder, Ma | 2007 |
Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine?
Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major | 2007 |
Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Disease Progression; Female; Fluoxetine | 2007 |
L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression.
Topics: Adult; Bipolar Disorder; Clomipramine; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Co | 2007 |
Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis.
Topics: Adult; Affect; Biogenic Monoamines; Brain Stem; Caudate Nucleus; Cyclohexanols; Depressive Disorder, | 2007 |
Autonomic reactivity to induced emotion as potential predictor of response to antidepressant treatment.
Topics: Adult; Antidepressive Agents; Arousal; Autonomic Nervous System; Blood Pressure; Depressive Disorder | 2007 |
Neural responses to happy facial expressions in major depression following antidepressant treatment.
Topics: Antidepressive Agents; Brain; Brain Mapping; Depressive Disorder, Major; Facial Expression; Fluoxeti | 2007 |
Ecchymoses as an adverse effect of fluoxetine treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Ecchymosis; Female; Flu | 2007 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disord | 2007 |
Simple options for improving signal detection in antidepressant clinical trials.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Databases, Factual; Depressive Disorder | 2007 |
Does early response predict outcome in psychotherapy and combined therapy for major depression?
Topics: Adult; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Diagnostic and | 2008 |
[Comparison of different antidepression therapy in perimenopausal and postmenopausal women with depression].
Topics: Adult; Depressive Disorder, Major; Estrogen Replacement Therapy; Female; Fluoxetine; Follow-Up Studi | 2007 |
A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Caudate Nucleus; Cerebral Co | 2007 |
Benefits and harms of pediatric antidepressant medications.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Fluoxetine; | 2007 |
Circadian rhythm of salivary serotonin in patients with major depressive disorder.
Topics: Adult; Case-Control Studies; Circadian Rhythm; Depressive Disorder, Major; Female; Fluoxetine; Human | 2007 |
Tics, anxiety, and possible PANDAS in an adolescent.
Topics: Adolescent; Adrenergic alpha-Agonists; Antidepressive Agents, Second-Generation; Anxiety; Autoimmune | 2007 |
Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression.
Topics: Amitriptyline; Animals; Anti-Inflammatory Agents; Antidepressive Agents, Tricyclic; Chronic Disease; | 2008 |
A case of unexpected and selective remission of a 20-year history of ephedrine dependence following treatment with low-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule; | 2007 |
Functional coupling of the amygdala in depressed patients treated with antidepressant medication.
Topics: Adult; Amygdala; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain Mapping; Depr | 2008 |
Sertraline and tic: case report.
Topics: Adult; Depressive Disorder, Major; Eyelids; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorde | 2007 |
Toxic epidermal necrolysis and fluoxetine: a case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum | 2008 |
Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine.
Topics: Adult; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Diagnostic | 2008 |
Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence.
Topics: Adolescent; Cannabinoids; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Diagnosti | 2008 |
A depressed adolescent at high risk of suicidal behavior.
Topics: Acetaminophen; Adolescent; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality Th | 2008 |
Continuation treatment with antidepressants in child and adolescent major depression.
Topics: Adolescent; Age Factors; Antidepressive Agents; Child; Depressive Disorder, Major; Fluoxetine; Human | 2008 |
Cost-effectiveness of depression treatment for adolescents.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Depressi | 2008 |
Antidepressant treatment, posttraumatic stress disorder, survivor guilt, and spiritual awakening.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Awareness; Combat Disorders; Combined Modality | 1997 |
Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine.
Topics: Adult; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Pregn | 1998 |
Divided attention in major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Attention; Decision Making; Depressive Disorder, Ma | 1998 |
Relationships between low red blood cell count and clinical response to fluoxetine in depressed elderly patients.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Blood Platelets; Carrier Proteins | 1998 |
Venlafaxine: new preparation. Just another antidepressant.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv | 1998 |
A case of sequential anti-stress medication in a patient with major depression resistant to amine-reuptake inhibitors.
Topics: Amines; Antidepressive Agents; Anxiety Disorders; Dehydroepiandrosterone; Depressive Disorder, Major | 1999 |
Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT.
Topics: Adult; Aged; Anti-Anxiety Agents; Benzamides; Benzodiazepines; Case-Control Studies; Contrast Media; | 1999 |
Fluoxetine efficacy in menopausal women with and without estrogen replacement.
Topics: Antidepressive Agents, Second-Generation; Climacteric; Depressive Disorder, Major; Drug Therapy, Com | 1999 |
Retardation in depression: assessment by means of simple motor tasks.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; | 1999 |
Defense mechanisms and personality in depression.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Defense Mechanisms; Depressive Disorder, Major; Female; | 1999 |
Maintenance treatment for recurrent depression in late life. A four-year outcome study.
Topics: Aged; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Drug Therapy, Co | 2000 |
Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications.
Topics: Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2000 |
Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Depress | 2000 |
Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy.
Topics: Adult; Aged; Brain; Depressive Disorder, Major; Female; Fluorine Radioisotopes; Fluoxetine; Fluvoxam | 2000 |
Treatment of depression with associated anxiety: comparisons of tricyclic antidepressants and selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Clomipramine; Depressive Disorder, Major; Fluox | 2000 |
Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response.
Topics: Brain; Depressive Disorder, Major; Drug Administration Schedule; Fluoxetine; Glucose; Humans; Limbic | 2000 |
Changes in energy during treatment of depression: an analysis of fluoxetine in double-blind, placebo-controlled trials.
Topics: Adult; Aged; Analysis of Variance; Controlled Clinical Trials as Topic; Depressive Disorder, Major; | 2000 |
Urinary retention with reboxetine-fluoxetine combination in a young man.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Fluoxetine; Hum | 2000 |
Prefrontal changes and treatment response prediction in depression.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder, Major; Electroencephal | 2001 |
Mood disorders in children and adolescents: psychopharmacological treatment.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Child; Depressive Disorder, Major; Drug Therapy, Combi | 2001 |
Ethical dilemmas in prescribing antidepressants.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Prescriptions; Ethics, Clinical; Fema | 2001 |
Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression.
Topics: Adenosine Triphosphate; Adult; Basal Ganglia; Depressive Disorder, Major; Energy Metabolism; Female; | 2001 |
Fluoxetine and olanzapine for resistant depression.
Topics: Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Fluoxet | 2002 |
Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients.
Topics: Adolescent; Adult; Aged; Blood Platelets; Depressive Disorder, Major; Dose-Response Relationship, Dr | 2002 |